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Zusammenfassung 
 
Einleitung 
Posttranslationale  Modifikationen,  z. B.  Phosphorylierung,  regulieren 
wesentliche Eigenschaften von  Proteinen, wie die  Lokalisation, Konformation, 
Aktivität,  Stabilität  und  Interaktionsfähigkeit.  Eine  besondere  Form  der 
Proteinmodifikation stellt die Ubiquitylierung dar. Dabei wird Ubiquitin, ein 76 
Aminosäure großes Protein, mit seinem C-Terminus kovalent an ein Lysin oder 
den  N-Terminus  eines  Substratproteins  gebunden.  Durch  Ubiquitylierung  von 
Proteinen  werden  verschiedene  zelluläre  Prozesse,  wie  Signalübertragung, 
Reparatur  von  DNA-Schäden,  Zellteilung,  Vesikeltransport  und  auch 
Proteinabbau reguliert.  
Die Ubiquitylierung wird durch eine geordnete Abfolge von drei verschiedenen 
Enzymen  katalysiert.  Zunächst  aktiviert  ein  E1  Enzym,  mittels  einer 
C-terminalen  Adenylierung,  freies  Monoubiquitin,  das  dann  über  eine 
Thioesterbindung an ein Cystein des E1 Enzyms gebunden wird. Anschließend 
wird das Ubiquitin auf eines von ca. 35 Ubiquitin konjugierenden E2 Enzymen 
übertragen  und  schließlich  mit  Hilfe  einer,  von  ca.  600,  E3-ligasen  an  ein 
Substratprotein gebunden.  
Ubiquitin hat die besondere Eigenschaft verschiedene Ketten zu bilden, indem 
ein Ubiquitinmolekül an eines der sieben Lysine (K6, K11, K27, K29, K33, K48, 
K63)  oder  den  N-Terminus  eines  anderen  Ubiquitinmoleküls  gebunden  wird. 
Somit kann Ubiquitylierung in verschiedenen Formen vorkommen, wobei diese 
unterschiedliche  Funktionen  besitzen.  Die  bekannteste  Auswirkung  der 
Ubiquitylierung ist der regulierte Abbau des modifizierten Proteins durch das 
Proteasom.  Dies  wird  hauptsächlich  durch  K48-verknüpfte  Ubiquitinketten 
verursacht.  Es  wurden  jedoch  bereits  alle  anderen  möglichen  Formen  von 
Ubiquitinketten in Zellen entdeckt, wobei einigen dieser Kettentypen spezifische 
Funktionen  zugewiesen  werden  konnten.  K63-verknüpfte  Ubiquitinketten 
spielen z. B. eine wichtige Rolle bei der Reparatur beschädigter DNA oder auch 
bei  der  Übertragung  von  zellulären  Signalen,  die  zur  Aktivierung  des 
Transkriptionsfaktors NF-κB führen. Zusammenfassung 
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Die zellulären Auswirkungen der Ubiquitylierung werden in den meisten Fällen 
durch  Ubiquitinrezeptoren  vermittelt,  die  eine  oder  mehrere 
Ubiquitinbindedomäne (UBD) besitzen. Bisher wurden mehr als 20 verschiedene 
UBD-Typen  identifiziert.  Die  meisten  UBDs  binden  Ubiquitin  an  einer 
hydrophoben Stelle im Bereich der Aminosäure I44. Einige UBDs können nur 
bestimmte Ubiquitinketten binden, was zu einer besseren Regulierbarkeit der 
Auswirkungen  der  Ubiquitylierung  führt.  Solche  spezialisierten  UBDs 
interagieren meistens an zwei Stellen mit den Ubiquitinketten, die sie selektiv 
binden  können.  In  diesen  Fällen  sind  die  Interaktionsstellen  nur  in  den 
jeweiligen  Kettentypen,  die  mit  der  selektiven  UBD  interagieren  können  so 
zueinander orientiert, dass es zu einer Bindung mit der selektiven UBD kommen 
kann.  
Das  Protein  NEMO  ist  ein  Ubiquitinrezeptor,  dessen  UBD,  die  UBAN  (UBD  in 
ABIN  proteins  and  NEMO),  selektiv  bestimmte  Ubiquitinketten  bindet.  NEMO 
spielt  eine  zentrale  Rolle  bei  der  Aktivierung  der  Transkriptionsfaktorfamilie 
NF-κB, indem es den IKK-Kinasekomplex reguliert. Dieser Kinasekomplex sorgt 
durch  die  Phosphorylierung  des  NF-κB-Inhibitors  IκBα  für  dessen 
proteasomalen Abbau, wodurch NF-κB aktiviert wird. NF-κB kann durch viele 
extra- und intrazelluläre Signale aktiviert werden, wozu auch die Aktivierung des 
TNF-Rezeptors  (TNFR)  durch  das  Zytokin  TNFα  zählt.  Am  aktivierten  TNFR 
werden  viele  Proteine  durch  verschiedene  Ubiquitinketten  modifiziert.  NEMO 
bindet Ubiquitin über seine UBAN und diese Interaktion ist absolut notwendig, 
um NF-κB zu aktivieren. Einige Studien kamen zu dem Schluss, dass die gezielte 
Bindung von NEMO an K63-verknüpfte Ubiquitinketten ausschlaggebend für die 
Aktivierung  von  IKK  ist.  Jedoch  spielen  lineare  Ubiquitinketten,  die  über  den 
N-Terminus verknüpft sind, auch eine wichtige Rolle bei der Aktivierung von 
NF-κB und außerdem hat die UBAN von NEMO hat eine sehr hohe Affinität zu 
linearen Ubiquitinketten.  
Aus  vorherigen  Studien  wurde  nicht  ganz  ersichtlich,  welche 
Ubiquitinkettentypen NEMO bevorzugt bindet und welche dieser Interaktionen 
relevant für die Aktivierung von NF-κB ist. Zusammenfassung 
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Ein  Ziel  dieser  Arbeit  war  daher  eine  detaillierte  Analyse  der 
Ubiquitinbindungspreferenz von NEMO. Da die meisten Studien zur Interaktion 
von  NEMO  mit  Ubiquitin  entweder  mit  einzelnen  NEMO-Domänen  oder  mit 
Zelllysat  durchgeführt  wurden, konnte  bisher  keine  klare  Aussage  über  die 
Ubiquitinbindungspreferenz von NEMO gemacht werden. In dieser Arbeit wurde 
bakteriell  aufgereinigtes  NEMO  verwendet,  um  die  Interaktionen  mit 
verschiedenen  Ubiquitinketten  unterschiedlicher  Länge  im  Detail  zu 
untersuchen. Durch die Rekonstitution von NEMO knock-out Zellen mit NEMO-
Mutanten,  die  kein  Ubiquitin  mehr  binden  können,  wurde  dann  analysiert, 
welche Rolle diese Interaktionen bei der Aktivierung von NF-κB durch den TNF-
Rezeptor spielen.  
 
Ergebnisse 
Um  In  vitro  Bindungsstudien  zwischen  NEMO  und  verschiedenen 
Ubiquitinketten  durchführen  zu  können,  wurden  K48-  und  K63-verknüpfte 
Ubiquitinketten  zunächst  enzymatisch  hergestellt.  Dazu  wurde  Monoubiquitin 
mit  einem  E1-aktivierendem  und  den  Kettentypen  spezifischen  E2-Enzymen 
inkubiert. Die so synthetisierten Ketten wurden durch Kationenaustausch ihrer 
Größe  nach  getrennt,  wodurch  aufgereinigte  Ubiquitinketten  mit  definierter 
Länge und Verknüpfung erhalten wurden. 
Um die Ubiquitinbindungspreferenz von NEMO zu untersuchen, wurden dann 
zunächst  linear-, K48- und K63-verknüpfte  tetra-Ubiquitinketten  mit  ver-
schiedenen bakteriell aufgereinigten NEMO-Domänen, sowie mit NEMO in voller 
Länge,  inkubiert  und  die  Bindungen  mittels  pull-down  und  Western  blot 
Analysen untersucht. Dabei wurde festgestellt, dass die UBAN von NEMO sehr 
stark mit linearem tetra-Ubiquitin interagiert, während die Bindung an K48- und 
K63-verknüpfte tetra-Ubiquitinketten sehr schwach ist. Die UBAN befindet sich 
im C-terminalen Bereich von NEMO und ganz am Ende des C-Terminus ist eine 
Zinkfingerdomäne  von  der  eine  Studie  zeigte,  dass  sie  schwach  an  Ubiquitin 
binden kann. Jedoch konnte diese Bindung bei pull-down Untersuchungen in der 
vorliegenden  Arbeit  nicht  bestätigt  werden.  Der  Zinkfinger  und  die  UBAN 
zusammen indes banden auch K48- und K63-verknüpfte tetra-Ubiquitinketten, Zusammenfassung 
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jedoch  um  einiges  schwächer  als  lineares  tetra-Ubiquitin.  Interessanterweise 
interagierte  NEMO  in  voller  Länge  hauptsächlich  mit  linearem-,  jedoch  nur 
schwach mit K48- und K63-verknüpftem tetra-Ubiquitin.  
Da  am  TNFR  verschiedene  Ubiquitinketten  zur  gleichen  Zeit  vorhanden  sind, 
stellte sich die Frage, welchen Ubiquitinkettentyp NEMO bevorzugt bindet, wenn 
es  auf  unterschiedliche  Kettentypen  trifft.  Um  dies  zu  untersuchen,  wurde 
bakteriell  aufgereinigtes  und  an  MBP  gebundenes  NEMO  mit  verschiedenen 
Ubiquitinketten unterschiedlicher Länge inkubiert. Dabei zeigte sich, dass NEMO, 
unabhängig  von  Kettenlänge  oder  Kettentyp,  immer  bevorzugt  mit  linear 
verknüpften Ubiquitinketten interagierte. Da in vorherigen Studien beobachtet 
wurde, dass NEMO hauptsächlich mit K63-verknüpften Ketten interagiert, und 
da lineare und K63-verknüpfte Ketten strukturell sehr ähnlich sind, wurde bei 
diesen  kompetitiven  Experimenten  ein  Hauptaugenmerk  auf  den  Vergleich 
zwischen  diesen  beiden  Kettentypen  gelegt.  In  diesen  Versuchen  stellte  sich 
heraus, dass NEMO auch dann bevorzugt mit linearen Ketten interagierte, wenn 
diese  gemeinsam  mit  sehr  langen  K63-verknüpften  Ubiquitinetten  mit  NEMO 
inkubiert wurden. Bei einer semiquantitativen Analyse zeigte sich, dass NEMO 
mindestens 50 mal stärker an lineares als an K63-verknüpftes Ubiquitin bindet, 
da bereits bei Zugabe von 20 ng linear verknüpften Ubiquitinketten eine ähnlich 
starke Bindung zu sehen war, wie bei 1 µg K63-verknüpften Ubiquitinketten.  
Eine  Kristallstruktur,  die  in  einer  Kooperation  im  Labor  von  Prof. Wakatsuki 
bestimmt wurde, zeigt, dass die NEMO-UBAN mit linearem di-Ubiquitin auf eine 
besondere Art interagiert, indem die UBAN die hydrophobe I44-Region eines der 
beiden Ubiquitinmoleküle, sowie  die Verbindungsregion  zwischen  den beiden 
Ubiquitinmolekülen  bindet.  Im  Gegensatz  dazu  interagiert  K63-verknüpftes 
di-Ubiquitin nur mit der hydrophoben Region um I44 mit der UBAN, was anhand 
einer  anderen  Kristallstruktur  gezeigt  werden  konnte.  Ausgehend  von  der 
Kristallstruktur des Komplexes aus der UBAN und linearem di-Ubiquitin, wurden 
Aminosäuren von NEMO mutiert, die mit der Verbindungsregion von Ubiquitin 
interagieren, um dadurch die Relevanz dieser Region für die Bindung an lineares 
Ubiquitin zu überprüfen. Interaktionsstudien mit diesen Mutanten zeigten dann, 
dass  die  Bindung  an  lineares  Ubiquitin  durch  diese  Mutationen  tatsächlich Zusammenfassung 
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verhindert wurden, jedoch konnten längere K63-Ketten – wahrscheinlich durch 
eine weitere Interaktionsstelle – immer noch schwach an NEMO binden.  
Da somit NEMO-Mutanten identifiziert wurden, die zwar noch an längere K63-
verknüpfte, aber nicht mehr an lineare Ubiquitinketten binden können, konnte 
der  Einfluss  der  Bindung  von  NEMO  an  lineare  Ubiquitinketten  auf  die 
Aktivierung  von  NF-κB  in  vivo  getestet  werden.  Dazu  wurden  MEF  (mouse 
embryonic fibroblast)-Zellen, die kein NEMO enthalten, mit Wildtyp NEMO oder 
den  NEMO-Mutanten  rekonstituiert  und  anschließend  mit  TNFα  behandelt. 
Dabei  zeigte  sich,  dass  NEMO-Mutanten,  die  keine  linearen  Ubiquitinketten 
binden können, nicht in der Lage sind NF-κB vollständig zu aktivieren. Zusätzlich 
zum NF-κB-Signalweg, aktiviert der TNFR auch den Apoptosesignalweg, wobei 
dieser  durch  NEMO  und  NF-κB  unterdrückt  wird.  Interessanterweise  starben 
Zellen mit NEMO-Mutanten, die kein lineares Ubiquitin binden können jedoch an 
TNFα  induzierter  Apoptose,  während  Zellen  die  Wildtyp  NEMO  exprimierten 
überlebten.  Dies  zeigte,  dass  die  Interaktion  zwischen  NEMO  und  linearem 
Ubiquitin nötig ist, um NF-κB und andere Signalwege am TNFR vollständig zu 
aktivieren.  Um  zu  überprüfen,  ob  eine  stärkere  Bindung  von  NEMO  an  K63-
verknüpfte  Ubiquitinketten  die  Aktivierung  von  NF-κB  ermöglicht,  wurden 
NEMO-Chimären  erzeugt,  bei  denen  der  Zinkfinger  durch  die  NZF  (Npl4  zinc 
finger)-Domäne  von  TAB2  ersetzt  wurde,  die  spezifisch  an  K63-verknüpfte 
Ubiquitinketten  bindet.  In  vitro  Interaktionsstudien  zeigten  dann,  dass  die 
NEMO-NZF-Chimären  eine  ähnlich  hohe  Affinität  zu  K63-verknüpften 
Ubiquitinketten  hatten,  wie  NEMO  mit  einer  intakten  UBAN  zu  linearen 
Ubiquitinketten. NEMO knock-out MEFs wurden anschließend mit NEMO-NZF-
Chimären,  bei  denen  die  UBAN  mutiert  war,  rekonstituiert  und  die  Zellen 
wurden mit TNFα behandelt. Dabei zeigte sich, dass NEMO-NZF-Chimären nicht 
in  der  Lage  waren  NF-κB  vollständig  zu  aktivieren.  Jedoch  konnte  NF-κB 
teilweise aktiviert werden, was darauf hindeutet, dass die Bindung von NEMO 
und linearen Ubiquitinketten zwar nötig ist, um NF-κB vollständig zu aktivieren, 
aber  die  Bindung  an  K63-verknüpfte  Ketten  auch  ein  gewisses  NF-κB 
Aktivierungspotential besitzt. 
 Zusammenfassung 
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Diskussion 
In  dieser  Arbeit  konnte  gezeigten  werden,  dass  NEMO  ein  selektiver 
Ubiquitinrezeptor  für  lineare  Ubiquitinketten  ist.  Anhand  der  Kristallstruktur 
des Komplexes aus der UBAN und linearem di-Ubiquitin wird ersichtlich, dass 
lineares di-Ubiquitin an zwei Stellen, über die Verknüpfungsregion und über die 
hydrophobe  Region  um I44, an die UBAN bindet. Diese Bindung ist bei K63-
verknüpftem Ubiquitin nicht möglich, was eine Kristallstruktur des Komplexes 
aus  der  UBAN  und  K63-verknüpftem  di-Ubiquitin  zeigt.  Diese  spezielle 
Interaktion zwischen der UBAN und linear verknüpftem Ubiquitin stellt wohl die 
molekulare Grundlage für die hohe Bindungsselektivität von NEMO gegenüber 
diesem Ubiquitinkettentyp dar. Interessanterweise können längere, über Lysine 
verknüpfte,  Ubiquitinketten  ebenso  die  UBAN  und  NEMO  binden,  vermutlich 
über  eine  zusätzliche  Bindungsstelle.  Sobald  aber  gleichzeitig  lineare 
Ubiquitinketten vorhanden sind, bindet NEMO ausschließlich diesen Kettentyp.  
Diese  Ubiquitinbindungspreferenz  hat  Auswirkungen  auf  die  Funktion  von 
NEMO. NEMO, das keine linearen Ubiquitinketten binden kann, ist nicht fähig 
TNFα-induziertes  NF-κB  vollständig  zu  aktivieren,  sowie  diese  Zellen  vor 
Apoptose zu schützen. Wie wichtig lineare Ubiquitinketten am TNFR sind zeigen 
auch Studien, bei denen LUBAC, die E3-Ligase, die diesen Kettentyp synthetisiert, 
entfernt wurde  und dadurch NF-κB nicht mehr durch TNFα aktiviert werden 
konnte.  Für  die  Aktivierung  von  NF-κB  ist  der  Kinasekomplex  IKK 
verantwortlich,  wobei  NEMO  (auch  IKKγ  genannt)  die  regulatorische  Unter-
einheit darstellt. Möglicherweise wird durch die spezifische Bindung von NEMO 
an  lineare  Ubiquitinketten  eine  hohe  Konzentration  an  IKK-Komplexen 
verursacht, die es diesen ermöglicht sich gegenseitig durch Phosphorylierung zu 
aktivieren.  Möglich  ist  auch,  dass  die  gezielte  Bindung  von  NEMO  an  lineare 
Ubiquitinketten  eine  Konformationsänderung  im  IKK-Komplex  verursacht, 
welche diesen aktiviert. Zusammenfassend konnte gezeigt werden, dass nur die 
spezifische  Bindung  von  NEMO  an  lineare  Ubiquitinketten  und  nicht  die 
schwächere Bindung an K63-verknüpfte Ketten, eine vollständige und effiziente 
Aktivierung von NF-κB und anderer Prozessen am TNFR gewährleistet.  Introduction 
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1. Introduction 
 
1.1 The ubiquitin system 
Posttranslational  modification  (PTM)  is  an  important  mechanism  to 
regulate various properties of a protein1. These properties modulated by PTMs 
include a proteins localisation, conformation, stability, activity and interaction 
with other proteins. One important type of PTM is the covalent attachment of a 
functional group to an amino acid. Probably the most intensively studied PTM is 
phosphorylation,  where  a  phosphate  gets  attached  to  a  serine,  threonine  or 
tyrosine residue. Analogous to phosphorylation proteins also get modified by a 
group of small proteins from the ubiquitin family. Ubiquitin itself consists of 76 
amino acids and protein ubiquitylation plays an important role in almost every 
aspect of cellular physiology2. Ubiquitin was discovered as a critical component 
of an energy dependent protein degradation process in the early 1980s by Aaron 
Ciechanover, Avram Hershko and Irwin Rose who were awarded the Nobel Prize 
in chemistry in 2004 for their findings related to the ubiquitin system3. Ubiquitin 
usually  gets  ligated  to  a  lysine  of  a  substrate  protein  through  a  cascade  of 
enzymatic reactions2, 4, 5. In contrast to most of the other protein modifications, 
ubiquitin can form chains on a substrate by attaching a ubiquitin molecule to an 
amino  acid  of  another  ubiquitin  molecule.  This  polyubiquitylation  is  mainly 
known for its role in the regulation of protein degradation4. However, in the last 
years it became evident that protein ubiquitylation can also function as a signal 
regulating a plethora of cellular events, ranging from protein quality control over 
DNA-damage and several signalling pathways to cellular proliferation2, 6.  
Ubiquitin  has  a  very  stable  globular  structure  comprised  of  an  -helix 
surrounded  by  five  -strand  folds.  It  is  the  founding  member  of  a  family  of 
proteins  that  have  a  ubiquitin-like  structure  and  most  of  them  can  also  get 
covalently attached to other proteins (or in some cases phospholipids), which 
can  alter  the  function,  localisation,  conformation  and  stability  of  their 
substrates5. So far, 17 members of the family of ubiquitin-like proteins (UBLs) 
have  been  discovered  (SUMO-1/-2/-3,  Nedd8,  FAT10,  URM1,  USM1  ISG15, 
GABARAP  and  GABARAPL-1/-2/-3,  LC3A/B/C  and  ATG12)7.  The  evolutionary Introduction 
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success  of  the  ubiquitin  fold  is  additionally  reflected  by  the  existence  of 
ubiquitin-like domains (ULDs) in many proteins, where they mediate important 
functions such as protein interactions8-10. 
The  relevance  of  ubiquitin  is  also  manifested  by  its  vast  abundance  in  all 
eukaryotic  cells.  Its  sequence  is  highly  conserved  throughout  the  eukaryotic 
kingdom, in which the human ubiquitin differs only in three amino acids from 
the sequence in Saccharomyces cerevisiae11. In order to ensure a proper ubiquitin 
supply  of  the  cell  the  human  genome  encodes  14  copies  of  the  ubiquitin 
sequence, distributed over four genes12. The genes UBB and UBC have 3 and 9 
ubiquitin  copies  respectively,  where  the  ubiquitin  sequences  are  directly 
connected, leading to the translation of ubiquitin chains linked in a head-to-tail 
fashion.  The  two  other  ubiquitin  genes,  UBA52  and  RPS27A,  are  linked  to 
ribosomal subunit proteins and translated as fusion proteins. After translation, 
single  ubiquitin  molecules  are  cleaved  by  specific  isopeptidases  to  form  the 
cellular pool of free monoubiquitin13, 14. 
 
1.1.1 Modification of proteins by different forms of ubiquitylation 
Proteins  can  get  modified  by  ubiquitin  in  many  different  ways,  which 
gives this modification a great variety of possible outcomes depending on the 
type of ubiquitylation2, 15. Some proteins are monoubiquitylated where only one 
ubiquitin is attached to a certain lysine residue. This form of ubiquitylation is for 
instance  involved  in  the  regulation  of  receptor  sorting  or  trans-lesion  DNA-
polymerisation16, 17.  A  special  form  of  monoubiquitylation  is  called  multi-
monoubiquitylation where more than one lysine in a protein is modified with a 
ubiquitin molecule.  
The  most  abundant  type  of  ubiquitylation  however  comes  in  form  of 
polyubiquitin chains. Ubiquitin has seven lysine residues (K6, K11, K27, K29, 
K33,  K48  and  K63)  and  each  can  be  the  target  of  another  ubiquitin 
molecule2, 15, 18 (Figure 1A). Additionally, in recent years it was discovered that 
also  the  N-terminal  methionine  of  ubiquitin  can  be  a  target  of  ubiquitin 
conjugation, forming linear ubiquitin chains19. This sums up to eight different 
linkage  types  that  can  possibly  be  formed  by  a  diubiquitin  (diUb)  unit  in  a Introduction 
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ubiquitin chain. Each linkage type leads to a different structure of diUb, which 
can result in different functions20,  21 (Figure 1B). Additionally, each chain type 
has a unique chemical environment surrounding its linker region, which gives 
every linkage an individual recognition site for protein interactions. Due to these 
aforementioned differences, each chain type can be considered as a distinct PTM. 
Adding even more complexity to the ubiquitin system is the fact, that ubiquitin 
can form chains of two to a yet unknown number of moieties in vivo and the 
length of the chain might also influence the physiological outcome. For example 
does the degradation of ubiquitylated proteins depend on the modification of at 
least four ubiquitin moieties for an efficient removal by the proteasome22, 23. For 
many other functions controlled by ubiquitylation however, the role of the chain 
length is still not clear. 
Most cellular functions mediated by ubiquitylation depend on the recognition by 
ubiquitin receptors, which are proteins with ubiquitin binding domains (UBDs)24 
(see chapter 1.1.3). These proteins “read” the ubiquitin signal and translate it 
into  a  physiological  response.  Many  UBDs,  which  selectively  bind  to  di-  or 
polyubiquitin chains, are able to specifically recognize the conformation or the 
special linkage area that exists only in a certain type of chain. A very important 
surface of ubiquitin for the interaction with other proteins is the hydrophobic 
area surrounding I4424 (Figure 1B). Depending on the linkage and thus on the 
conformation,  the  two  I44  patches  of  a  diUb-molecule  can  be  positioned 
differently in relation to each other. The structures of several diUb-types have 
been solved and this shows that diUbs linked via K6, K11 and K48 have a rather 
compact structure enabling the two moieties to interact with each other, while 
K63  and  linearly  linked  diUb  are  rather  elongated  without  intramolecular 
interactions (Figure 1B). However, recently it has been reported that linear diUb 
can  also  have  a  more  compact  structure  under  certain  circumstances21.  This 
indicates, that the conformation of diUbs is somewhat flexible giving them the 
possibility to interact with different surfaces. Although some types of linkages 
share a more compact conformation, their I44 patches can still be positioned 
differently  and  thus  can  also  mediate  different  interactions  and  physiological 
outcomes. Introduction 
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Figure 1: Structure of ubiquitin and different diUb-molecules. A) Ubiquitin has a 
compact globular structure with a characteristic β-grasp fold. The C-terminus of one 
ubiquitin can get attached to one of the lysine residues (red), or to the N-terminal 
methionine of another ubiquitin. K63 is very close to M1 enabling similar structure in 
K63- and M1- linked diUbs (compare K63 and linear elongated structures in B. B) 
diUb molecules with different linkages have distinct structures. K6-, K11- and K48- 
linked diUbs have a compact conformation where the hydrophobic I44 patches (red) 
facilitate intramolecular interaction, while K63-linked diUb is elongated. Linear diUb 
can have a compact structure but can also be elongated and the elongated linear diUb-
conformation is similar to K63-linked diUb. The proximal ubiquitin is the one that 
would be attached to a lysine residue of a substrate and thus has a free C-terminus in 
the diUb-molecule. Fig. 1A is modified from
25. Structure: PDB code 1UBQ,
26. Fig. 
2A is modified from
21. Structures: K11 (PDB code 3nob,
27), K6 (PDB code 2xk5,
28), 
K48 (PDB 1aar,
29), K63 (PDB code 2jf5,
20), linear elongated (PDB code 2w9n,
20), 
linear compact (PDB code 3axc,
21). 
 
 
1.1.2 The ubiquitin conjugation machinery  
An elaborate system has evolved in order to covalently attach ubiquitin 
and other UBLs to a substrate. A cascade of enzymatic reactions leads from the 
ATP-dependent  activation  of  ubiquitin  to  its  ligation  to,  usually,  the  ε-amino 
group  of  a  lysine  of  a  target  protein.  These  ubiquitin  conjugation  steps  are 
catalysed by the activating enzymes E1, a conjugating enzyme E2 and a ligating 
enzyme E35 (Figure 2). Introduction 
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Ubiquitin and other UBLs are first activated by E1 enzymes7. At present eight E1 
enzymes  are  known  and  most  of  them  activate  only  one  type  of  UBL  (e. g. 
Uba2/SAE1-heterodimer  activates  SUMO-1/-2/-3  and  Uba7  activates  ISG15). 
Until recently it was thought that only Uba1 is able to activate ubiquitin, but now 
it  has  been  discovered  that  also  Uba6  is  an  activator  of  this  most  abundant 
member of the UBL family. Uba6 can additionally activate FAT10, a UBL that 
consists of two ULDs. The first step in the ubiquitylation process is the only one 
that needs ATP as a source of energy. In order to activate ubiquitin the E1 first 
has to adenylate it at its C-terminus5 (Figure 2). The next step leads to a covalent 
thioester linkage between the catalytic cysteine of the E1 and the C-terminus of 
ubiquitin7. 
After the activation of ubiquitin by the E1 enzyme, it gets transferred to an E2 
ubiquitin-conjugating enzyme30, 31. In this step ubiquitin gets covalently attached 
to  the  cysteine  in  the  catalytic  centre  of  the  E2  to  form  a  thioester.  A 
characteristic feature of many UBLs is that they only have one or two E2s that 
catalyse their conjugation. Ubc9 e.g. is specific for SUMO-proteins while NEDD8 
has its cognate E2s Ubc12 and NCE231. In contrast, around 35 E2s are able to 
accept ubiquitin from an E1 enzyme. This much higher E2 enzyme diversity for 
ubiquitin reflects its various functions in all aspects of cellular physiology as well 
as  its large  number of substrates32. Such variety of E2 enzymes can give the 
ubiquitin system a layer of regulation in two ways. First, ubiquitin E2 enzymes 
combine only with a subset of E3 ligases to ubiquitylate a substrate30, 31. Since 
the substrate specificity for ubiquitylation is determined by the E3 enzymes (see 
below),  E3  activation  and  thus  substrate  ubiquitylation  can  specifically  be 
regulated on the level of E2s. The second regulatory process controlled by E2s is 
achieved by the ability of some E2s to define the linkage type of a chain, which 
can cause distinct physiological outcomes2. 
 Introduction 
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Figure 2: The ubiquitin conjugation pathway. In the first step, catalysed by the E1 
enzyme, ubiquitin gets adenylated, which is the reaction that needs ATP. This leads to 
formation of a thioester bond of the ubiquitin C-terminus with the E1. Next ubiquitin 
is transferred to an E2 enzyme also by forming a thioester bond. RING E3 ligases 
transfer ubiquitin directly  from the E2  to  a substrate, while the E3 facilitates the 
interaction. HECT E3-ligases on the other hand first bind the ubiquitin covalently and 
then transfer it to a substrate. (Modified from (Kerscher et al, 2006)) 
 
 
The  final  step  in  the  ubiquitylation  process  is  the  ligation  of  ubiquitin  to  its 
-amino-
group of a lysine residue. However, it is also possible that ubiquitin gets bound to 
the amino group of a methionine at the N-terminus of a target protein, which 
might also be another ubiquitin molecule19, 33, 34. Normally this ligation process is 
catalysed by an E3 enzyme, although there are a few examples known where 
proteins can get monoubiquitylated by transferring ubiquitin to a target protein 
only  with  the  assistance  of  an  E235.  For  some  UBLs  their  respective  E2  is 
normally sufficient for the transfer to a substrate. SUMO-UBLs e.g. have with 
Ubc9 only one cognate E2 and only in certain cases the SUMO-conjugation is 
assisted  by  an  E3  enzyme36.  A  molecular  explanation  for  this  difference  in Introduction 
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ubiquitylation  and  SUMOylation  is  that  SUMOylation  only  takes  place  at  a 
defined amino acid motif in the substrate. This motif is a recognition site for the 
Ubc9, giving SUMOylation its specificity and leaving SUMOylation without need 
for an E3. The substrate selection of ubiquitylation on the other hand is executed 
by a set of approximately 600 E3 protein ligases, which all can have different 
substrate recognition sites, making it difficult to predict a lysine residue as target 
for  ubiquitylation37,  38.  The  existence  of  this  set  of  different  E3  ligases  is  an 
advantage in terms of the regulation of ubiquitylation. This way ubiquitylation 
can get regulated on the level of E3 activation, leading to ubiquitin modification 
only of the specific pool of proteins that are substrates for a certain E3.  
There are two major groups of E3-ligases: the HECT-family and the RING-domain 
containing E3-ligases, which will be discussed in the following sections. 
 
1.1.2.1 HECT-domain containing E3-ligases 
Around  30  E3-ligases  with  a  HECT-domain  are  encoded  in  the  human 
genome37. The HECT-domain comprises around 350 amino acids and is always 
located at the C-terminus of the E3-ligase. The N-termini of HECT-type E3-ligases 
on the other hand are diverse and important for substrate selection. HECT-type 
E3-ligases, in contrast to RING-domain E3s, have a conserved cysteine residue to 
which  the  C-terminus  of  ubiquitin  gets  covalently  attached,  forming  an 
intermediate  thioester  bond  (Figure  2).  The  N-terminus  of  the  HECT  domain 
binds the E2-enzyme, while the C-terminus contains the cysteine to which the 
ubiquitin gets attached39. The ubiquitin then gets transferred to a lysine residue 
of a substrate, which can lead to the formation of different types of ubiquitin 
chains.  The  mechanism  for  the  chain  formation  can  differ  among  the  HECT-
ligases. The HECT-E3-ligase E6AP e.g. synthesises K48-linked ubiquitin chains on 
its conserved cysteine, while the ligase KIAA10 can produce K48- and K29-linked 
ubiquitin  chains  as  free  entities40, 41.  Itch,  an  E3-ligase  important  for  innate 
immunity,  on  the  other  hand  produces  preferentially  K63-linked  ubiquitin 
chains42. The ubiquitin chain type specificity can be independent of the E2 but 
can be regulated by the HECT-domain alone, as 60 amino acids at the C-terminus Introduction 
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of the HECT domain determine the chain type specificity of Rsp5, a S. cerevisiae 
HECT-type E3-ligase, producing preferentially K63-linked ubiquitin chains43. 
 
1.1.2.2 RING-domain containing E3-ligases 
RING-domain E3-ligases are by far the more abundant type, comprising 
around 600 putative members, accounting for approximately 95% of the human 
E3-ligases38.  A  typical  RING-domain  coordinates  two  zinc  atoms  and  forms  a 
rather globular structure important for protein interaction. The U-box domain is 
a  variant  of  the  RING-domain  that  has  a  similar  structure  but  lacks  the  zinc 
binding residues. Instead, structural integrity is conveyed by hydrogen bonding, 
facilitated  through  conserved  charged  and  polar  residues44.  Ring-domain  E3-
ligases can function as monomers, homo- or heterodimers or as multi-subunit 
complexes. In contrast to HECT-type E3-ligases, ubiquitin does not get covalently 
attached  to  the  RING-finger  protein.  Instead,  the  RING-domain  binds  the 
ubiquitin  loaded  E2-enzyme,  to  bring  the  thioester  bond  of  the  ubiquitin-E2 
linkage in close proximity to the target lysine of the substrate, which is bound to 
another site of the E3.  
There are principally two different kinds of RING-domain containing proteins. 
Some bind as monomers or dimers directly the E2 and the substrate as e.g. Cbl or 
IAP-proteins45-47.  The  other  group  of  RING-E3s  is  the  family  of 
cullin-RING-ligases  (CRL),  which  are  composed  of  multisubunit  complexes 
containing  many  interchangeable  subunits48.  CRLs  usually  consist  of  the 
scaffolding  cullin-protein,  which  can  interact  with  a  RING-domain  containing 
adapter  protein  that  is  responsible  for  E2-binding.  Substrate  specificity  is 
reached by another adapter protein that binds to the cullin and to the substrate 
that gets ubiquitylated. An interesting feature of CRLs is that they have to get 
modified  with  the  UBL  NEDD8  on  the  cullin  subunit.  This  leads  to  a 
conformational change, bringing the E2-ubiquitin thioester in close proximity to 
the lysine residue of the substrate49. 
Recently, a third mechanism, how E3-ligases transfer ubiquitin to a substrate 
was discovered. Members of a subfamily of RING-containing E3 ligases harbour 
two RING domains separated by a domain in between and are thus called RBR Introduction 
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(Ring Between Ring) E3s50. So far 15 members of this protein family have been 
shown to be encoded by the human genome. The first RING domain of RBRs has 
high  sequence  and  structural  similarity  to  other  RING  domains,  which  is  the 
reason  why  it  has  been  hypothesized  that  these  E3-ligases  use  the  same 
mechanism  as  other  RING-E3  ligases  to  catalyse  the  ubiquitin  transfer  to  a 
substrate. However, Klevit et al. could show that in some RBRs the second RING 
domain contains a cysteine that covalently binds ubiquitin before the ubiquitin 
gets transferred to a lysine51, 52. This mechanism resembles rather that of HECT-
domain  E3s  making  RBR-proteins  in  a  way  a  hybrid  of  RING  and  HECT  E3-
ligases. 
A special RBR containing E3 that uses this conjugation mechanism is the linear 
ubiquitin chain assembling complex (LUBAC)19, 53. LUBAC consists of the RBR 
containing proteins HOIL-1L, HOIP and SHARPIN (LUBAC can be composed of a 
HOIP/HOIL/SHARPIN-trimer  or  a  HOIP/HOIL-  or  HOIP/SHARPIN-dimer)54-56. 
This  E3-complex  specifically  synthesises  linear  ubiquitin  chains  regardless  of 
which E2 provides the ubiquitin, resembling rather the chain type determining 
mechanism of HECT E3s19. 
 
1.1.3 Ubiquitin-binding domains: Ubiquitin signal deciphering devices 
Most  of  the  cellular  events  that  are  regulated  by  ubiquitylation  are 
executed by so called ubiquitin receptors24. These proteins have the ability to 
bind  to  ubiquitin,  which  can  have  various  outcomes  such  as  activation, 
translocation or accumulation of the modified protein. Ubiquitin receptors have 
distinct  domains,  which  facilitate  the  ubiquitin  binding  and  are  thus  called 
ubiquitin-binding domains (UBDs). 
 
 
 
 
 
 
 Introduction 
 
 
  16 
Table 1: Ubiquitin binding domains 
UBD 
Ubiquitin-binding 
specificity  Representative protein  Function 
α- helical          
UIM  MonoUb, K63, K48   S5a/Rpn10, Vps27, STAM, 
Epsins, Rap80 
Degradation, endocytosis, MVB 
biogenesis, DNA repair 
MIU (IUIM)  K48-, K63-linked chains,  Rabex-5  Endocytosis 
DUIM  2 x MonoUb  Hrs  MVB biogenesis 
UBM  MonoUb  Pol-i, Rev-1  DNA damage tolerance 
UBA  MonoUb, K63-, K48-
linked chains 
Rad23/hHR23A, Dsk2, p62 Proteasome targeting; kinase 
regulation; autophagy 
CUE  MonoUb  Vps9, TAB2, TAB3  Endocytosis, kinase regulation 
GAT  MonoUb  GGA3  MVB biogenesis 
VHS  MonoUb  STAM, GGA3  MVB biogenesis 
UBAN  Linearly linked chains  NEMO, ABIN1-3, 
optineurin 
NF-κB signalling 
Zinc finger          
UBZ   MonoUb, K63-, K48-
linked chains 
Pol-h; Pol-k, Tax1BP1, 
NEMO 
DNA damage tolerance, NF-κB-
signalling 
NZF  MonoUb  Npl4, Vps36, TAB2, TAB3  ERAD, MVB biogenesis, kinase 
regulation, TNFR-signalling 
Znf_UBP 
(PAZ) 
MonoUb, K63, K48  USP5/IsoT; HDAC6  Proteasome function, 
aggresome/autophagy 
ZnF_A20  K48-. K63- linearly 
linked chains, 
Rabex-5, A20  Endocytosis, kinase regulation 
PH domain          
PRU  MonoUb, K48-linked 
chains 
Rpn13  Proteasome function 
GLUE  MonoUb  Eap45  MVB biogenesis 
Ubc-like          
UEV  MonoUb  Uev1/Mms2  DNA repair, MVB biogenesis, kinase 
regulation 
Ubc  MonoUb  UbcH5C  Ubiquitin transfer 
Others          
SH3  MonoUb  Sla1/CIN85  Endocytosis 
PFU  MonoUb  Doa1/Ufd3  ERAD 
jab1/MPN  MonoUb  Prp8  RNA splicing 
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1.1.3.1 Types of UBDs 
All UBDs described so far contain regular secondary structures24. This is 
in contrast to sites that interact with other UBLs, like SUMO- or ATG8-proteins, 
where  a  short  motif  of  around  four  hydrophobic  amino  acids,  flanked  by  a 
stretch of negatively charged residues, is sufficient for a targeted interaction57, 58. 
UBDs can be found in a multitude of proteins, which are involved in all kinds of 
cellular  processes.  Considering  the  high  functional  diversity  of  ubiquitin 
interaction,  as  well  as  the  many  different  kinds  of  ubiquitin  signals,  it  is  not 
surprising  that  various  distinct  domains  have  evolved  to  facilitate  ubiquitin 
interaction with high accuracy and specificity24. Around 20 families of UBDs are 
known  so  far  and  according  to  their  structure  they  can  get  categorized  into 
different  groups  (Table  1).  The majority of the UBDs consist of one  or more 
α-helices. Another large structural group are UBDs that have a zinc finger fold. 
The UBDs of E2s consist of a beta-sheet and at least two UBD-families have a PH-
domain structure24. 
 
1.1.3.2 UBD-interaction with monoUb 
The  surface  of  ubiquitin  consists  of  rather  polar  residues.  An  area 
surrounding I44 however contains mainly hydrophobic residues, including L8 
and V702. This hydrophobic patch is the interaction surface for most UBDs and in 
many  cases  the  interaction  is  lost  when  I44  is  mutated.  Exceptions  are  for 
instance the ZnF-A20 of Rabex-5, which mainly interacts with D58, or the ZnF-
UBP  of  the  deubiquitylase  (DUB)  IsoT,  which  mainly  interacts  with  the 
C-terminal part of ubiquitin24. This unconventional interaction of the ZnF-UBP of 
IsoT ensures that it only cleaves unanchored ubiquitin chains59. 
 
1.1.3.3  Avid  interactions  increase  the  affinity  of  ubiquitin  receptors 
towards ubiquitin 
The affinity of most UBDs to monoubiquitin is rather low, with Kds in high 
µM  ranges24, 60.  This  fact  leads  to  the  question  how  ubiquitin  receptors  can 
efficiently interact with ubiquitylated substrates to reliably propagate a cellular Introduction 
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event. In order to overcome this problem, certain mechanisms have evolved to 
increase  the  affinity  of  ubiquitin  receptors  and  ubiquitylated  proteins24, 60, 61. 
These mechanisms can be grouped in three different forms of avid interactions. 
First, a ubiquitin receptor has, additionally to its UBD, another interaction site 
with  the  ubiquitylated  protein.  Second,  a  UBD  has  two  or  more  interaction 
surfaces for ubiquitin and can thus bind two moieties at the same time. Third, a 
ubiquitin  receptor  can  contain  more  than  one  UBD,  which  can  be  used  for 
ubiquitin binding. A variant of this mechanism is the dimer- or multimerisation 
of UBD-containing proteins, which brings many UBDs together to interact with 
an ubiquitylated protein. UBDs that can interact with more than one ubiquitin 
molecule can either bind to multiple monoubiquitin or to several moieties in a 
polyubiquitin  chain.  This  kind  of  interaction  however  can  also  cluster  two 
monoubiquitylated proteins, which e.g. are integrated in a membrane60. 
 
1.1.3.4  Multivalent  recognition  of  di-or  polyUb  enables  chain  type 
selectivity 
As  already  discussed,  a  multivalent  interaction  between  a  UBD  and  a 
ubiquitin chain can lead to higher affinity24. Moreover, it can also be responsible 
for  a  selective  binding  to  distinct  types  of  ubiquitin  chains.  This  selective 
interaction  is  important  for  the  targeted  recognition  of  a  certain  chain  type 
conveying a distinct signal. This signal, which should mediate a certain cellular 
process,  is  integrated  in  the  structure  of  the  chain  type  (Figure  1B).  Some 
ubiquitin receptors, e.g. ones responsible for targeting ubiquitylated proteins to 
the  proteasome  for  their  degradation,  preferentially  interact  with  K48-linked 
ubiquitin  chains,  which  is  the  most  important  ubiquitin  signal  for  protein 
degradation62. The proteasomal receptor RAD23A has a UBA-domain that binds 
around  four  times  stronger  to  K48-  than  to  K63-linked  ubiquitin  chains  and 
around 70 times stronger to K48-linked chains than to monoubiquitin63. A UBD-
binding preference for a certain chain type can be either due to a characteristic 
positioning of the ubiquitin moieties or due to the difference in the linker region 
(Figure  1  and  Figure  3).  The  difference  in  the  linker  region  results  from  the 
different ubiquitin surfaces around each lysine to which the C-terminus of the Introduction 
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next ubiquitin is attached to. Since most UBDs interact with the I44 patch, the 
orientation of this surface area from two ubiquitins in a chain is an important 
factor for the determination of the binding of either a UBD with two interaction 
surfaces or a protein with two UBDs. Thus the proper binding of a receptor to a 
ubiquitin  chain  relies  on  the  potential  orientation  of  two  or  more  defined 
interaction sites with the UBD(s)24.  
The co-crystal structure of RAD23A-UBA2 with K48-linked diUb thus explains 
the preferential interaction with this chain type64. The UBA2 of RAD23A contacts 
the I44 patches of both K48-linked ubiquitin moieties, which wrap around the 
UBD.  K48-linked  diUb  has  a  compact  conformation,  where  the  I44-patches 
interact with each other (Figure 1B). Since the conformation of ubiquitin and 
also polyubiquitin  fluctuates21, 61, the  UBA2 could slip in during a  more  open 
state, which causes a relatively strong binding. This cannot be accomplished with 
rather elongated diUbs such as linear or K63-linked chains.  
Another  example  how  the  positioning  of  the  I44-patch  in  different  ubiquitin 
chains types determines UBD-interaction specificity is the selective interaction 
between RAP80 and K63-linked ubiquitin chains65 (Figure 3A). RAP80 has two 
UIMs in a tandem, enabling and restricting it to interact only with K63-linked 
ubiquitin chains. The structural basis for this selectivity is the distance of the two 
UIMs, determined by the length of the linker. This ensures that each UIM can 
interact with I44 of K63-linked diUb but not with diUb of other linkages such as 
linear- or K48-linked diUb. The specific interaction of RAP80 with K63-linked 
ubiquitin chains is important to target DNA-damage repair proteins to the sites 
of DNA-damage, which is labelled by this type of chains66.  
As described above RAP80 utilises two UIMs to accomplish specific binding to 
K63-linked ubiquitin chains. The adaptor protein TAB2 on the other hand uses a 
different mechanism, where only one UBD, its NZF, ensures binding specificity to 
K63-linked  ubiquitin  chains67, 68  (Figure  3A).  The  co-crystal  structure  of  the 
TAB2-NZF  with  K63-linked  diUb  shows,  that  it  interacts  with  both  ubiquitin 
moieties via their I44-patch. This interaction is only possible, when the two I44 
patches are positioned properly, which is only assured by the K63-linkage. 
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Figure 3: Ubiquitin chain type selectivity of different ubiquitin receptors. A) Two 
RAP80 UIMs (pink) in tandem bind to the I44 patches of two K63-linked ubiquitin 
moieties (green) and the length of the UIM-linker determines chain type selectivity. 
The NZF of TAB2 (pink) also specifically binds to the I44 patches of two K63-linked 
diUbs (green). In this case the moieties have to bend in a way that is only possible 
with  the  K63-linkage  (red).  B)  The  NZF  of  HOIL  (gray),  in  contrast  specifically 
interacts with linear linked diUb. The NZF binds the distal moiety (blue) at its I44 
patch while it contacts the proximal ubiquitin (pink and green) at a region close to the 
linker, which is only possible in the context of the linear linkage. Fig. 3A is modified 
from
24.  Structure  RAP80-UIMs/diUb  (PDB  code  3A1Q
65).  Structure  TAB2-
NZF/diUb (PDB code 2WWZ
67). Fig. 3B is modified from
69. 
 
 
A different mechanism, how the ubiquitin chain linkage conveys UBD-binding 
specificity  is  exhibited  by  the  interaction  of  the  NZF-domain  of  the  LUBAC-
subunit  HOIL  with  linear  diUb  (Figure  3B)69.  Linear  chains  were  recently 
discovered to be important for the activation of NF-κB-signalling and the E3-
ligase  LUBAC  specifically  produces  linear  ubiquitin  chains70.  The  elongated 
structure of linear and K63-linked diUb is similar since the K63-residue is in 
close proximity to the M1-residue of the N-terminus, however, the linker region 
differs20  (Figure  1).  In  contrast  to  previously  described  examples  of  UBD-
ubiquitin interactions, the binding of the NZF of HOIL to diUb is facilitated by the Introduction 
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linker region. The distal moiety (the one where the C-terminus is attached to the 
methionine)  interacts  with  the  NZF  via  its  hydrophobic  I44  patch,  while  the 
proximal ubiquitin binds via its residues Q2, F4 and T12, which are close to the 
linker  region.  Only  the  linear  linkage  brings  these  residues  close  to  their 
interacting residues in the HOIL-NZF, when at the same time the distal moiety 
binds the UBD with the I44 patch69.  
Taken together UBDs display decoding devises for ubiquitin signals. The ability 
of many ubiquitin receptors to interact with more than one site on ubiquitin 
increases their affinity. This is often also important for the specific interaction 
with a certain type of ubiquitin chain, which enables their specific function in a 
distinct cellular process24.  
 
1.1.4 Deubiquitylating enzymes (DUBs) 
A  set  of  deubiquitylating  enzymes  (DUBs),  analogous  to  protein 
dephosphorylating  phosphatases,  is  responsible  for  the  removal  of  ubiquitin 
from  a  substrate13, 71.  There  are  around  100  DUBs  encoded  in  the  human 
genome, which can be grouped in the five families USP, UCH, OTU, Josephin and 
JAMM.  
Removal of ubiquitin by DUBs is important for various cellular events. DUBs are 
important for the production of monoubiquitin after the translation of ubiquitin 
genes13, 14. Since all ubiquitin genes get translated as a fusion protein, DUBs cut 
off  monoubiquitin  molecules  from  the  translated  pro-proteins,  which  brings 
ubiquitin  into  its  activatable  form.  One  of  the  main  functions  of  the 
ubiquitylation of proteins is their proteasomal degradation (see chapter 1.1.5.1). 
Many DUBs are associated with the proteasome either for the coupled removal of 
ubiquitin from degraded proteins or to inhibit protein degradation directly at the 
proteasome4. Another important task of DUBs is to regulate signalling events 
that  are  mediated  by ubiquitylation.  By  deubiquitylating  proteins  involved  in 
cellular  signalling,  DUBs  can  inhibit  or  shut  down  the  signal.  Most  signalling 
events only get initiated by ubiquitin chains with a certain linkage2. Many DUBs 
have a selective activity towards distinct linkage types and therefore specifically 
regulate cellular events. The importance of deubiquitylation is also reflected by Introduction 
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many  diseases  such  as  cancer  or  neurological  disorders,  that  are  linked  to 
dysfunctions of DUBs72. The DUB USP7/HAUSP e.g. can deubiquitylate MDM2, 
which is an E3-ligase for p53. A high expression of USP7 can thus lead to higher 
MDM2-stability, which leads to degradation of the important tumour suppressor 
p53 due to its ubiquitylation by K48-linked ubiquitin chains.  
An important function of DUBs is displayed in the NF-κB signalling pathway. This 
pathway  is  highly  regulated  by  various  ubiquitylation  events,  where  certain 
types of ubiquitin chains have specific functions (see chapter 1.2.3). In order to 
shut  down  NF-κB  signalling  the  DUBs  CYLD  and  A20  perform  important 
functions by deubiquitylating proteins in this pathway73.  
 
1.1.5 Physiological functions of ubiquitylation 
The  functions  of  ubiquitylation  are  extremely  diverse  covering  almost 
every aspect of cellular physiology. Protein ubiquitylation is involved in various 
cellular  processes,  including  cell-cycle  regulation,  signal  transmission,  DNA-
repair,  endocytosis  and  endosome  sorting4, 46, 74-77.  Many  of  these  processes 
depend  on  the  most  prominent  outcome  of  ubiquitylation,  which  is  the 
degradation  of  proteins4.  However,  in  the  late  1990’s  it  was  discovered  that 
ubiquitylation  can have  non-proteolytic functions  and since  than a  myriad of 
non-degradative roles of protein ubiquitylation has been discovered78, 79. 
 
1.1.5.1 Proteasomal degradation 
Responsible  for  the  degradation  of  ubiquitylated  proteins  is  a  large 
protein complex called the proteasome4. The 26S proteasome consists of a 20S 
catalytic  core  and  two  19S  regulatory  lids.  The  20S  core  consists  of  four 
heptamer rings where the two rings in the middle possess protease activity. In 
the hollow cavity of the proteolytic 20S core proteins get degraded into short 
peptides consisting of about seven or eight amino acids. The 19S proteasome 
regulates  substrate  recognition  and  entry  into  the  20S  proteasome.  The  19S 
proteasome  contains  six  ATPases,  which  are  important  for  several  processes 
leading to specific substrate degradation4.  Introduction 
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Proteins  that  have  to  be  targeted  for  proteasomal  degradation  are  usually 
modified with K48-linked polyubiquitin chains, however also other chain types 
as  well  as  monoubiquitylation  can  function  as  degradation  signals.  These 
ubiquitin  modifications  constitute  a  specific  signal,  which  is  recognized  by 
ubiquitin receptors. Some ubiquitin receptors, such as RPN10 and RPN13, are 
part  of  the  19S  proteasome  and  directly  recruit  ubiquitylated  substrates. 
Additionally these ubiquitin binding proteins might also bind to a ULD in, so 
called,  shuttling  receptors9.  These  ULD-containing  shuttling  receptors  also 
contain a UBD and thus can bind ubiquitin chains, to recruit substrates to the 
proteasome via interaction of their ULD with the UBD of RPN10 or RPN13, giving 
the system a higher order of selectivity and specificity.  
Protein degradation by the proteasome can serve two major purposes. The first 
is to remove misfolded and non-functional proteins that might damage the cell 
since these proteins might aggregate4. The second function is the regulation of 
the  presence  of  a  protein  either  for  homeostasis  or  in  cellular  signalling.  In 
cellular signalling, proteasomal removal of endogenous inhibitors can lead to a 
regulated activation of a signalling pathway. In the NF-κB signalling pathway 
(see chapter 1.2) e.g. the inhibitor of this transcription factor is ubiquitylated 
upon pathway activation leading to its destruction und thus activation of the 
transcription  factor80.  Another  example  how  proteasomal  protein  removal 
regulates  cellular  processes  is  mitosis.  The  chromosomes  in  anaphase  are 
attached to each other by a tethering complex during mitosis. Upon activation of 
the E3-ligase complex APC/C the proteins holding the chromosomes together get 
ubiquitylated and degraded which enables progression of mitosis81. 
 
1.1.5.2 Non-degradative roles of ubiquitylation 
 
1.1.5.2.1 Ubiquitylation and DNA damage 
Ubiquitylation  plays  a  pivotal  role  in  various  DNA-repair  or  tolerance 
processes75.  When  a  DNA-polymerase  encounters  a  DNA-damage  site  during 
replication  it  stops.  This  is  a  signal  for  the  monoubiquitylation  of  PCNA,  the Introduction 
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polymerase leading DNA-clamp, which then induces the loading of the y-family 
polymerase pol η and pol ι via their UBDs82. These two polymerases can replicate 
DNA  across  lesions,  preventing  larger  genomic  defects,  however,  without 
repairing  the  DNA  lesions.  In  contrast,  the  ubiquitylation  of  PCNA  with  K63-
linked  ubiquitin  chains  leads  to  an  error-proof  replication  over  DNA-damage 
sites83. 
A  well  analysed  example  for  the  scaffolding  function  of  K63-linked  ubiquitin 
chains  is  its  role  in  the  signalling  cascade  at  the  sites  of  DNA  double  strand 
breaks84.  The  unprotected  open  ends  of  DNA  are  recognised  by  the  MRN-
complex, which subsequently activates the kinase ATM. ATM phosphorylates a 
plethora of proteins, which, among other effects, leads to the recruitment of the 
E3-ligases  RNF8  and  RNF168.  These  ligases  specifically  synthesise 
non-degradative  K63-linked  ubiquitin  chains  on  histones  and  possibly  other 
proteins at the DNA-damage site. The K63-linked ubiquitin chains are a signal for 
the recruitment of the UIM containing protein RAP80 that specifically recognizes 
this  chain  type.  This  specificity  gives  the  process  a  regulated  directionality 
important for the efficient and ordered repair of the damage85. Recruitment of 
RAP80 is essential, since it is part of a complex, which among others, contains 
the tumour suppressor BRCA1 and this complex is crucial for the repair of the 
damage. BRCA1 itself is also an E3-ligase giving the ubiquitin signalling events at 
DNA double strand breaks another layer of complexity86. 
  
1.1.5.2.2 Ubiquitylation in endocytosis and endosome sorting 
Endocytosis is another process where ubiquitin plays an important role. 
Many transmembrane receptors that get internalised get modified with (multi-) 
monoubiquitin or K63-linked chains76, 87. This constitutes a signal for the UBD-
containing receptors Eps15 and Epsin, which assist clathrin driven endocytosis. 
The  later  sorting  of  vesicles  in  multivesicular  bodies  also  depends  on 
modification by (multi-) monoubiquitylation or K63-linked chains. This signal is 
received by some members of the ESCRT (Endosomal Sorting Complex Required 
for  Transport)-complexes  including  STAM  (Signal  transducing  adapter Introduction 
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molecule), Vps27 (vacuolar protein sorting) and Hrs (Hepatocyte growth factor 
receptor substrate), which all contain ubiquitin binding domains. 
 
1.1.5.2.3 Ubiquitylation in protein expression 
Ubiquitylation  also  has  non-degradative  roles  in  the  splicing  and 
translation process. Some spliceosomal proteins get modified with K63-linked 
chains, which stabilises the snRNP-complex and is important for efficient mRNA 
maturation88, 89. Polysomes on translated mRNA molecules get stabilised during 
translation by the modification of ribosomal proteins with K63-linked chains90. 
 
 
1.2 NF-κB signalling 
An  important  cellular  system,  that  exemplifies  the  different  regulatory 
functions ubiquitin can have, is the NF-κB signalling pathway91. In this pathway 
ubiquitylation is important for degradative as well as non-degradative events 
and many forms of ubiquitin chains are present and perform distinct tasks. Most 
of  the  non-degradative  functions  of  ubiquitin  are  transmitted  by  K63-linked 
chains  or  monoubiquitin2.  However,  recent  findings  suggest  that  also  linear 
ubiquitin chains play a crucial role in NF-κB signalling54, 56, 70. 
NF-κB (Nuclear Factor of kappa light polypeptide gene enhancer in B cells) is a 
family  of  transcription  factors  that  was  discovered  about  25  years  ago  as  a 
binder to the kappa light chain gene enhancer in B cells92. Since then NF-κB has 
become  one  of  the  most  thoroughly  investigated  transcription  factors80. 
Although best known for its role in inflammation and the innate and adaptive 
immune system, NF-κB also has crucial effects on a plethora of other cellular 
processes, including the regulation of cell death, differentiation and proliferation. 
The NF-κB family consists of five members, p65/RelA, RelB, c-Rel, p50 (p105 as 
its precursor) and p52 (p100 as its precursor). All members bind to DNA in form 
of  hetero-  or  homodimers,  resulting  in  15  potential  dimer  combinations,  of 
which  some  activate  and  others  inhibit  gene  transcription.  All  NF-κB  family 
members  contain  a  Rel-homology  domain  (RHD)  that  is  necessary  for Introduction 
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dimerisation and DNA binding. Only RelA, RelB and c-Rel have a transactivation 
domain (TAD), which mediates transcription, but the other two members can 
heterodimerise with a TAD-domain containing member and thus still assist gene 
activation80. 
 
1.2.1 NF-κB activation 
NF-κB transcription factors are usually sequestered in the cytoplasm and 
get  only  activated  upon  a  stimulus80.  A  family  of  ankyrin  repeats  containing 
inhibitors, the Inhibitor of NF-κBs (IκBs), bind to the RHD of the NF-κB dimer, 
keeping it inactive. IκBα, IκBβ and IκBε are the three classical members of the 
IκB-family, where IκBα is the prototype and the best studied one. Interestingly, 
the  precursors  of  p50  (p105)  and  p52  (p100)  also  contain  ankyrin  repeats, 
which enables them to function as NF-κB inhibitors similar to the IκBs. p105 and 
p100 have to get processed by the proteasome, which removes the inhibitory 
ankyrin  repeat,  to  transform  them  into  their  active  forms  p50  and  p52 
respectively. In order to remove the ankyrin repeats containing inhibitors, they 
first have  to  get phosphorylated, which is  executed by the  IκB  Kinase  (IKK)-
complex. Phosphorylation triggers their K48-linked ubiquitylation by the cullin 
E3-ligase SCFβTrCP, which leads to their proteasomal degradation. The removal of 
the  inhibitor exposes a  nuclear localisation  signal  of the  NF-κB dimer, which 
enables  it  to  translocate  to  the  nucleus  and  bind  to  DNA  to  initiate  gene 
transcription. 
A huge variety of intra- and extracellular signals can activate NF-κB. For example 
many extracellular ligands bind to different kinds of transmembrane receptors 
that can activate NF-κB, including members of the TNF-receptor (TNFR) family 
(e.g.  TNFR  I  and  II,  CD40,  BAFF-receptor),  IL-1β-receptor  (IL-1βR),  Toll-like-
receptors  (TLRs),  T-  and  B-cell  receptors  (TCR,  BCR)  and  growth  factor 
receptors.  Intracellular  NF-κB  activation  signals  are  e.g.  DNA-damage,  ROS-
production, and pathogen receptors, including RIG-I and NOD80. 
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1.2.1.1 Canonical NF-κB activation  
There  are  two  major  pathways  that  can  activate  NF-κB  transcription 
factors: the canonical and the non-canonical pathway80. The canonical pathway 
is activated by intracellular signals as well as certain transmembrane receptors 
(Figure  4).  The  activation  of  any  of  these  receptors  leads  to  recruitment  of 
adapter proteins, such as members of the TRAF-family. This protein recruitment 
cascade eventually activates the IKK-complex, which then phosphorylates IκBs. 
The IKK complex in the canonical pathway consists of the kinases IKKα, IKKβ 
and the regulatory subunit NEMO (IKKγ). Important and characteristic for the 
canonical pathway are NEMO and IKKβ, while IKKα is dispensable80. The main 
NF-κB members involved in the canonical pathway are RelA, c-Rel and p50. A 
well-investigated  concept  of  canonical  NF-κB  signalling  is  its  activation  by 
extracellular  signals  via  transmembrane  receptors,  including  the  TNFR,  the 
IL-1βR, TLRs and B- and TCR (Figure 4). All these receptors have in common, 
that they don’t have enzymatic activity and upon activation adaptor proteins that 
mediate the signal get recruited. All receptors have a different set of adaptor 
molecules but their activation always leads to the activation of the IKK-complex 
(see 1.2.2). 
An important theme in the induction of NF-κB is protein ubiquitylation91, 93. The 
recruitment  of  E3-ligases  has  been  observed  for  most  of  the  NF-κB  inducing 
transmembrane receptors. These E3-ligases produce different kinds of ubiquitin 
chains, which are important for the activation of NF-κB and will be discussed in 
more detail in chapter 1.2.3. 
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Figure 4: Canonical NF-κB activation. 
The  ligand  induced  activation  of 
transmembrane  receptors  leads  to  the 
recruitment  of  adapter  proteins  and 
enzymes. The enzymes catalyse PTMs 
such  as  phosphorylation  and 
ubiquitylation.  This  recruits  and 
activates  the  IKK-complex,  mediated 
by its regulatory subunit NEMO. The 
IKK-complex phosphorylates IκB at a 
certain  motif  and  this  signal  is 
recognized  by  the  cullin  E3-ligase 
SCF
βTrCP.  The  E3  facilitates  K48-
linked ubiquitylation of IκB, inducing 
its  degradation,  which  exposes  a 
nuclear localisation signal of the NF-
κB-dimer.  NF-κB  can  translocate  to 
the  nucleus  and  initiate  gene 
transcription.  (Modified  from  Wong 
and Tergaonkar Clin. Sci. (2009) 116, 
451-465). 
 
 
1.2.1.2 Non-canonical NF-κB activation 
The non-canonical pathway is activated by certain receptors that belong 
to  the  TNFR  family  (e.g.  BAFF-receptor,  CD40,  RANK,  LTβR  and  FN14)94.  A 
fundamental  difference  to  the  canonical  pathway  is  that  the  regulatory  IKK 
member  NEMO,  which  is  crucial  for  canonical  NF-κB,  is  not  involved  in  the 
activation of the non-canonical pathway. Instead, the non-canonical pathway is 
regulated by the MAP3-kinase NIK, which is indispensable for this NF-κB branch, 
but  is  not  involved  in  the  canonical.  Under  steady  state  conditions  NIK  gets 
modified with K48-linked ubiquitin chains by an E3-ligase complex consisting of 
TRAF2, TRAF3 and cIAP1/2, which leads to a constitutive NIK degradation by the 
proteasome. Upon receptor activation TRAFs and cIAPs get ubiquitylated and 
degraded, which stabilises NIK. NIK can then activate IKKα, the distinctive kinase 
for  the  non-canonical  pathway,  to  activate  NF-κB.  The  characteristic  NF-κB 
members  for  the  non-canonical  pathway  are  RelB  and  p52  (p100).  In 
unstimulated state RelB and p100 form an inactive heterodimer, since activation Introduction 
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is blocked by the ankyrin repeats of p100. When the non-canonical pathway gets 
activated, IKKα phosphorylates p100 at two serines in a recognition site for the 
E3-ligase SCFβTrCP. This leads to the ubiquitylation and processing of p100 to p52 
by the proteasome und thus to the activation of the RelB/P52 NF-κB dimer94. 
 
1.2.2 The IKK-complex 
As described above, NF-κB signalling is a very complex system, where a 
huge amount of activators can lead to the activation of different kinds of NF-κB 
dimers that can be blocked by various endogenous inhibitors80. This activation 
can result in all kinds of cellular outcomes, mediated by transcription activation 
or inhibition. However, all these diverse  signals, that induce  canonical NF-κB 
activation, lead to activation of one single kinase complex which was already 
mentioned  before:  the  IKK-complex95  (Figure  4).  The  IKK-complex  usually 
consists  of  the  two  kinases  IKKα  and  IKKβ  and  a  regulatory  subunit  NEMO 
(Figure 5). The composition of the IKK-complex, together with the utilisation of 
the  IκBs,  is  the  actual  factor  that  distinguishes  the  canonical  from  the  non-
canonical pathway, reflecting its central role in NF-κB signalling96. In contrast to 
the canonical IKK-complex, where the IKK-holoenzyme consists of IKKα, IKKβ 
and NEMO, the non-canonical pathway relies on IKKα alone. 
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Figure 5: The IKK-complex. A) The canonical IKK-complex consists of the kinases 
IKKα and IKKβ and the regulatory subunit NEMO. B) Alignment of the UBAN-
domain  which  is  known  to  exist  in  five  proteins  C)  Model  of  the  IKK-complex 
assembled  from  different  X-ray  crystal  structures.  (Modified  from
97).  *ULD  from 
IKKα  has  been  assumed  from  sequence  comparison  after  solving  the  structure  of 
IKKβ.  KD  (kinase  domain),  SDD  (scaffold/dimerisation  domain),  NBD  (NEMO 
binding domain), IKK-BM (IKK- binding motif), CC (coiled coil), ZnF (zinc finger). 
 
 
1.2.2.1 The kinase subunits IKKα and IKKβ  
The two kinases in the canonical IKK-complex, IKK and IKK, have a 
similar  structure  and  around  50%  sequence  identity95.  The  kinase  domain  is 
located at the N-terminus (Figure 5A). IKKβ has a ULD after the kinase domain 
and  sequence  comparison  in  combination  with  structural  analysis  of  IKKβ 
suggests that also IKKα has a ULD97. The α-helical scaffold/dimerisation domain 
(SDD) is at the C-terminus and it contains 6 α-helices that are important for Introduction 
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kinase homo- or heterodimerisation, as well as for the binding to the regulatory 
subunit  NEMO95,  97.  At  the  very  C-terminus  of  the  SDD  domain  is  the  NEMO 
binding domain (NBD), which is highly conserved among different species and 
indispensable for the interaction with NEMO. 
 
1.2.2.2 The regulatory subunit NEMO is a ubiquitin receptor 
In  order  to  be  able  to  activate  canonical  NF-κB,  the  presence  of  IKKs 
regulatory  subunit  NEMO  is  absolutely  essential,  as  is  the  interaction  of  the 
kinases  with  NEMO  via  their  NBD95.  NEMO  itself  forms  a  dimer  that  binds 
IKKα/β with an N-terminal IKK binding motif (IKK-BM), which is followed by a 
coiled coil domain (Figure 5). A UBD called UBAN (Ubiquitin Binding in ABIN 
proteins and NEMO) follows towards the C-terminus, and at the very C-terminus 
is a ZnF-domain. 
The UBAN is composed of a coiled-coil and a leucine zipper that resides roughly 
between residues 280 and 340 in the human NEMO variant (Figure 5B). A highly 
homologous domain exists in at least four other proteins, optineurin and ABIN 
1/2/3, of which at least some are involved in NF-κB signalling, and all UBANs 
have been shown to bind to ubiquitin chains98-100. First it was hypothesised that 
the  UBAN  is  a  UBD  specific  for  K63-linked  ubiquitin  chains,  but  with  the 
discovery  of  physiologically  relevant  linear  ubiquitin  chains, this  concept  has 
been  challenged70.  Several  laboratories  could  show  that  the  UBAN  of  NEMO 
binds with approximately 100 times higher affinity to linear than to K63-or other 
lysine-linked ubiquitin chains99, 101, 102.  
The  importance  of  NEMO  and  especially  its  ability  to  bind  ubiquitin  is 
emphasised by human genetic diseases that are linked to mutations in NEMO 
and  its  UBAN  domain95.  Two  examples  are  the  X  chromosome-linked  human 
diseases, incontinentia pigmenti (IP) and anhydrotic ectodermal dysplasia with 
immuno deficiency (EDA-ID). 
The predicted structure of the intact canonical IKK-complex was modelled based 
on  data  obtained  from  different  structural  studies97, 99, 103-105.  Thus  obtained 
structural model reveals a highly elongated protein complex that consists of a 
NEMO dimer and a  kinase  homo-  or heterodimer (Figure  5C).  This structure Introduction 
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underlines the important function of NEMO as a scaffolding protein, containing a 
large  surface,  which  enables  interactions  with  various  proteins,  including 
ubiquitin chains. 
  
1.2.3 The role of ubiquitin in TNF-receptor induced signalling and NF-κB    
regulation 
 
1.2.3.1 Activation of the TNFα-Receptor signalling complex 
The binding of the cytokine TNFα activates the TNFα-receptor (TNFR) by 
inducing its trimerisation106. This leads to the recruitment of various adaptor 
proteins and enzymes in order to promote the transduction of the signal. The 
activation of the TNFR initiates four different signalling pathways: the NF-κB 
pathway, the MAP-kinase pathway, the Caspase-8-dependent apoptotic and the 
RIP1/RIP3-dependent necrotic pathway. The TNFR has a death domain (DD), 
which is important for the recruitment of the DD-containing proteins RIP1 and 
TRADD. The DD of TRADD can bind to FADD, which activates Caspase-8 and 
apoptosis106. 
The further composition of the TNFR signalling complex (TNFRSC) depends on 
ubiquitin and on members of the ubiquitylation machinery and different types of 
ubiquitin  chains  are  essential  for  the  proper  regulation  of  the  signalling 
events91, 106, 107. First, the putative E3-ligases TRAF2 and potentially TRAF5 bind 
to TRADD, which has a TRAF-binding domain. This TRADD bound TRAF-trimer 
binds  the  E3-ligases  c-IAP1  and  2.  cIAPs  and  possibly  also  TRAF2/5  then 
synthesise  K63-linked  ubiquitin  chains  on  RIP1,  TRADD,  TRAFs  and  other 
members  of  the  TNFRSC.  Additionally,  cIAPs  modify  RIP1  with  K11-linked 
polyubiquitin108. All these ubiquitin chains help to recruit further members of 
the TNFRSC. The MAP3-kinase TAK1 e. g. localises to the complex via two of its 
adapter  molecules,  TAB2  and  TAB3.  TAB2/3  both  contain  a  C-terminal  NZF-
domain that selectively binds K63-linked ubiquitin chains68. This interaction is 
important for the initiation of the MAP-kinase pathway by TAK1109. The non-
degradative ubiquitin chains in the complex are also responsible for recruiting Introduction 
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the  E3-ligase  complex  LUBAC,  consisting  of  the  proteins  HOIP,  HOIL  and 
SHARPIN54, 55, 110. All LUBAC members have ubiquitin binding domains that are 
important for LUBAC recruitment and function in the complex. LUBAC is an E3-
ligase that makes linear ubiquitin chains on RIP1, NEMO and itself and most 
likely also on other proteins19, 54, 55, 70. Linear ubiquitin chains have been shown 
to be crucial for an efficient activation of NF-κB. This novel ubiquitin chain type 
gives the  ubiquitylation  network in the  complex another layer of  complexity. 
NEMO as the regulatory subunit of the IKK-complex gets also recruited to the 
complex via its UBAN-domain and the binding of NEMO to ubiquitin chains is 
absolutely necessary for the activation of NF-κB99,  111. These different types of 
ubiquitin  chains  mentioned  above  form  a  platform  that  is  important  for  the 
stability of the whole complex, since many participants are ubiquitylated and 
many also contain UBDs106, 110. 
 
1.2.3.2 Silencing of the TNFα-receptor signalling complex 
The  importance  of  the  ubiquitin  system  also  becomes  evident  in  the 
cellular processes, which are implemented to deactivate NF-κB signalling. E3-
ligases as well as DUBs participate in the attenuation of NF-κB. A20, CYLD and 
Cezanne are three DUBs that are involved in removing ubiquitin chains that are 
important for TNFRSC activity73. CYLD belongs to the USP-family of DUBs and 
also functions as a tumour-suppressor. It inhibits NF-κB signalling by removing 
K63-linked  ubiquitin  chains  from  various  proteins  in  the  TNFRSC.  However, 
CYLD also has strong DUB-activity towards linear ubiquitin chains, making it 
possible that it also removes this chain type from the TNFRSC20. Cezanne is an 
OTU-domain containing DUB involved in silencing of NF-κB. It is upregulated by 
NF-κB and shows specific deubiquitylation activity towards K11-linked chains, 
which have been found on RIP1108, 112. However, the role of the presence and the 
removal of K11-linked chains has not been elaborated. 
A20 is another DUB from the OTU-family that is usually expressed at low levels 
and  gets  induced  by  NF-κB73.  A20  is  a  special  member  of  the  ubiquitylation 
machinery,  since  it  was  shown  that  it  also  has  E3-ligase  activity.  In  vivo  it 
removes K63-linked ubiquitin chains from RIP1 (and possibly other substrates) Introduction 
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and attaches K48-linked ubiquitin chains instead, which removes RIP1 by the 
proteasome, thus acting as a fast and persistent silencer of NF-κB113. However, 
in vitro A20 preferably hydrolyses K48-linked ubiquitin chains, making it likely 
that additional factors are responsible for the A20 dependent removal of K63-
linked ubiquitin chains from RIP120. Indeed, several other proteins involved in 
the ubiquitin system interact with A20 and are important for the downregulation 
of  NF-κB  signalling  and  together  they  have  been  described  as  A20-ubiquitin 
editing complex73. Examples are the E3-ligases RNF11 and Itch, which have been 
shown to inhibit NF-κB signalling. Two other proteins that interact with A20 and 
inhibit NF-κB signalling are Tax1BP1 and ABIN1. Tax1BP1 contains two UBZ-
domains at its C-terminus, of which only one binds ubiquitin and this ubiquitin 
interaction is important for A20 mediated NF-κB inhibition114. ABIN1, as already 
discussed,  contains  a  UBAN  that  binds  linear  ubiquitin  chains  but  also  K63-
linked ubiquitin  chains and this  ubiquitin interaction  is  also required for the 
downregulation of NF-κB98.  Aims of the Study 
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2. Aims of the Study 
 
Ubiquitin can form a diverse set of chains, which is based on the linkage type that 
connects  two  ubiquitin  molecules2.  The  different  ubiquitin  chain  types  have 
distinct  conformations  and  topologies.  These  diverse  surfaces  can  be 
distinguished through binding of UBDs, which results in a selective interaction 
leading to a regulated and specific function24. NEMO is an important regulator of 
the  NF-κB  signalling  pathway  and  has  a  UBD,  called  UBAN,  which  displays 
ubiquitin  chain  binding  selectivity98, 99, 111.  It  was  assumed  that  the  UBAN 
selectively binds K63-linked ubiquitin chains. However, it was found that the 
newly discovered linear ubiquitin chains have an important role in the activation 
of NF-κB and an interesting question to address was if NEMO might also bind to 
linear ubiquitin chains and if this binding is involved in NF-κB activation70. 
To get a better understanding of the ubiquitin binding properties of NEMO, this 
study set out to thoroughly investigate in detail the direct interaction of purified 
NEMO domains and full-length NEMO with different types of ubiquitin chains in 
regards to the linkage as well as the length. This also included the determination 
of residues important for the NEMO-ubiquitin interaction, based on structural 
and homology comparison analysis.  
On the functional side the aim of the study was to elucidate the role of NEMO 
binding to ubiquitin chains during the activation of NF-κB, with a focus on TNFR-
dependent NF-κB signalling. The role of NEMO in other pathways regulated by 
the TNFR, such as apoptosis and MAP-kinase signalling, was analysed as well. 
Finally, it is crucial to dissect the ubiquitin binding details of NEMO in order to 
properly  understand  the  signalling  activation  mechanisms  at  the  TNFR. 
Therefore, the aim of this study was to gain insights into the functional outcomes 
of the binding selectivity of NEMO towards different types of ubiquitin chains, 
especially  the  different  binding  preference  towards  linear-  and  K63-linked 
ubiquitin chains. Material and Methods 
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3. Material and Methods 
 
3.1 Material 
 
3.1.1 Chemical compounds  
Reagent  Source 
Agarose  Lonza 
Ampicillin  Roth 
Amylose Resin  Biolabs 
Aprotinin   Sigma-Aldrich  
APS  Roth 
Bovine serum albumin  Roth 
Bromphenol Blue  Roth 
Chemiluminescence Luminol Reagent  Santa Cruz 
Coomassie Brilliant Blue R250  Roth 
Cyclohexamide  Sigma-Aldrich 
1,4-diazabicyclo (2,2,2) octan (DABCO)  Fluka  
4’,6-Diamidin-2-2phenylindol (DAPI)  Roth 
Distilled water  GIBCO 
1,4-dithio-DL-threitol (DTT)  Thermo scientific 
dNTPs  Roche 
Fetal calf serum  PAA Laboratories 
FugeneHD   Roche  
GeneJuice  Merck-Chemicals  
Glutathione Sepharose 4B  GE Healthcare 
IPTG  Invitrogen 
Kanamycin  Roth 
Leupeptin  BioMol  
Lipofectamine   Invitrogen 
β-Mercaptoethanol  Roth 
Mounting medium  Biometra  Material and Methods 
 
 
  37 
Na-orthovanadate  Sigma-Aldrich 
N-Ethylmaleimide (NEM)  Sigma-Aldrich 
Ni-NTA  Qiagen 
Penicillin/Streptomycin   Gibco, Invitrogen 
Phenylmethylsulfonyl fluoride (PMSF)  Roth  
Ponceau S  Roth 
Puromycin  Roth 
Random hexamer primer  Fermentas 
RiboLock Ribonuclease inhibitor  Fermentas 
Sodium vanadate  Sigma-Aldrich 
TEMED  Roth 
Triton X-100  Roth 
Trypsin  Gibco, Invitrogen 
Tween20  Roth 
 
3.1.2. Kits 
Kit  Source 
QIAfilter plasmid Mini kit  Qiagen 
QIAfilter plasmid Midi kit  Qiagen 
QIAquick PCR purification kit  Qiagen 
RNeasy mini kit  Qiagen 
SensiMix real-time PCR kit  Bioline 
 
3.1.3 Antibodies and recombinant or extracted proteins  
Primary antibodies   
Antibody (source species; species reactivity)  Source 
Ubiquitin-P4D1 (m; h)  Santa Cruz 
Ubiquitin- (m; h)  Invitrogen 
Phospho-IκBα (m; m and h)  Cell signaling 
IκBα (r; h and m)  Cell signaling Material and Methods 
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Phospho-p38 (m; h and m)  Cell signaling 
p38 (r; h and m)  Cell signaling 
Phospho-JNK (m; h and m)  Cell signaling 
JNK (r; h and m)  Cell signaling 
IKKα (r; h and m)  Cell signaling 
NEMO (IKKγ) (r; h and m)  Santa Cruz 
Tubulin (m; h and m)  Sigma-Aldrich 
Actin (m; h)  Sigma-Aldrich 
Activated Caspase-3 (r; h and m)  Cell signaling 
PARP (r; h)  Cell signaling 
p65 (r; m and h)  Santa Cruz 
MBP (m; Salmonella)  Sigma-Aldrich 
GAPDH (r; h)  Cell signaling 
h, human; m, mouse; r, rabbit 
 
Secondary antibodies     
Antibody  Source 
Rabbit-HRP  Goat (dako) p0448 
Rabbit-HRP  Mouse anti light chain (Cell signaling) 
3677 
Mouse-HRP  Goat (Bio-Rad) (170-6516) 
 
Recombinant or extracted proteins   
Reagent  Source 
Murine TNFa  Peprotech 
IL-1b  Peprotech 
Ubiquitin from bovine erythrocytes   Sigma-Aldrich 
T4-DNA ligase  NEB 
PFU-Ultra DNA-polymerase  Aplicam 
Reverse Transcriptase   Promega 
PWO-DNA-Polymerase  Peqlab Material and Methods 
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DNaseI  Fermentas 
Protein Marker I  Bio-Rad 
Protein Marker II  Aplicam 
PreScissionTM Protease  GE Healthcare 
Protein A/G  Roche 
Thrombin  Novogen 
 
3.1.4 Buffers, media and solutions 
Solutions  Composition 
Pull-down buffer  50 mM Tris pH 7.5 
150 mM NaCl 
5 mM DTT 
0.1% NP-40 
Ubiquitin chain reaction buffer  40 mM Tris, pH 7.5 
10 mM MgCl2 
0.6 mM DTT 
Ubiquitin chain purification buffer A  50 mM NH4Ac, pH 4.5   
Ubiquitin chain purification buffer B  50 mM NH4Ac, pH 4.5 
1 M NaCl   
Cationic exchange buffer  Buffer A: 50 mM NH4Ac, pH 4.5 
Buffer B: 50 mM NH4Ac, pH 4.5 
                  1000 mM NaCl 
SDS-PAGE sample buffer  50 mM Tris HCl, pH 6.8 
2% SDS 
10% glycerol 
0,1% bromphenol blue 
25 mM DTT 
5% b-Mercaptoethanol  
SDS-PAGE running buffer  Tris 30 g 
glycine 144 g 
SDS 5 g Material and Methods 
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dH2O up to 1 L 
Western blot transfer buffer  Tris 22.3 g 
glycine 105 g 
20% Methanol 
dH2O up to 1 L 
Western blot blocking solution (TBS-BSA)  100 mM Tris, pH 7.5 
150 mM NaCl 
0.1% NaN3 
5% BSA 
TBS-Tween   100 mM Tris, pH 7.5 
150 mM NaCl 
0.05% Tween20 
TBS  100 mM Tris, pH 7.5 
150 mM NaCl 
Stacking gel buffer  0.5 M Tris, pH 6.8 
0. 4% SDS 
Resolving gel buffer  1.5 M Tris, pH 8.8 
0.4% SDS 
PBS   GIBCO  10x  D-PBS  (+CaCl 2, 
+MgCl2) 
PAA Dulbecco’s 1x PBS (-CaCl2, 
-MgCl2 
Hypotonic buffer  20 mM HEPES, pH 7.9 
10mM KCl 
1mM EDTA 
0.2% NP-40 
10% Glycerol 
1.5 mM MgCl2 
1 mM Na-Vanadate 
1mM PMSF 
10 µg/ml Aprotinin 
10 µg/ml Leupeptin Material and Methods 
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1 mM DTT 
Hypertonic buffer  20 mM HEPES, pH7.9 
10 mM KCl 
0.2 mM EDTA 
20% Glycerol  
400 mM NaCl 
1.5 mM MgCl2 
1 mM Na-Vanadate 
1 mM PMSF 
10 µg/ml Aprotinin 
10 µg/ml Leupeptin 
1 mM DTT 
Lysis buffer  HEPES 50 mM, pH 7.5 
NaCl 150 mM 
10% glycerol 
1mM EGTA 
1 mM EDTA 
25 mM NaF 
10 µl ZnCl2 
1 mM Na-Vanadate 
1 mM PMSF 
10 µg/ml Aprotinin 
10 µg/ml Leupeptin 
GST-buffer 1  20 mM Tris-HCl, pH 7.5 
10 mM EDTA 
5 mM EGTA 
150 mM NaCl 
1mM PMSF 
10 µg/ml Aprotinin 
10 µg/ml Leupeptin 
0.1% b-Mercaptoethanol 
GST-buffer 2  20 mM Tris-HCl, pH 7.5 Material and Methods 
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10 mM EDTA 
150 mM NaCl 
0.5% Triton X-100 
1mM PMSF 
10 µg/ml Aprotinin 
10 µg/ml Leupeptin 
0.1% b-Mercaptoethanol 
GST-buffer 3  20 mM Tris-HCl, pH 7.5 
0.1% b-Mercaptoethanol 
10% NaN3 
PreScissionTM protease cleavage buffer  50 mM Tris HCl, pH 8.0 
100 mM NaCl  
1 mM EDTA  
1 mM DTT 
Ponceau S  0.5% Ponceau S 
10% acetic acid 
in H2O 
Coomassie brilliant blue staining  45% Methanol 
10% Acidic acid 
0,1% Coomassie brilliant blue 
in dH2O 
Coomassie brilliant blue destaining   45% Methanol 
10% Acidic acid 
in dH2O 
50x TAE-buffer  240 g Tris 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA 
ad to 1 l H2O 
Luria-Bertoni (LB) media  10g/L tryptone 
5g/L yeast extract 
10g/L NaCl 
Dulbecco’s modified Eagle’ medium (DMEM)  Gibco, Invitrogen Material and Methods 
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3.1.5 Plasmids 
For reconstitution of NEMO knock-out MEFs the retroviral derived vector pBABE 
puro  (purchased  from  Addgene)  was  used.  Isoform  1  of  the  NEMO-gene 
sequence from Mus musculus was cloned into pBABE using the restriction sites 
EcoRI/BamHI.  The  human  TAB2-NZF  domain  was  exchanged  with  the  NEMO 
UBAN domain (aa 250-339) or the ZnF (aa 389-412), in the full-length NEMO 
gene integrated into pBABE.  
For expression of recombinant GST-tagged proteins the full-length sequence (aa 
1-412), the UBAN (aa 250-338), the C-terminus (aa 250-412) or the ZnF (aa 389-
412) of isoform 1 of the Mus musculus NEMO gene and the full-length gene of 
human RAP80 was cloned into pGEX-4T1 (GE Healthcare). The human TAB2-NZF 
domain was exchanged with the NEMO UBAN (aa 250-339) or the ZnF (aa 388-
412), in the full-length NEMO gene cloned into pBABE. 
For expression of recombinant MBP-tagged proteins the sequence of the full-
length isoform 1 of the Mus musculus NEMO-gene (aa 1-412) was cloned into 
pMAL-c2X (New England Biolabs).  
The plasmids pGEX-6P-1-Ubc13, pGEX-6P-1Uev1a and pET16His10-cdc34 were 
kindly provided by David Komander (MRC, Cambridge, UK).  
 
3.1.6 Oligonucleotides 
MBP-NEMO for  gcgaattcaacaagcacccctggaag 
MBP-NEMO rev  gcggattcctactctatgcactccatgac 
BamHI NEMOmM for  aaaggatccgccaccatgaacaagcaccc 
EcoRI-NEMOmM rev  aaagaattcctactctatgcactccatgac 
Nemo R309A a  gctgacttccaagctgaggcgcatgcccgggagaagc 
Nemo R309A b  gcttctcccgggcatgcgcctcagcttggaagtcagc 
Nemo R312A a  gctgagaggcatgccgcggagaagctggtgg 
Nemo R312A b  ccaccagcttctccgcggcatgcctctcagc 
Nemo R313A a  gctgagaggcatgcccgggcgaagctggtggagaagaagg 
Nemo R313A b  ccttcttctccaccagcttcgcccgggcatgcctctcagc 
Swap-NEMO-CoZi- cgacagccacattaagagcagcaaggatgagggagctcagtggaattgtacc Material and Methods 
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TAB2-NZF 
megaprimer for 
Swap-NEMO-CoZi-
TAB2-NZF 
megaprimer rev 
cctcaatcctggctgactcatggcagaaatgccttggcatctcacactgttc 
SWAP  NEMO-UBZ-
TAB2-NZF GST for 
cctgaagaacctcctgacttcgatgagggagctcagtggaattgtacc 
SWAP  NEMO-UBZ-
TAB2-NZF GST rev 
gcggccgctcgagtcagaaatgccttggcatctcacactgttc 
SWAP  NEMO-UBZ-
TAB2-NZF pB rev 
ccactgtgctggcgaattcctagaaatgccttggcatctcacactgttc 
SWAP  NEMO-UBZ-
TAB2-NZF AU1 rev 
gttaacgcggccgctcctagaaatgccttggcatctcacactgttc 
 
3.1.7 Additional materials and machines 
Nitrocellulose membranes (GE healthcare) 
PVDF membranes (Hybond) 
Mono S 5/50 GL column (GE Healthcare) 
Äkta Purifier (GE Healthcare) 
Concentrators (GE Healthcare) 
Empty Disposable PD-10 Columns (GE Healthcare) 
 
3.1.8 Bacterial strains and cell lines  
DH5a (Invitrogen) 
BL21 (Amersham) 
BL21 pRARE (Novagen) 
MEFs (Marc Schmitt-Supprian) 
HEK293-T (ATCC) 
HEK293 Phoenix Ecotrophic (ATCC) 
 Material and Methods 
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3.2 Methods 
 
3.2.1 Mammalian cell culture methods 
 
3.2.1.1 Cultivation of mammalian cells 
Mammalian  cells were grown  in Dulbecco’s  Modified Eagle  Medium (DMEM), 
supplemented  with  10%  fetal  calf  serum  and  5 µg/l  penicillin  and  5 mg/l 
streptomycin (DMEM-FCS-P/S). The cells were incubated with 5% CO2 in 95% 
humidity at 37° C. Cells were passaged by trypsinisation (0.05% (w/v) Trypsin, 
0.5 mM EDTA in PBS) for 2-3 minutes at 37° C.  
 
3.2.1.2 Transfection of mammalian cells 
Mammalian cells were transfected using GenejuiceTM or FugeneHDTM. 3x105 Cells 
were seeded into a dish with a diameter of 3.5 cm one day before transfection. 
Usually 1 µg of DNA was mixed with the recommended amount of transfection 
reagent and 100 µl of DMEM and the mix was added to the cells.  
 
3.2.1.3 Viral transduction of cells and generation of MEFs stably expressing 
transduced genes 
In order to produce viral particles containing the gene of interest Ecotrophic 
Phoenix  retroviral  packaging  cells  (ATCC)  were  transfected  with  pBABE-
plasmids in which the gene was integrated. After 36-48 h the supernatant (2 ml) 
containing the virions was removed and filtered through a sterile filter with a 
pore size of 0.4 µm, which allows the virions to pass through. 500 µl of virion-
containing medium was added to the MEFs that were seeded the day before in a 
dish with 3.5 cm diameter. The cells were incubated with the virions over night 
and the medium was exchanged the next day with DMEM-FCS-P/S. When the 
cells reached 90% confluency they were trypsinised and seeded in 10 ml DMEM-
FCS-P/S and 3.5 mg/ml puromycin to select cells that have the plasmid stably Material and Methods 
 
 
  46 
integrated into their genome. Positive selected cells were constantly kept under 
selection pressure with puromycin containing DMEM-FCS-P/S.  
 
3.2.1.4 Cell lysis 
Mammalian  cells from cell cultures  were  lysed by adding chilled lysis  buffer. 
Lysed cells were collected in a 1.5 ml tube and centrifuged for 15 min at 16,000 
rcf  to  remove  aggregates  and  membrane  particles.  The  supernatant  was 
transferred to another tube and used either for Western blot analysis, pull-down 
assays or immunoprecipitation.  
 
3.2.2 Molecular biology techniques 
 
3.2.2.1 Agarose gel electrophoresis  
DNA fragments were separated with 0.5% to 2% agarose gels according to their 
size. For preparation of the gels agarose was solubilised in 1x TAE buffer and 
heated in the microwave. Before loading the sample on the gel 6x concentrated 
loading  buffer  was  added.  For  running  the  gel  electrophoresis  the  gels  were 
embedded in 1x TAE and run at 100 Volt for 30 min. In order to visualize the 
DNA the gel was put in an ethidium bromide containing solution for 15 min and 
afterwards illuminated with UV-light.  
 
3.2.2.2 DNA fragment amplification with PCR 
DNA  fragments  of  interest  were  amplified  using  polymerase  chain  reaction 
(PCR). PCR was performed in a Biometra thermocycler using Pfu or PWO DNA 
polymerases.  A  typical  reaction  contained  10 ng  template  cDNA,  10 pmol  of 
primer-oligonucleotides  and  0,5 µl  of  enzyme  in  a  total  volume  of  50 µl.  35 
reaction  cycles  were  applied  using  annealing  temperatures  suitable  for  the 
primer and elongation time suitable for the DNA fragment length. 1 µl of 6x DNA-
sample loading buffer was added to 5 µl of the PCR-product and the DNA was 
separated with an agarose gel and visualised with ethidium bromide staining. Material and Methods 
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3.2.2.3 Restriction digestion of plasmids and PCR-fragments 
20 µl of purified PCR-product or 3 µg of vector or 1 µg of extracted plasmid from 
a  ligation  was  digested  in  a  volume  of  50 µl  using  buffer  and  restriction 
conditions as suggested by the manufacturer. The reaction was stopped by the 
addition  of  6X  DNA-sample  buffer.  Restricted  PCR  products  or  vectors  were 
purified with the QIAquick PCR purification kitTM and eluted in 40 µl distilled 
water (GIBCO).  
 
3.2.2.4 Ligation of DNA fragments 
In order to ligate two DNA fragments usually 4 µl of restriction enzyme digested 
and purified vector and PCR-product were incubated with T4-DNA ligase in 10 µl 
reaction volume for 1 h at RT or at 16° C o/n. For plasmid amplification E. coli 
bacteria  of  the  DH5a  strain  were  transformed  with  10 µl  of  the  mutagenesis 
reaction. 
 
3.2.2.5 Site directed mutagenesis of plasmid DNA 
DNA  primer  with  the  corresponding  mutations  were  used  to  create  point 
mutations in plasmids in a PCR reaction with usually 18 min elongation time in a 
50 µl reaction volume. In order to remove methylated template DNA 1 µl of DpnI-
restriction enzyme was added to the finished PCR-reaction and incubated for 1 h 
at  37° C.  For  plasmid  amplification  E.  coli  bacteria  of  the  DH5α  strain  were 
transformed with 10 µl of the mutagenesis reaction. 
 
3.2.2.6  Exchange  or  insertion  of  larger  DNA  fragments  with  mega-
mutagenesis primers 
The insertion or exchange of the NZF-domain in NEMO was done by site directed 
mutagenesis using mega-mutagenesis primers. Mega-mutagenesis primers were 
produced by PCR using the human NZF-domain as template (aa 663-693) with 
oligonucleotides that contain the complementary NZF-sequence followed by the 
sequence of the site of insertion of the NEMO plasmid. 
 Material and Methods 
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3.2.2.7 E. coli transformation with plasmid DNA  
Competent E. coli strains DH5a or BL21 were transformed with plasmid DNA by 
heat  shock.  0.5 µg,  10 µl  of  a  mutagenesis  PCR  or  10 µl  of  a  ligation  were 
incubated on ice with 50-100 µl of competent bacteria for 10 min. Heat shock 
was performed for 90 seconds at 42° C. Immediately after the heat shock one ml 
of LB medium was added to the bacteria and the cells were mixed at 37° C for 
1 h. The cells afterwards plated on LB-agar plates with the appropriate selection 
medium (100 µg/ml Ampicillin or 25 µg/ml Kanamycin).  
 
3.2.2.8 Plasmid extraction from bacterial cells 
Plasmids from bacterial cells were isolated using Miniprep or Midiprep kits from 
Qiagen. DNA from a miniprep was eluted with 40 µl distilled H2O. DNA from a 
midiprep was washed in 70% ethanol and resuspended in 100 µl distilled H2O. 
  
3.2.2.9 RNA isolation and cDNA production 
Total RNA was isolated with the RNeasy Mini Kit (Qiagen) from MEFs grown in a 
dish with a  diameter of 3.5 mm having a  confluency of ~90%. The  RNA was 
eluted in distilled H2O and the concentration was measured photometrically. To 
assess the quality of the RNA 2 µg were separated on a 1% agarose gel and the 
RNA was used for further experiments only if the 28S and the 18S rRNA were not 
degraded.  
To remove DNA contaminations 2 µg of RNA were treated with 1 µl of DNaseI 
(Fermentas) with the appropriate buffer in a 20 µl reaction volume at 37° C for 
30 min. In order to inactivate the DNaseI 1 µl of 25 mM EDTA was added to 
remove MgCl2 and the reaction was heated for 10 min with 65° C. 
To produce cDNA, 2 µg DNaseI treated RNA was incubated with 2 µg of random 
hexamer primer in a reaction volume of 20 µl, denatured for 5 min with 70° C 
and briefly chilled on ice. Subsequently 2 µl of RiboLock Ribonuclease inhibitor 
(Fermentas) and 4 µl of 10 mM dNTPs were added to a total volume of 39 µl and 
the reaction was incubated at RT for 5 min. 1 µl reverse transcriptase was added 
and the reaction was incubated for 10 min at 25° C and then for 60 min at 42° C. Material and Methods 
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Afterwards the reaction was stopped by increasing the temperature to 70° C for 
10 min. 
 
3.2.2.10 Quantitative Real-time PCR 
qPCR was done using the SensiMixTM real-time PCR-kit (Bioline). 40 ng of cDNA 
were mixed with the appropriate amount of SensiMixTM real-time PCR-kit SYBR® 
green mix and 200 mM primer-oligonucleotides in a total volume of 10 µl.  
The following program was used for quantitative PCR: 
 
Initial denaturation   95° C, 10 min 
            Denaturation  95° C, 15 sec 
            Annealing        55° C, 20 sec 
            Elongation       72° C, 30 sec 
 
3.2.3 Biochemical methods 
 
3.2.3.1 SDS-PAGE 
To separate proteins electrophoretically according to their molecular weight the 
denaturating  SDS  polyacrylamid  gel  electrophoresis  (SDS-PAGE)  was  used. 
Resolving gels that were used had concentrations of 8-15% of acrylamid. Before 
loading samples were incubated with 2x SDS-PAGE sample buffer for 5 min at 
95° C (ubiquitin chains were not boiled and ubiquitin pull-downs were boiled for 
2 min).  The  electrophoresis  was  done  using  SDS-PAGE  running  buffer  and 
voltage ranging from 80 (stacking gel) to 120 volt (resolving gel). 
 
3.2.3.2 Coomassie staining 
To stain proteins with Coomassie a SDS-PAGE gel was incubated in Coomassie 
brilliant  blue  staining  solution  for  4 h  to  o/n  and  afterwards  incubated  in 
Coomassie brilliant blue destaining solution for ~1 h.  
  Material and Methods 
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3.2.3.3 Western blot 
To detect specific proteins with antibodies they were separated by SDS-PAGE 
and  transferred  onto  either  a  nitrocellulose  membrane  with  a  pore  size  of 
0.45 µM (cell lysates) or onto a PVDF membrane (in vitro ubiquitin pull-down 
assays). Transfer was done in a wet electroblot system (Mino Trans-blot cell, 
Bio-rad), for 90 min with 90 volt in WB transfer buffer. The membranes were 
stained with Ponceau S to assess amount of GST- or MPB- fusion proteins used 
for pull-down assays. To block unspecific antibody binding sites the membranes 
were  incubated  for  1 h  at  RT  or  o/n  at  4° C  in  WB  blocking  solution.  The 
membranes  were  incubated  with  primary  antibodies  diluted  in  WB  blocking 
solution o/n at 4° C or for 2-4 h at RT. Afterwards the membranes were washed 
4x for 15 min in TBS-Tween and incubated with secondary antibody (coupled 
with horseradish peroxidase [HRP]) diluted in 5% milk in TBS for 45 min. The 
membranes  were  washed  4x  for  15 min  in  TBS-Tween  and  incubated  in 
chemiluminescence luminol reagent (Santa Cruz) for 1 min. A photosensitive film 
was laid on the membrane to visualise proteins bound to antibodies. 
 
3.2.3.4 Concentration measurement of purified proteins 
The  concentration  of  purified  recombinant  proteins  was  measured 
photometrically at a wavelength of 280 nm, which corresponds to the absorption 
spectrum of the aromatic amino acids tryptophan and tyrosin. In order to get the 
exact concentration of the protein its extinction coefficient and molecular weight 
had  to  be  correlated  to  the  measured  value.  The  extinction  coefficient  was 
determined with the ProtParam software (http://web.expasy.org/protparam/). 
The measured value was divided by the quotient of the extinction coefficient and 
the molecular weight of the measured protein. 
 
Conc.  (mg/ml)  =  conc.  Measured  (mg/ml)/[extinction  coefficient/  molecular 
weight]  
 Material and Methods 
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3.2.3.5 Recombinant protein purification 
In order to purify GST-, MBP- or 6xHis-tagged recombinant proteins a 5 ml LB-
culture  (+  ampicillin  or  kanamycin)  of  BL21  E.  coli  bacteria  containing  the 
plasmid that encodes the recombinant protein was grown at 37° C o/n. The next 
day  the  culture  was  transferred  to  a  0.2–2 l  LB  medium  (+  ampicillin  or 
kanamycin) and grown at 37° C to an OD of ~0.6- 0.8 photometrically measured 
at a wavelength of 600 nm. Protein expression was induced with 0.1 mM IPTG 
and  the  culture  was  grown  at  16° C  o/n.  The  cells  were  harvested  by 
centrifugation for 20 min at 5,500 rcf and 4° C. The cells were resuspended in 20-
40 ml GST-buffer1 and lysed by sonication with 100% amplitude for 2 min with 
impulses of 1 sec on and 1 sec off. Triton X-100 with a final concentration of 
0.5% was added and the lysates were centrifuged for 20 min at 10,000 rcf and 
4° C. The supernatant containing the proteins was filtered through a filter with a 
pore size of 0.4 µm and glutathione sepharose beads (GST-tag), amylose beads 
(MBP-tag) or Ni-NTA beads (His-tag) were washed with 1x PBS and added to the 
lysates. The beads were incubated for 1-2 h and washed 3x in 30 ml GST-buffer2. 
Finally the beads were resuspended in 500 µl GST-buffer3 and stored at 4° C. In 
order to assess the quality of the purified proteins 5 µl of the beads suspension 
was separated by SDS-PAGE and visualised by Coomassie staining.  
 
3.2.3.6 Cleavage of recombinant proteins with PreScissionTM protease 
The E2 Ubc13 and Uev1a were inserted in the vector pGEX-6P-1 (GE healthcare) 
that contains a PreScissionTM protease (GE healthcare) cleavage site between the 
GST gene and the multiple cloning site. GST-Ubc13 and GST-Uev1a were purified 
as  described  in  3.2.3.5.  The  purified  GST-proteins  were  incubated  with  the 
recommended  amount  of  PreScissionTM  protease  in  PreScissionTM  protease 
cleavage buffer at 4° C for 16 h under rotation in 1 ml reaction volume. Since the 
proteins were cleaved while they were coupled to the glutathione beads and the 
protease also has a GST-tag, which immobilises it to the beads, the supernatant 
of  the  cleavage  reaction  only  contained  the  cleaved  protein.  The  beads  were 
loaded on a PD-10 column to obtain a complete separation of the supernatant 
and the beads. 3x 1 ml cleavage buffer was added to the beads on the column and Material and Methods 
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the  flow  through  was  collected  combined  with  the  first  flow  through  and 
concentrated  with  a  protein  concentrator  with  a  cut  off  of  10  kDa  to  a  final 
concentration of ~2 mg/ml. The proteins were shock frozen in liquid nitrogen 
and stored at -80° C. 
  
3.2.3.7 Production of linear ubiquitin chains 
Linear  ubiquitin  chains  were  first  purified  as  GST-di,  tri-  and  tetraUb  as 
described in 3.2.3.5. The ubiquitin gene sequences were inserted in the vector 
pGEX-4T-1, which has a thrombin protease restriction site between the GST-gene 
and the multiple cloning site. In order to cleave the ubiquitin chains from the 
GST-tag, the beads containing the fusion protein were incubated with thrombin 
protease according to the instructions of the provider in 1x PBS for 16 h at RT. 
The reaction was stopped by addition of the serine protease inhibitor PMSF to a 
final concentration of 1 µM. The separation of the cleaved ubiquitin chains in the 
supernatant  from  the  beads  was  done  as  described  for  the  separation  of 
PreScissionTM protease cleaved proteins in 3.2.3.6.  
 
3.2.3.8 Lysine linked ubiquitin chain production  
 
3.2.3.8.1 polyubiquitin chain reaction in vitro 
Lysine linked polyubiquitin chains were produced in vitro using the following 
reaction compositions.  
 
K63-linked ubiquitin chains: 
1.4 mM ubiquitin (Sigma-Aldrich) 
10 mM ATP 
1 µM E1 enzyme 
8 µM E2 Ubc13 
8µM E2 Uev1a 
1x Ubiquitin chain reaction buffer 
ad 1 ml H2O  
K48-linked ubiquitin chains: 
2.8 mM ubiquitin (Sigma-Aldrich) 
10 mM ATP 
1 µM E1 enzyme 
25 µM E2 cdc34 
1x Ubiquitin chain reaction buffer 
ad 1 ml H2O Material and Methods 
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E1  enzyme  was  a  kind  gift  from  David  Komander  and  was  produced  in  and 
purified from insect cells. GST-Uev1a and GST-Ubc13 were bacterially purified 
and cleaved with PreScissionTM protease. 
Reactions  were  incubated  for  4 h  at  37° C  and  controlled  by  SDS-PAGE  and 
Coomassie staining of 0.1% of the reaction.  
 
3.2.3.8.2 Purification of polyubiquitin chains by cationic exchange 
In order to purify and separate the polyubiquitin chains according to their length 
the finished polyubiquitin chain reaction was first diluted with 50 mM NH4Ac, 
pH 4.5  to  25 ml  and  left  on  ice  for  10 min  to  precipitate  the  enzymes.  The 
ubiquitin chain dilution was loaded on a Mono S 5/50 GL (GE healthcare) column 
using the Äkta purifier system (GE healthcare). In order to separate the ubiquitin 
chains  according  to  their  size  the  bound  ubiquitin  was  eluted  with  a  linear 
gradient from 0 to 50% high salt buffer (50 mM NH4Ac, pH 4.5, 1 M NaCl) over 
180 column volumes. The elution of ubiquitin was monitored with UV-light at a 
wavelength of 230 nm. Fractions corresponding to a peak containing ubiquitin 
chains of a certain length were analysed by SDS-PAGE and Coomassie staining 
and pooled. Pooled fractions were concentrated with a sample concentrator with 
3 kDa cut off (Vivaspin GE healthcare). To exchange the buffer the samples were 
diluted and concentrated 3x with 15 ml of 50 mM Tris, pH 7.6. Ubiquitin chains 
were stored at -80° C. 
 
3.2.3.9 (Co-)Immunoprecipitation 
The interaction of endogenous proteins was studied using immunoprecipitation 
combined with SDS-PAGE and Western blot analysis. Cell lysates were incubated 
with an antibody raised against the protein of interest with a ratio of 1 :100 o/n 
at 4° C. The next day the cell lysates were incubated with Protein A/G-sepharose 
beads for 1 h. The beads were washed 3x in lysis buffer and bound proteins were 
eluted  with  25-50 µl  of  SDS-PAGE  sample  buffer.  The  immunoprecipitated 
proteins were analysed by SDS-PAGE and Western blot with antibodies against 
the directly immunoprecipitated or against co-immunoprecipitated proteins.  Material and Methods 
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 3.2.3.10 MBP- and GST- pull-down assays 
In  order  to  investigate  the  interaction  of  proteins  with  ubiquitin  10-20 µg  of 
immobilised  MBP-  or  GST-tagged  bacterially  expressed  and  purified 
recombinant proteins were incubated with 1 µg of ubiquitin in pull-down buffer 
on a rotator o/n at 4° C. In order to ensure incubation with equal amounts of 
ubiquitin a pull-down buffer/ubiquitin mix was prepared and the same amount 
of mix was added to each immobilised protein used for a certain experiment. 
After  incubation  the  beads  were  3x  centrifuged  at  300  rcf  and  washed  with 
500 µl pull-down buffer without BSA. The bound proteins were eluted with 50 µl 
SDS-PAGE  sample  buffer  and  analysed  by  SDS-PAGE  and  either  Coomassie 
staining or Western blot. The usage of equal amounts of immobilised proteins 
was confirmed by staining the PVDF membranes with Ponceau S or the proteins 
were detected by probing with a specific antibody in a Western blot. 
 
3.2.3.11 Nuclear extraction 
Nuclei of MEFs were isolated by first lysing a 90% confluent 3.5 cm dish with 
600 µl hypotonic buffer. Cells were transferred to a 1.5 ml tube and in order to 
burst the cell membrane cells were incubated with hypotonic buffer on ice for 15 
min. Samples were centrifuged for 1 min at 16,000 rcf to harvest intact nuclei 
and the supernatant containing the cytoplasm was transferred to another 1.5 ml 
tube. To remove traces of cytoplasm the nuclei were washed 2x with 500 µl of 
hypotonic buffer and centrifuged at 16,000 rcf. After the last wash the pelleted 
nuclei  were  lysed  in  30 µl  hypertonic  buffer  and  incubated  for  30 min.  The 
lysates were centrifuged for 5 min at 16,000 rcf and the supernatant containing 
the nucleoplasma was collected. 
 
3.2.4 Confocal laser scanning microscopy 
Cells  were  grown  on  cover  slips  under  conditions  described  in  3.2.1.1.  After 
treatment  cells  were  fixed  in  2%  PFA  and  mounted  on  mounting  media 
containing  DAPI  (1:1000).  Images  were  taken  by  Carl-Zeiss  510 UV  confocal 
microscope with 400 times magnification. Results 
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4. Results 
 
4.1 In vitro production and purification of K48- and K63- linked ubiquitin 
chains 
An important aim of this study was to thoroughly analyse the interaction 
of NEMO with different types of ubiquitin chains and to investigate how these 
interactions influence the activation of NF-B. For the biochemical interaction 
analysis it was necessary to  first produce sufficient amounts of polyubiquitin 
chains.  Linear  linked  ubiquitin  chains  were  expressed  in  and  purified  from 
bacteria as described in (3.2.3.7). However, it is not possible to produce lysine-
linked  ubiquitin  chains  this  way,  since  they  cannot  be  genetically  encoded. 
Instead K48- and K63- linked ubiquitin chains were synthesised in an enzymatic 
reaction in vitro (protocol modified from115). In order to obtain polyubiquitin 
chains with a certain linkage type, bacterially purified ubiquitin conjugating E2 
enzymes that specifically produce only one ubiquitin chain type, were used. 
 
4.1.1 Production and purification of K48-linked ubiquitin chains 
K48-linked polyubiquitin chains were produced by incubating 25 mg of 
monoubiquitin with the ubiquitin activating enzyme E1 and the E2 cdc34, which 
specifically catalyses the conjugation of the C-terminus of one ubiquitin to the 
lysine 48 of another ubiquitin116. In order to assess the quality of the chains 
produced by this  reaction 1% of the reaction volume was separated by SDS-
PAGE and the gel was stained with Coomassie, which visualised a ladder of K48-
linked ubiquitin chains with defined length, ranging from diUb to tetraUb, as well 
as higher molecular weight polyubiquitin chains of undefined length (Figure 6A). 
Since for the interaction experiments it was necessary to have isolated ubiquitin 
chains  of  defined  length,  K48-linked  ubiquitin  chains  of  mixed  length  were 
separated by cationic exchange. Eluted ubiquitin chains were measured with UV-
light at a wavelength of 230 nm and fractions corresponding to a single peak on 
the  chromatogram  contained  chains  with  the  same  length  (Figure  6B).  The 
fractions  containing  K48-linked  ubiquitin  chains  with  two  or  four  ubiquitin Results 
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molecules  or  monoubiquitin  were  pooled,  concentrated  and  the  purity  was 
checked by SDS-PAGE and Coomassie-staining (Figure 6C). This confirmed that 
K48-linked  di-  and  tetraUb  were  separated  sufficiently  to  perform  binding 
studies with these ubiquitin chains. 
 
Figure 6: Synthesis and purification of K48-linked ubiquitin chains. A) 1% of an 
in vitro reaction to produce K48-linked ubiquitin chains was separated by SDS-PAGE 
and the gel was stained with Coomassie. B) Chromatogram of eluted ubiquitin chains 
by cationic exchange from a MonoS 50/5 column. Peaks represent fractions with a 
K48-linked  chain  of  defined  length.  C)  Coomassie  stained  SDS-PAGE  gel  with 
purified and concentrated K48-linked ubiquitin chains. 
 
 
4.1.2 Production and purification of K63-linked ubiquitin chains 
The production of K63-linked ubiquitin chains followed principally the 
same procedure as with the K48-linked chains. The E2s used to produce K63-
linked chains were Ubc13 and Uev1a, which form a heterodimer that specifically 
synthesises this type of chains79. The fractions containing K63-linked chains of 
the same length, judged by the peaks of the elution chromatogram, were pooled, 
concentrated and buffer exchanged (Figure 7A). Afterwards the samples were 
separated by SDS-PAGE and visualised by Coomassie staining (Figure 7B). This 
revealed  a  purity  of  the  K63-linked  chains  from  di-  to  heptaUb  sufficient  for 
in vitro  interaction  studies.  The  fractions  that  contained  chains  of  different 
lengths were also pooled and concentrated to obtain K63-linked ubiquitin chains 
of mixed lengths (Figure 7B, lane 8). 
 Results 
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Figure  7:  Synthesis  and  purification  of  K63-linked  ubiquitin  chains.  A) 
Chromatogram of eluted ubiquitin chains by cationic exchange from a MonoS 50/5 
column.  Peaks  represent  fractions  with  K63-linked  chains  of  defined  length.  B) 
Coomassie  stained  SDS-PAGE  gel  with  purified  and  concentrated  K48-linked 
ubiquitin chains. 
 
 
4.2 Analysis of the interaction mode of NEMO with polyubiquitin chains 
 
4.2.1 Analysis of the interactions of full-length NEMO and NEMO domains 
with different types of tetraUb 
It  is  known  that  NEMO  can  interact  with  ubiquitin  and  that  this 
interaction  is  important  for  its  function  as  a  regulator  of  the  NF-B 
pathway102, 111, 117. It has been proposed, that NEMO selectively interacts with 
K63-linked ubiquitin chains, however a detailed analysis of the ubiquitin chain 
binding  preference  of  full-length  NEMO  hasn’t  been  done.  In  order  to  better 
understand the interaction of NEMO with ubiquitin, it is essential to analyse in 
detail how full-length NEMO and certain NEMO domains interact directly with 
different  types  of  ubiquitin  chains.  To  this  end  in  vitro  binding  studies  with 
bacterially  purified  recombinant  NEMO  proteins  and  K48-,  K63-  and  linearly 
linked tetraUb chains were performed (Figure 8). The binding of GST-full-length 
NEMO as well as the UBAN, the ZnF and the C-terminus (comprising the UBAN 
and the zinc finger (ZnF)) of NEMO to different types of ubiquitin chains was 
compared  (Figure  8A).  The  ZnF  of  NEMO  has  been  shown  to  bind  monoUb, Results 
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though with a rather low Kd of ~250 µM118. However, when the interaction of 
tetraUb  with  the  ZnF  of  NEMO  was  assessed  in  pull-down  experiments,  no 
interaction of the GST-ZnF with all types of tetraUb chains tested was observed 
(Figure 8B). The UBAN domain has recently been identified as a UBD in ABIN-
proteins and, with high sequence homology, also in the proteins optineurin and 
NEMO98, 99 (Figure 5B). In agreement, a region comprising the UBAN has been 
shown to be important for the interaction of NEMO with ubiquitin111. In order to 
analyse  the  interaction  of  the  NEMO-UBAN  with  ubiquitin  in  more  detail, 
purified GST-UBAN was incubated with different types of tetraUb. In accordance 
with previous interaction studies111, 117, the UBAN of NEMO strongly interacted 
with  ubiquitin  chains  (Figure  8B).  However,  in  contrast  to  aforementioned 
studies,  reporting  a  selective  binding  to  K63-linked  ubiquitin  chains,  this 
interaction showed strong chain type selectivity towards linear tetraUb while 
interaction with K63-linked tetraUb was extremely weak and only visible after 
very long exposure of the film (Figure 11B). The C-terminus of NEMO interacted 
with  linear  tetraUb  with  a  similar  strength  as  the  UBAN.  Interestingly,  the 
C-terminus  also  interacted  with  K63-  and  K48-linked  tetraUb,  although  the 
interaction was weaker than with linear tetraUb. The increase in affinity of the 
C-terminus of NEMO towards lysine-linked ubiquitin chains in comparison to the 
UBAN alone was not surprising, since Laplatine et al. could show that the whole 
C-terminus of NEMO has a higher affinity towards K48- and K63-linked tetraUb 
than the isolated UBAN domain, when analysed in a fluorescence spectroscopy 
assay119. In line with this, similar binding strengths of the C-terminus to K48- and 
K63-linked  tetraUb  were  observed  (Figure  8B;  binding  in  comparison  to  the 
input), suggesting that the C-terminus has only weak binding selectivity towards 
K63-  and  K48-linked  ubiquitin  chains.  When  the  binding  of  full-length  GST-
NEMO was analysed, it revealed that the binding of K63- and K48-linked tetraUb 
was  rather  weak.  On  the  other  hand,  full-length  NEMO  showed  a  strong 
interaction  with  linear  tetraUb,  indicating  a  selective  binding  mechanism 
towards linear ubiquitin chains of full-length protein. 
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Figure 8: Analysis of the interaction of NEMO with ubiquitin. A) Schematic model 
of recombinant  NEMO  peptides  fused with  GST. Full-length  NEMO or indicated 
domains  were  fused  with  GST  and  expressed  in  and  purified  from  bacteria.  B) 
Interaction of NEMO and NEMO-domains with different types of tetraUb. 1 µg of 
linear, K63- or K48-linked tetraUb were incubated with the indicated recombinant 
GST-tagged NEMO peptides, that were bound to glutathion-sepharose beads and a 
pull-down assay was performed. Bound proteins were eluted with SDS-sample buffer 
and  separated  by  SDS-PAGE.  Ubiquitin  was  visualised  by  Western  blot  analysis. 
IKK-BM, IKK-binding motif; CC, coiled coil; FL, full-length; ZnF, zinc finger. 
 
 
Since the previous interaction studies revealed a rather weak interaction of full-
length NEMO with K63-linked tetraUb (Figure 8B), the interaction of NEMO with 
longer K63-linked ubiquitin chains was assessed. To this end, full-length NEMO 
was  incubated  with  K63-linked  chains  of  mixed  length  and  pull-down  assays 
were performed (Figure 9). Interestingly, only longer K63-linked ubiquitin chains Results 
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of unclear length bound efficiently to GST-full-length NEMO, while shorter chains 
only weakly interacted with full-length NEMO. This is consistent with previous 
studies, where also only longer K63-lined chains bound efficiently to NEMO, but 
shorter chains, as tetraUb, did not111, 117. Results in Figure 8 and Figure 9 together 
show that full-length NEMO is not a strong and efficient binder of K63-linked 
chains,  but  only  very  long  chains  seem  to  bind  NEMO  more  potently.  This 
indicates  that  the  interaction  of  full-length  NEMO  with  K63-linked  chains  is 
rather unspecific, while already linear tetraUb strongly interacts with full-length 
NEMO. Moreover, the interaction between all NEMO domains and linear tetraUb 
is much stronger than with K63- and K48-linked tetraUb (Figure 8B). 
 
 
Figure 9: Full-length NEMO interacts 
preferentially  with  longer  K63-linked 
ubiquitin chains than with K63-linked 
tetraUb.  Mixed  K63-linked  ubiquitin 
chains  were  incubated  with 
immobilized  GST-NEMO  and  GST-
pull-down  assays  were  performed. 
Bound proteins were eluted with SDS-
sample buffer and separated by SDS-
PAGE.  Ubiquitin  was  visualised  by 
Western blot analysis. 
 
 
4.2.2 Binding selectivity of NEMO to linear ubiquitin is determined by an 
unconventional ubiquitin interaction surface 
An important method to determine the interaction mode of proteins is the 
structural analysis of a crystal of these proteins in complex. Since NEMO seems 
to interact preferentially with linear ubiquitin chains and this interaction seems 
to depend on the UBAN, a co-crystal structure of the NEMO-UBAN and linear 
diUb should shed light on the nature of this strong interaction. In a collaborative 
effort Prof. Soichi Wakatzuki and his co-workers were able to solve the co-crystal 
structure of the mouse NEMO-UBAN and linear diUb, which revealed a novel Results 
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modus of how ubiquitin interacts with a UBD99 (Figure 10A). The UBAN of NEMO 
forms a coiled-coil dimer and one diUb molecule binds to each side of the dimer 
in an almost symmetrical fashion. The distal ubiquitin with the free N-terminus 
in the linear diUb molecule binds the UBAN at its N-terminal part, thus called the 
distal patch (the distal ubiquitin makes a peptide bond with the N-terminus of 
the proximal ubiquitin, which has a free C-terminus that could be ligated to a 
substrate). The proximal ubiquitin moiety interacts with the, so-called proximal 
patch of the UBAN, which is at the C-terminal end of the UBAN-domain. 
 
 
Figure 10: Co-crystal structure of the NEMO-UBAN and linear diUb. A) Structure of 
the UBAN-homodimer in complex with two linear diUb molecules. B) Schematic 
diagram of the interaction of the distal and the proximal ubiquitin with the UBAN-
domain.  Residues  circled  in  red  are  found  mutated  in  patients  with  ectodermal 
dysplasia and interact with residues of either the distal or the proximal ubiquitin. The 
crystal structure was obtained in the lab of Prof. Wakatsuki, Tokyo, Japan
99. 
 
 
The distal ubiquitin binds mainly via hydrophobic residues of the classical UBD 
interacting I44 patch to hydrophobic regions of the N-terminal part of the UBAN 
(Figure 10B). Interestingly, the proximal ubiquitin binds to the more C-terminal 
part of the UBAN in a novel fashion, involving residues around the linker region. 
This includes residues R72 and R74 of the distal moiety and Q2, E16, T14, E64, Results 
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T12 and G10 of the proximal moiety, which engage mainly in polar interactions 
with residues R309, R312, E313, E117 and E120 of the UBAN. These residues 
around the linker of linear diUb are crucial for the interaction with NEMO, since 
mutating R72, R74 and Q2 could inhibit the binding99. This explains the high 
binding  selectivity  of  the  UBAN  towards  linear  ubiquitin  chains,  since  the 
proximal patch of the UBAN interacts with certain residues of the proximal and 
the distal moiety and these residues are only in the right orientation for UBAN 
interaction with a linear linkage, leading to a higher affinity. Moreover, the co-
crystal  structure  of  the  UBAN  in  complex  with  K63-linked  diUb  explains  the 
weak binding to this type of chains120 (Figure 20B). The distal moiety of K63-
linked diUb also interacts with its hydrophobic patch with the distal patch of the 
UBAN. However, the UBAN cannot bind the linker region in K63-linked diUb, 
which  means  there  is  only  one  interaction  site  between  the  UBAN  and  K63-
linked diUb. In conclusion, the high affinity of linear ubiquitin towards the UBAN 
is enabled by a second binding site at its linker region and this binding is only 
possible with this type of chain and gives this binding a high selectivity. 
To confirm the  interaction  modes  discovered in the  crystal structure, certain 
amino acid residues of the UBAN and ubiquitin were analysed biochemically for 
their importance  for the  interaction. Derived from the  co-crystal structure  of 
NEMO with linear diUb several residues were chosen and mutated to alanine, 
using site directed mutagenesis. Work done by colleagues in the lab revealed 
that bacterially purified GST-UBAN interacts with linear diUb but not with K63-
linked diUb99. This interaction with linear diUb was lost when the amino acids 
V293, Y301 and K302 were mutated. These residues are part of the distal patch 
of the UBAN, which binds to the distal ubiquitin in diUb molecules and they are 
also important for the interaction with K63 and linear tetraUb99 (Figure 10B). 
When the residues R309, R312 and E313 were mutated the interaction to linear 
di- and tetraUb was lost while the interaction with K63-linked tetraUb was still 
intact,  indicating  a  qualitatively  different  binding  mode.  In  order  to  further 
investigate the ubiquitin binding relevance  of UBAN residues in the proximal 
patch, which is important for the selective high affinity interaction with linear 
ubiquitin, a UBAN mutant where only residue E313 was mutated to alanine was Results 
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used  for  interaction  studies  (Figure  11).  This  revealed,  that  this  single  point 
mutation  was  sufficient  to  abrogate  the  interaction  between  GST-UBAN  and 
linear diUb, emphasising the  importance  of the  proximal  UBAN-patch for the 
selective interaction with linear ubiquitin chains (Figure 11A). The next question 
was if the mutation of residue E313 inhibited the interaction of the UBAN with 
ubiquitin  in  general  or  if  residue  E313  is  of  specific  importance  for  the 
interaction with linear ubiquitin chains. Since the UBAN doesn’t interact on a 
detectable  level  with  K63-linked  diUb  using  GST-pull-downs,  but  a  weak 
interaction is observed for K63-linked tetraUb, these longer K63-linked chains 
were used for this analysis. K63-linked tetraUb chains were incubated with GST-
wild-type UBAN and various UBAN mutants and pull-down experiments were 
performed (Figure 11B). This showed, that the triple mutant V293A, Y301A and 
K302A, as well as the mutant F305A blocked the binding of the UBAN to K63-
linked  tetraUb.  These  are  all  residues  in  the  UBAN  that  bind  to  the  distal 
ubiquitin. In contrast a mutation in residue E313 didn’t inhibit the interaction of 
the  GST-UBAN  to  this  ubiquitin  chain  type.  This  shows,  that  a  single  point 
mutation in the part of the UBAN that binds to the proximal ubiquitin of linear 
diUb is sufficient to selectively block this interaction, while this mutant is still 
able to bind with low affinity to K63-linked tetraUb.  
 
 
Figure 11: UBAN residue E313 is important for the interaction with linear diUb but 
not with K63-linked tetraUb. A) 1 µg linear diUb was incubated with the indicated 
recombinant  GST-tagged  NEMO  peptides,  that  were  immobilised  on  glutathion-
sepharose beads and a GST-pull-down assays were performed. Bound proteins were Results 
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eluted  with  SDS-sample  buffer  and  separated  by  SDS-PAGE.  Ubiquitin  was 
visualised by Western blot analysis. B) 1 µg K63-linked tetraUb was incubated with 
the  indicated  recombinant  GST-tagged  NEMO  peptides  and  GST-pull-down  and 
Western blot analysis were performed as in A. *Background from GST-proteins. 
 
 
4.3 A competitive interaction study reveals preferential interaction of full-
length NEMO with linear ubiquitin chains  
The results shown above, together with structural data, indicate that the 
UBAN  needs  at  least  two  interaction  sites  to  efficiently  bind  ubiquitin99,  120 
(Figure 10 and Figure 11). This is suggested since both, the binding of K63-linked 
diUb with the wild-type UBAN or linear linked tetraUb with the UBAN that is 
mutated at one patch, and thus can only interact with the other patch, doesn’t 
seem to be sufficient for a high affinity interaction. On the other hand, K63-linked 
tetraUb does interact with the wild-type UBAN, indicating that this longer K63-
linked chain has an additional binding site with this UBD. Linear diUb has a up to 
100 times higher affinity towards the UBAN than diUbs of other chain types and 
also  linear  tetraUb  shows  stronger  interaction  with  NEMO  than  other  chain 
types99,  101,  102  (Figure  8).  However,  the  UBAN  combined  with  the  ZnF  has  a 
higher affinity towards K63 and K48-linked tetraubiquitin than the UBAN alone, 
possibly by providing an additional binding site (Figure 8). In line with this, it 
was also shown, in a fluorescence spectroscopy based interaction study, that the 
C-terminus of NEMO, containing the UBAN and the ZnF, has a higher affinity 
towards  longer  K63-  and  K48-linked  ubiquitin  chains  compared  to  the  diUb 
variant of each chain type119. If longer lysine linked chains have an additional 
binding  site  with  NEMO,  increasing  their  affinity,  the  question  is,  if  NEMO 
preferably binds to lysine linked chains or to linearly linked ubiquitin chains that 
have  also  two  binding  sites  with  the  UBAN  in  a  longitudinal  orientated 
interaction (Figure 10A). Since it seems that most, if not all types of ubiquitin 
chains have to bind to the distal patch of the UBAN to be able to interact with 
NEMO99, 120 (Figure 11), it is not possible that different ubiquitin chain types bind 
to NEMO at the same time. This means, that binding of NEMO to different chain 
types, present at a given time, occurs in a competitive manner. To address the Results 
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question of ubiquitin binding preference of NEMO, here an approach was used, 
where equal concentrations of different ubiquitin chain types were incubated 
with purified MPB- or GST-tagged NEMO in the same tube and binding to NEMO 
was monitored by washing off unbound chains and subsequent Western blot 
analysis (Figure 12 and Figure 13). First the binding preference of GST-tagged 
NEMO-UBAN as well as the full C-terminus towards K63 and linear tetraUb was 
compared.  To  this  end,  1 µg  of  each  tetraUb  chain  was  incubated  with  the 
indicated  recombinant  GST-proteins  and  a  competitive  pull-down  assay  was 
performed  (Figure  12).  Since  ubiquitin  chains  of  the  same  length  but  with 
different  linkage  display  distinctive  mobility  on  SDS-gels20,  it  is  possible  to 
distinguish the different types of chains, using the same anti-ubiquitin antibody. 
In this experiment we observed a clear binding preference of the UBAN and the 
C-terminus  of  NEMO  towards  linear  tetraUb,  while  an  interaction  with  K63-
linked  tetraUb  could  not  be  detected.  This  shows  that  although  the  affinity 
towards K63-linked tetraUb increases when the ZnF is added to the UBAN of 
NEMO119 (Figure 8), the binding to linear ubiquitin is still clearly preferred in a 
situation where both types of chains are present (Figure 12). 
 
 
Figure  12:  The  UBAN  and  the  C-
terminus  of  NEMO  preferentially 
interact  with  linear  tetraUb  in 
competition  with  K63-linked  tetraUb. 
1 µg of K63- and linear tetraUb were 
incubated  with  the  indicated 
recombinant  GST-Proteins,  that  were 
bound  to  glutathion-sepharose  beads 
and  a  GST-pull-down  assay  was 
performed. Bound proteins were eluted 
with SDS-sample buffer and separated 
by  SDS-PAGE.  Ubiquitin  was 
visualised by Western blot analysis. 
 
 
After  discovering  that  the  UBAN  as  well  as  the  C-terminus  of  NEMO 
preferentially  interact  with  linear  tetraUb  the  questions  arose,  if  full-length 
NEMO shows a binding preference towards a certain type of ubiquitin chain and 
if  a  possible  binding  preference  might  depend  on  the  length  of  the  chains. Results 
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Recently  it  was  shown  that  the  UBAN  also  binds  to  K11-linked  chains  with 
similar  affinity  than  K48-  and  K63-linked  chains108.  In  order  to  analyse  in  a 
competition  assay  which chain  type full-length NEMO preferentially  binds to, 
MPB-NEMO was incubated with K11-, K63- and linear-triUb (Figure 13A). This 
showed that full-length NEMO selectively bound linear triUb, while no binding to 
K11- and K63-linked chains was observed (Figure 13A). So far it was shown that 
longer  lysine  linked  ubiquitin  chains  with  at  least  four  moieties  bind  to  full 
length NEMO (Figure 8) and structural as well as biochemical analysis indicates 
that they bind only to the distal patch of the NEMO UBAN domain as compared to 
a longitudinal arrangement of linear chains that recognizes both, the proximal 
and  the  distal  patch99  (Figure  10  and  Figure  11).  In  accordance  with  results 
shown in Figure 12, when GST-NEMO or MBP-NEMO was incubated with linear 
and K63-linked tetraUb, linear tetraUb was able to block binding of K63-linked 
tetraUb  (Figure  13B).  In  contrast  to  NEMO,  receptor-associated  protein  80 
(RAP80)  selectively  bound  to  K63-linked  tetraUb,  while  no  binding  to  linear 
tetraUb was detected (Figure 13C). This is in agreement with a previous study, 
showing that the  two  UIM-domains  of RAP80  as  a  unit  selectively bind K63-
linked, but not K48- or linearly linked diUb65, 121 (Figure 3). Since the length of 
ubiquitin  chains  influences  the  affinity  towards  NEMO  and  especially  longer 
lysine-linked ubiquitin chains show an increase in binding, possibly by providing 
additional  binding  sites99  (Figure  9  and  Figure  11),  the  binding  of  K63-linked 
hexa- and heptaUb to NEMO was investigated in competition with linear tetraUb 
(Figure 13D). In both cases NEMO bound only to linear tetraUb, while binding to 
hexa- or to hepta- K63-linked ubiquitin chains could not be observed. Comparing 
the  ubiquitin binding preference  of NEMO with a  mixture  of long K63-linked 
ubiquitin  chains  and  linear  tetraUb  revealed  that  the  selective  interaction 
preference for linear chains is high enough to compete out even very long K63-
linked  chains,  since  NEMO  didn’t  pull  down  K63-linked  chains  up  to  at  least 
decaUb in the presence of linear tetraUb (Figure 13E). Chains that were longer 
than  decaUb  showed  interaction  with  NEMO  despite  the  presence  of  linear 
tetraUb, but since ubiquitin chains longer than decaUb were not separated, it’s 
not clear what size of K63-linked chains was necessary for binding and also if Results 
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this  precipitation  of  high  molecular  weight  ubiquitin  chains  is  a  specific 
interaction.  In  order  to  get  more  detailed  information  about  the  ubiquitin 
binding preference of NEMO towards linear chains, 1 µg of K63-linked tetraUb 
were  incubated  together  with  different  amounts  of  linearly  linked  tetraUb 
(Figure 13F). Interaction of NEMO with K63-linked tetraUb alone is rather weak 
(Figure 13F). In contrast, already the addition of 20 ng of linear tetraUb leads to a 
strong linear chain binding, emphasising the high binding preference of NEMO to 
this chains type. The increase of binding of NEMO to linear chains correlates 
strongly with an increasing input where already 100 ng of linear ubiquitin chains 
shows  a  much  stronger  binding  than  1 µg  of  K63-linked  ubiquitin  chains. 
Moreover,  the  linear  chains  compete  out  the  binding  toward  K63-linked 
ubiquitin chains, clearly visible by a decreased K63-linked chain binding, already 
in the presence of only 200 ng of linear ubiquitin chains. Taken together, these 
results  demonstrate  the  quantitative  distinction  in  ubiquitin  chain  binding 
selectivity of full-length NEMO towards linear ubiquitin chains compared with 
long K63-linked ubiquitin chains. 
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Figure 13: Full-length NEMO selectively interacts with linear ubiquitin chains. A-E) 
1 µg of the indicated ubiquitin chains (in F the indicated amounts of ubiquitin chains 
were used) were incubated with MBP or GST-full-length NEMO, or GST-full-length 
RAP80,  which  were  immobilised  by  sepharose  beads  and  pull-down  assays  were 
performed.  Bound proteins  were eluted with  SDS-sample buffer and separated by 
SDS-PAGE. Ubiquitin was visualised by Western blot analysis. 
 
 
4.4  Analysis  of  the  interaction  of  the  A20-ZnF7  with  different  types  of 
ubiquitin chains 
Ubiquitin chain binding of NEMO is important for the activation of NF-κB 
and as shown, NEMO preferentially interacts with linear ubiquitin chains99, 111 
(Figure 9, Figure 12 and Figure 13). The DUB A20 is a ubiquitin editing enzyme, Results 
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that can also act as an E3-ligase113. A20 is crucial for silencing NF-κB activity in 
various ways and for many of its NF-κB inhibiting functions the seven zinc finger 
domains at its C-terminus are important113, 122, 123. Recently, the ZnF4 and ZnF7 
have  been  shown  to  be  involved  in  ubiquitin  chain  binding  with  a  possible 
preference of the ZnF4 for K63-linked ubiquitin chains123, 124. In collaboration 
with the group of Rudi Beyaert, the biochemical evaluation of the binding of the 
A20 ZnF7 to ubiquitin chains and its functional relevance in the TNFα-induced 
activation of NF-κB was assessed125. 
Since linear ubiquitin chains play an important role in the activation of TNFα-
induced activation of NF-κB54, 70, 99, and A20 is important for silencing NF-κB, the 
A20-ZnF7  was  probed  for  its  ability  to  bind  linear  ubiquitin  chains  in 
competition with other chain types (Figure 14). Incubation of GST-A20-ZnF7 with 
linear- and K48-linked tetraUb together exhibited a clear binding preference for 
linear  tetraUb,  while  a  ZnF7  mutant  was  not  able  to  bind  ubiquitin  at  all 
(Figure 14A).  Interestingly,  when  linear  tetraUb  was  incubated  with  the 
structural similar K63-linked ubiquitin chains (Figure 1B), there was a weaker 
binding preference of the ZnF7 for linear ubiquitin chains (Figure 14B compare 
binding  to  input).  Since  the  length  of  ubiquitin  chains  might  influence  the 
interaction  with  a  UBD  (Figure  11),  the  competitive  binding  of  A20-ZnF7  to 
linear- and K63-linked triUb was assessed (Figure 14C). Interestingly, in contrast 
to tetraUb, the ZnF7 showed a high binding preference towards linear ubiquitin 
with these shorter chains. To further investigate the role of the length of the 
ubiquitin chains in binding to the A20-ZnF7, a pull-down analysis with GST-A20-
ZnF7 and different types of diUb was performed (Figure 14D). Surprisingly, with 
diUb  no  interaction  between  the  ZnF7  and  K63-linked  chains  was  observed, 
which was  in harsh contrast to  longer K63-linked chains  that even  bound in 
competition with linear chains (Figure 14B). Even more surprising was the clear 
and  strong  binding  between  the  ZnF7  and  linear  diUb,  revealing  a  strong 
contrast  in  the  interaction  quality  of  the  ZnF7  with  these  two  chain  types 
depending on their length (Figure 14 compare B and D). K11- and K48- linked 
diUb, the two other chain types examined for their binding with the ZnF7, hardly 
showed  any  interaction  and  also  longer  K48-linked  ubiquitin  chains  don’t Results 
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interact with the ZnF7 of A20125 (Figure 14D). These results indicate that the 
A20-ZnF7 is a highly selective binder of short linear ubiquitin chains, but it can 
also interact with longer ubiquitin chains of other linkages. 
 
Figure 14: The ZnF7 of A20 preferentially interacts with linear ubiquitin chains and 
this selectivity depends on the length of the chains. A-D) 0.5 µg of the indicated 
ubiquitin chains were incubated with GST-A20-ZnF7 (wild-type and ubiquitin non-
binding mutant), which were immobilised by sepharose beads and pull-down assays 
were performed. Bound proteins were eluted with SDS-sample buffer and separated 
by  SDS-PAGE.  Ubiquitin  was  visualised  by  Western  blot  analysis.  GST-ZnF7* 
represents a mutant that is not able to bind ubiquitin. 
 
 
4.5  Functional  relevance  of  the  interactions  of  NEMO  with  linear 
polyubiquitin 
 
4.5.1 Interaction of NEMO with linear ubiquitin chains is necessary for the 
activation of NF-κB  
Several  studies  investigated  the  role  of  the  interaction  of  NEMO  with 
ubiquitin  chains  in  the  activation  of  NF-κB111, 117, 126, 127.  It  was  proposed  that 
especially the interaction with K63-linked ubiquitin chains is the key mechanism 
how NEMO and IKK get activated by various NF-κB inducers. However, it was 
also  shown  that  K63  of  ubiquitin  is  not  important  for  the  TNFα-induced Results 
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activation  of  NF-κB  and  the  knock-out  of  the  K63-specific  E2  Ubc13  in  mice 
didn’t  affect  NF-κB-signalling128, 129.  Considering  aforementioned  and  the 
discovery that NEMO preferentially interacts with linear ubiquitin chains,  the 
question arose what relevance that interaction has for the activation of NF-κB 
(Figure 8, Figure 12, Figure 13). 
After identifying NEMO mutants that selectively lose the interaction with linear 
but  not  with  K63-linked  ubiquitin  chains99  (Figure  11),  the  impact  of  the 
interaction of NEMO with linear ubiquitin chains on NF-κB signalling could be 
tested in vivo (Figure 15). To this end NEMO knock-out MEFs were reconstituted 
with  wild-type  and  mutant  NEMO  and  their  function  in  the  TNF  induced 
activation of NF-B was examined. When NEMO knock-out MEFs, reconstituted 
with wild-type NEMO were treated with TNF similar activation of NF-B as 
with wild-type MEFs was observed, as judged by the phosphorylation status and 
the  subsequent  degradation  of  IB5  and  15  minutes  after  treatment 
respectively. In contrast, cells reconstituted with the triple NEMO mutant V293A, 
Y301A, K302A were not able to activate NF-B. These residues are in the distal 
UBAN patch and thus are important for the binding to linear and lysine linked 
ubiquitin chains99. However, also the mutant R309A, R312A, E313A was not able 
to  efficiently  propagate  the  signal  to  activate  NF-B.  This  mutant  selectively 
inhibits the interaction of NEMO with linear ubiquitin chains, but not with K63-
linked  tetraUb99,  indicating  that  the  specific  interaction  of  NEMO  with  linear 
ubiquitin chains is important for the full activation of NF-B. 
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Figure 15: The interaction of NEMO with linear ubiquitin chains is necessary for the 
activation of NF-κB. Wild-type or NEMO deficient MEFs, stably reconstituted with 
NEMO or different NEMO-mutants, were untreated or treated with TNFα (20 ng/ml) 
for the indicated times. The cell lysates were separated by SDS-PAGE and protein 
content was analysed by Western blot. 
 
 
TNF  is  also  an  inducer  of  MAP-kinase  signalling  pathways  that  lead  to  the 
activation  of  p38-  and  JNK-  MAP-kinases129.  Both  MAP-kinases,  p38  and  JNK 
were  activated  similarly  in  wild-type  MEFs  or  NEMO  knock-out  MEFs, 
reconstituted  with  wild-type  or  mutant  NEMO  constructs,  indicating  that  the 
inhibition of the NF-B pathway in cells expressing ubiquitin binding selective 
NEMO-mutants is not affecting the MAP-kinase pathway and that TNF-receptor 
signalling in these cells was intact (Figure 15). 
 
4.5.2 Interaction of NEMO with the proximal UBAN patch is necessary to 
rescue cells from apoptosis 
Apart  from  the  NF-B  and  the  MAP-kinase-signalling  pathway,  is  the 
activated TNFR also responsible for the induction of TNF activated cell death 
via Caspase-8 and -3 dependent apoptosis130. NEMO and the NF-B pathway are 
crucial negative regulators of TNF induced apoptosis131. In order to investigate Results 
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the role of NEMO binding to ubiquitin in the pro-survival regulation of TNF 
treated cells, we used the reconstituted NEMO knock-out MEFs and treated them 
for 6 hours with TNF and cyclohexamide (to inhibit cellular TNF-production) 
(Figure  16).  Cells  that  didn’t  express  NEMO  (mock)  massively  underwent 
apoptotic  death  upon  TNF  treatment,  evaluated  by  the  degree  of  Caspase-3 
cleavage and the condensation of DAPI-stained nuclei (Figure 16). In contrast, 
wild-type MEFs or NEMO knock-out MEFs, reconstituted with wild-type NEMO, 
did not show signs of apoptotic death. However, cells reconstituted with NEMO 
protein that is not able to bind linear ubiquitin chains showed strong activation 
of Caspase-3 as well as nuclear condensation (Figure 16). This indicates that the 
interaction of NEMO with linear ubiquitin chains is important for rescuing cells 
from TNF induced apoptosis. 
Overall  these  results  strongly  support  the  hypothesis  that  the  interaction  of 
NEMO with ubiquitin chains and especially with linear ubiquitin chains is crucial 
for its function as a regulator of signalling by TNF. 
 
 
Figure  16:  NEMO  mutants  that  are  not  able  to  bind  linear  ubiquitin  chains  are 
impaired  in  rescuing  cells  from  TNFα  induced  apoptosis.  A)  Wild-type  and 
reconstituted NEMO knock-out MEFs were treated with TNFα/CHX for 6 h. Total 
cell lysate was separated by SDS-PAGE and Western blot analysis was performed. B) 
Cover slips with cells grown in the same dishes as in A were fixed in 2% PFA and 
mounted on mounting media (Biometra) containing DAPI (molecular probes 1:1000). Results 
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Apoptosis was assessed by epifluorescense microscopy showing condensed chromatin 
in apoptosis positive cells. 
 
 
4.6  The  interaction  of  NEMO  with  K63-linked  ubiquitin  chains  is  not 
sufficient for full NF-B activation 
  
4.6.1 TAB2-NZF containing NEMO has a high affinity towards K63-linked 
ubiquitin chains  
Previous studies proposed that complex formation between NEMO and 
K63-linked  ubiquitin  chains  is  important  for  the  TNFα-induced  activation  of 
NF-κB signalling111, 117. In order to test, whether a high affinity binding of NEMO 
to K63-linked ubiquitin chains can be sufficient to activate the NF-κB pathway, 
NEMO  chimeras  that  contain  the  NZF-domain  of  TAB2  were  engineered 
(Figure 17).  This  NZF-domain  is  an  exclusive  binder  of  K63-linked 
polyubiquitin67, 68. To this end, the NEMO-ZnF was swapped with the TAB2-NZF 
domain in combination with or without UBAN mutation at the residue F305 that 
blocks interaction with ubiquitin (F305A-NZF-ΔZnF-K63 or NZF-ΔZnF-K63/M1) 
(Figure 17A). In addition, a NEMO chimera was constructed, where the UBAN of 
NEMO was replaced with the NZF (NZF-ΔUBAN-K63) (Figure 17A). With these 
selective K63 binding NEMO chimeras the relevance of NEMO binding to K63-
linked ubiquitin chains in the activation of NF-κB was analysed. 
To first confirm the ubiquitin-binding properties of these NEMO variants, the 
respective GST-fusion proteins were purified and incubated with linearly or K63-
linked tetraUb (Figure 17B). As expected, an exclusive binding of the two NZF-
containing chimeras F305A-NZF-ΔZnF-K63 and NZF-ΔUBAN-K63 to K63-linked 
ubiquitin  chains  was  observed.  On  the  other  hand,  NEMO  mutant 
NZF-ΔZnF-K63/M1 bound to both linearly and K63-linked ubiquitin chains. In 
contrast, GST-wild-type-NEMO is a selective linear ubiquitin chain binder. The 
F305A mutation abolished the binding to ubiquitin, as also previously shown 
(Figure 11B). Results 
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To  further  test  how  these  chimeras  bind  to  different  ubiquitin  chain  types, 
binding competition assays with the different GST-NEMO-chimeras and linearly- 
and K63-linked tetraUb was performed (Figure 17C). While wild-type NEMO and 
the NZF-containing but UBAN-deficient chimeras selectively bound linearly and 
K63-linked tetraUb chains  respectively, the NEMO mutant NZF-ΔZnF-K63/M1 
bound to linearly and K63-linked tetraUb chains with similar strength. This is an 
interesting fact, since thus it is possible to compare the physiological relevance 
of the interactions of NEMO-proteins with similar affinity towards K63-linked or 
linear ubiquitin chains. 
 
 
Figure 17: TAB2-NZF-containing NEMO chimeras with UBAN-mutation selectively 
bind K63-linked ubiquitin chains. A) Domain structures of wild-type and different 
NEMO-mutant  constructs.  NEMO  constructs  with  indicated  ubiquitin  binding 
selectivity were used to analyse ubiquitin binding and reconstitute NEMO deficient 
MEFs. B) NEMO with intact UBAN has high affinity to linear ubiquitin chains and 
NEMO-chimeras with NZF-domain have high affinity to K63-linked ubiquitin chains. 
Purified GST-tagged NEMO-mutants were incubated with 1 µg of either K63- or 
linearly linked ubiquitin chains and pull-downs were performed. Bound proteins were 
eluted  with  SDS-sample  buffer  and  separated  by  SDS-PAGE.  Ubiquitin  was Results 
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visualised by Western blot analysis. C) NZF- and UBAN-containing chimeras bind 
K63-  or  linearly  linked  ubiquitin  chains  with  similar  strength,  while  UBAN-only 
containing wild-type-NEMO selectively binds linear ubiquitin chains and NZF- but 
UBAN-mutant NEMO-proteins selectively bind K63 ubiquitin chains when exposed 
to  both  chain  types.  Purified  GST-wild-type  and  mutant  NEMO  proteins  were 
incubated with 1 µg of indicated ubiquitin chains and pull-downs were performed. 
Bound proteins were eluted with SDS-sample buffer and separated by SDS-PAGE. 
Ubiquitin was visualised by Western blot analysis. 
 
 
4.6.2 TAB2-NZF containing NEMO is impaired in the activation of NF-B 
In order to address, if these K63-selective NEMO chimeras are able to 
mediate  TNFα-induced  NF-κB  signalling,  NEMO-deficient  MEF  cell  lines  were 
reconstituted  with the  NEMO mutants or wild-type  NEMO. In  these cell lines 
wild-type NEMO and the mutants were expressed at similar levels and could 
form an IKK complex when immunoprecipitated with an anti-NEMO antibody 
(Figure 18). 
 
 
 
 
 
 
 
 
Figure 18:  NZF-containing 
NEMO-chimeras  can  form  an 
IKK complex. NEMO deficient 
MEFs,  stably  reconstituted 
with  wild-type  or  different 
NEMO-mutants were lysed and 
immunoprecipitated  using  a 
NEMO-specific  antibody. 
Immunoprecipitated  proteins 
were  eluted  with  SDS-sample 
buffer and immunoblotted. Co-
immunoprecipitation  of  IKKα 
was  verified  with  anti-IKKα 
antibody  and  expression  level 
of  NEMO  variants  was 
analysed  with  anti-NEMO 
specific antibody. 
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With these tools in hand, the effect of strong K63-linked ubiquitin chain binding 
NEMO-chimeras  on  TNFα-induced  IKK-dependent  NF-κB  activation  was 
examined  (Figure 19).  In  NEMO  deficient  MEFs  reconstituted  with  wild-type 
NEMO  or  the  linear  and  K63-linked  chain-binding  mutant  NEMO-
NZF-ΔZnF-K63/M1, IκBα got phosphorylated and degraded after treatment with 
TNFα for 5 and 15 minutes respectively. In contrast, NEMO deficient MEFs or 
cells expressing the mutant F305A, that cannot bind ubiquitin, were not able to 
induce IκBα phosphorylation and degradation (Figure 19A). Interestingly, MEFs 
which express NEMO-NZF-ΔUBAN-K63 or NEMO-F305A-NZF-ΔZnF-K63 showed 
only  partial  degradation  of  IκBα  with  both  mutants.  Additionally,  NEMO-K63 
only binding chimeras  expressing MEFs  were impaired in  phosphorylation  of 
IκBα, indicating a defect in IKK-activity. These observations suggest that binding 
of NEMO to K63-linked ubiquitin chains is not sufficient to efficiently regulate 
TNFα-induced activation of NF-κB signalling. In order to further examine if the 
signalling  defects  in  NEMO  mutant-expressing  cells  were  specific  for  NF-κB 
activation, TNFR-dependent activation of MAP kinase signalling pathways was 
tested (Figure 19A). As indicated by their phosphorylation, both MAP-kinases, 
p38  and  JNK,  are  activated  in  cells  expressing  wild-type  NEMO  and  NEMO-
chimeras,  suggesting  that  strong  K63-linked  ubiquitin  chain  binding  NEMO-
chimeras do not non-specifically affect MAP kinase signalling functions at the 
TNFR. 
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Figure  19:  K63-linked  binding  specific  NEMO-chimeras  are  impaired  in  the 
activation  of  NF-κB.  A)  NEMO  deficient  MEFs,  reconstituted  with  linear  chain 
binding deficient and K63-binding selective NEMO mutants are impaired in IκBα 
degradation upon TNFα stimulation. NEMO-deficient MEFs stably reconstituted with 
wild-type NEMO or different NEMO mutants were untreated or treated with TNFα 
(20 ng/ml) for the indicated times. The lysates were separated by SDS-PAGE, and 
protein  content  was  analysed  by  Western  blotting.  B)  NEMO  deficient  MEFs 
reconstituted with linear chain binding-deficient and K63 binding selective NEMO 
mutants  are  hampered  in  nuclear  translocation  of  p65  upon  TNFα  stimulation. 
NEMO-deficient  MEFs  stably  reconstituted  with  wild-type  NEMO  or  different 
NEMO mutants were untreated or treated with TNFα (20 ng/ml) for the indicated 
times. Nuclear and the cytoplasmic fractions were separated by SDS-PAGE, and the 
presence  of  p65  in  the  nuclear  fraction  was  analysed  by  Western  blotting. 
Densitometrical quantification of p65 in the nuclear fraction in the shown Western 
blot is indicated in the graphs, where the intensity for vector (Mock) containing cells 
was set to 1, and the intensity of the other cell lines was related to mock. The p65 
signal was measured using the software ImageJ and normalized by PARP level. C) 
NEMO-deficient  MEFs,  reconstituted  with  linear  ubiquitin  chain  binding-deficient 
but K63 binding selective NEMO mutants are impaired in the induction of NF-κB 
target  gene expression. NEMO-deficient MEFs  stably reconstituted with wild-type 
NEMO or different NEMO mutants were untreated or treated with TNFα (20 ng/ml) 
for  30  minutes  and  mRNA  was  extracted.  Quantitative  PCR  was  performed  as 
described under  “Methods”. Ct  values of target gene A20  were normalized to  Ct 
values  of  α-actin.  Induction  of  gene  expression  in  a  cell  line  was  determined  by 
comparison with the expression level of the untreated sample of the same cell line. 
Values shown are means ±SEM (error bars) of at least three individual experiments. 
*p < 0.05: significant difference between wild-type NEMO expressing and NEMO 
deficient MEFs or NEMO mutants expressing MEFs. 
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To analyse NF-κB activation downstream of IκBα-degradation in these MEFs the 
nuclear  translocation  of  the  NF-κB  subunit  p65  was  examined  in  TNFα-
stimulated  cells  (Figure 19B).  MEFs  reconstituted  with  wild-type  NEMO  or 
NEMO-NZF-ΔZnF-K63/M1 showed strong activation of NF-κB, as determined by 
the amount of nuclear p65 after 15 and 30 minutes of TNFα-treatment. On the 
other  hand,  MEFs  reconstituted  with  the  ubiquitin  binding  deficient  F305A-
mutant did not mediate efficient p65 translocation. In  contrast to MEFs with 
linear ubiquitin chain binding NEMO and in agreement with the results of the 
degradation of IκBα (Figure 19A), was the nuclear translocation of p65 markedly 
impaired  in  MEFs  expressing  NEMO-NZF-ΔUBAN-K63  or  NEMO-
F305A-NZF-ΔZnF-K63 (Figure 19B). 
To  further  assess  the  NF-κB  activation  potential  of  K63-selective  NEMO 
chimeras, the induction of the NF-κB target gene A20 was analysed (Figure 19C). 
After 30 min of TNFα treatment, A20 gene expression was induced 24.8 ± 2.33 
SEM fold higher in wild-type NEMO expressing cells and 19.1 ± 4.6 SEM fold 
higher in NEMO-NZF-ΔZnF-K63/M1 cells compared to NEMO deficient cells. In 
contrast, induction of A20 gene expression was significantly impaired in cells 
with K63- only binding NEMO or NEMO-F305 mutant. Although only wild-type 
NEMO  or  the  chimeras  that  bind  linear  ubiquitin  chains  activated  NF-κB 
properly, the K63-binding selective NEMO chimera NEMO-F305A-NZF-ΔZnF-K63 
was also able to induce A20-expression at a certain level, which is significantly 
higher than with the non-ubiquitin binding NEMO-F305A-mutant (Figure 19C). 
This  is  in  agreement  with  a  recent  study  showing  that  linear  chain  binding 
deficient NEMO-mutants could still partially activate NF-κB through their lower 
affinity binding towards K63-linked ubiquitin chains intrinsic in the wild-type 
protein132. However, even a higher affinity binding of NEMO to K63-linked chains 
doesn’t activate NF-κB as efficiently as NEMO that is able to bind to linear chains, 
emphasising the importance of the binding of NEMO to linear ubiquitin chains 
for an efficient activation of TNFα-induced NF-κB-signalling. Discussion 
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5. Discussion 
 
The modification of proteins with ubiquitin is a versatile process, to regulate 
many aspects of cellular physiology2. The many different ways how ubiquitin can 
modify proteins, provides the cell with a myriad of potential and specific signals 
that  can  participate  in  cellular  functions.  Most  functions  controlled  by 
ubiquitylation are mediated by ubiquitin receptors, which read the signal with 
their UBDs24. Since ubiquitin can form so many different signals, receptors have 
evolved that specifically recognize only a small variety of the palette of potential 
ubiquitin forms, such as different types of ubiquitin chains or monoubiquitin. In 
order to understand the signalling networks that are regulated by ubiquitin it is 
eminent to unravel the detailed recognition processes of ubiquitin signals. In this 
light  this  study  mainly  aimed  at  elucidating  the  detection  specificity  of  the 
ubiquitin  receptor  NEMO,  the  central  regulator  of  the  NF-κB  transcription 
system,  as  well  as  the  role  these  interactions  play  in  the  activation  of  this 
transcription factor.  
 
5.1 NEMO chain binding selectivity 
Previous  studies  reported,  that  NEMO  selectively  binds  K63-linked 
ubiquitin chains111, 117. However, it was also shown that the UBAN has an up to 
100 fold higher affinity towards linear diUb than towards K63-linked diUb99, 101. 
In line with that, a detailed analysis of the ubiquitin binding modes of NEMO in 
the present study showed, that the UBAN alone, as well as full-length NEMO, 
have a high binding selectivity towards linear ubiquitin chains (Figure 8B, Figure 
10 and Figure 13). Here it was revealed, that the binding of K63- and K48-linked 
ubiquitin chains to the UBAN is rather weak (Figure 8B and Figure 11). On the 
other hand,  the  C-terminus of NEMO,  which includes  the  UBAN  and the  ZnF, 
exhibited an increased binding to tetraUb of these chain types compared to the 
UBAN alone. This is in agreement with previous studies that discovered that the 
addition of the ZnF increases the affinity to longer lysine linked chains compared 
to the UBAN alone119, 132. However, this binding is still weaker than the binding of 
the  C-terminus  to  linear  chains  and  additionally  does  full-length  NEMO  bind Discussion 
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weaker  to  the  tested  lysine-linked  chains  than  to  linear  polyubiquitin 
(Figure 8B). K63-linked tetraUb has a higher affinity to the UBAN compared to 
K63-linked  diUb99  and  the  UBAN  plus  the  ZnF  have  an  even  higher  binding 
strength towards K63-linked tetraUb in comparison to the UBAN alone119. On the 
other hand, there is no ZnF dependent increase in the binding to the shorter 
K63-linked  diUb132.  It  is  possible  that  the  longer  K63-linked  ubiquitin  chains 
have a second binding site with the UBAN to increase the binding strength, which 
doesn’t exist for K63-linked diUb as seen by the structure120. Moreover, the ZnF 
might  provide  an  even  better  additional  binding  site  for  longer  K63-linked 
chains, since the UBAN plus ZnF has an increased affinity towards K63-linked 
tetraUb compared to the UBAN alone119 (Figure 8B). 
Indeed, current data point to the fact that NEMO needs to bind at least at two 
sites to ubiquitin to get an efficient interaction. The structure of the UBAN in 
complex with linear diUb reveals an interaction site of one moiety via its I44 
patch and a second interaction site at the linker region of the diUb molecule99 
(Figure 10). This binding mode with the unconventional linker-UBD interaction is 
responsible for the selective high affinity between the UBAN and linear diUb, 
since a structure of a complex between the UBAN and K63-linked diUb shows 
that in this case only one moiety interacts with the UBAN120. The K63 diUb-UBAN 
interaction also happens via the hydrophobic patch of the distal moiety, as it is 
the  case  with  the  distal  moiety  of  linear  diUb120  (Figure  20B).  A  second 
interaction site in this crystal was observed between the hydrophobic patch of 
the proximal moiety and the distal patch of the UBAN of another UBAN dimer. 
This cross-UBAN interaction however might also be due to the tight packaging of 
the molecules in the crystal and thus be a forced second interaction site that is 
necessary to get sufficient binding for crystal formation, yet may not reflect a 
physiological situation133. In contrast to K63-linked diUb, it could be that longer 
chains  with  this  linkage  have  an  additional  binding  site  with  the  UBAN, 
explaining the higher binding strength. This binding site could depend on the 
distal  patch, since  mutating it also abrogates  the  interaction  with  K63-linked 
tetraUb99 (Figure 11). A modelled structure of the UBAN in complex with K63-
linked  tetraUb  displays  a  possible  interaction  mode  how  longer  K63-linked Discussion 
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chains  bind  to  two  sites  of  the  UBAN-dimer  (Figure  20A).  In  this  scenario  a 
ubiquitin moiety at one end of the chain interacts with the distal patch on one 
side of the UBAN, while another ubiquitin binds to the distal patch on the other 
side of the UBAN. 
As outlined above, it seems that NEMO needs at least two interaction sites to 
efficiently interact with ubiquitin. However, there are probably differences in the 
binding strength, depending on the sites utilised for the interaction. For example 
K63-linked tetraUb interacts much stronger with the C-terminus of NEMO than 
with the UBAN alone, though in both cases additional binding sites might be the 
reason  for  binding  compared  to  the  non-binding  K63-linked  diUb99,  119 
(Figure 8). It was shown that the ZnF has a weak affinity towards ubiquitin with 
a Kd of ~250 µM118, thus it might be that this is a second binding site for K63-
linked tetraUb which is favoured to a possible second interaction site with the 
second distal patch of the UBAN. It might also be that the longitudinal binding 
arrangement for ubiquitin chains on UBAN is favoured since this orientation is 
also  the  way  the  high  affinity  binding  linear  diUb  interacts  with  the  UBAN99 
(Figure 10). Thus, a stronger interaction between longer K63 linked chains with 
the  C-terminus  compared  to  the  UBAN  alone  might  be  favoured  due  to  a 
preferred additional binding site or a favoured orientation or a combination of 
these models. A previous study using a fluorescence spectroscopy assay showed 
that the C-terminus of NEMO has an affinity towards longer K63-linked chains 
with a Kd of 0.22 µM, which in this case was even stronger than the interaction of 
the C-terminus with linearly linked ubiquitin which had an affinity of 1.7 µM119. 
Another study on the other hand revealed, that the C-terminus of NEMO can 
exhibit a different binding behaviour with K63-linked tetraUb, depending on if 
the C-terminus was fixed or in solution132. Using a method where the C-terminus 
was in solution didn’t lead to a binding of K63-linked tetraUb, while it still bound 
strongly to linear di- and tetraUb. Surprisingly, when the C-terminus of NEMO 
was fixed to a surface it bound to longer K63-linked chains132. However, results 
from experiments in the present study revealed that when the C-terminus of 
NEMO was incubated with linear- and K63-linked tetraUb together there was a 
clear binding preference towards linear ubiquitin chains (Figure 12). This shows Discussion 
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that  linearly  linked  polyUb  can  outcompete  the  binding  of  longer  K63-linked 
chains  even  though  the  C-terminus  of  NEMO  is  fixed  to  sepharose  beads, 
reflecting a more solid state, that seems to be more favourable for binding to 
longer K63-linked chains than being in solution132. Possibly the special binding 
mode of the UBAN has a higher interaction efficiency compared to a putative 
binding mode of longer K63-linked chains at the ZnF. An explanation for this 
clear preference might be that an interaction between the UBAN and linearly 
linked ubiquitin chains is more efficient, maybe due to a cooperative binding of 
its binding sites, which might cause a faster association rate, thus this different 
kinetics outcompete the interaction with longer K63-linked chains. Additionally, 
it should be mentioned that the physiological relevant full-length NEMO has a 
lower affinity towards K63-linked chains than the C-terminus alone, while full-
length  NEMO  binds  linear  ubiquitin  chains  with  only  a  bit  less  efficiency, 
indicating some kind of regulatory role for the N-terminus for the ubiquitin chain 
binding of NEMO (Figure 8). Until structural data is available the reason for the 
binding difference of full-length NEMO and the C-terminus as well as the actual 
binding  mode  of  longer  K63-linked  ubiquitin  with  the  C-terminus  remains 
enigmatic. In accordance with the preference of the C-terminus for linear chains 
in competition with K63-linked tetraUb (Figure 12) as well as the less decrease in 
affinity of the full-length NEMO for linear tetraUb (Figure 8), full-length NEMO 
preferentially interacts with linear chains, when incubated together with K63 
linked chains (Figure 13). Moreover, even longer K63-linked chains, up to at least 
decaUb don’t bind efficiently to full-length NEMO in the presence of the shorter 
linear tetraUb, although these longer chains might offer even further interaction 
sites (Figure 13B, D and E). Recently it has been shown, that RIP1 gets modified 
with K11-linked ubiquitin chains at the activated TNFR and that the UBAN of 
NEMO also binds to K11, with a similar affinity than to K63- and K48- linked 
chains55, 108. However, when K63-, K11- and linearly linked triUb were incubated 
together with full-length NEMO, there was a clear binding preference of NEMO 
for linear chains (Figure 13A). This, and the analysis of the binding to K48-and 
K63-linked tetraUb (Figure 8), indicates that full-length NEMO is a low affinity 
receptor for lysine linked ubiquitin chains, while being a selective and highly Discussion 
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efficient receptor for linear linked ubiquitin chains, due to its special interaction 
mode that is only possible with this linkage type. This is also emphasised by 
semi-quantitative  interaction  experiments,  that  estimated  that  the  binding 
preference of full-length NEMO towards linear tetraUb is at least 50 fold higher 
than for K63-linked tetraUb (Figure 13F), although single measurements of the 
C-terminus suggested that the difference in affinity for these two chain types is 
smaller119  (Figure 8B).  Taken  together  these  results  revealed,  that  there  is  a 
binding preference for linear chains of full-length NEMO and the efficient binding 
of NEMO to linear chains through its UBAN outcompetes the binding of any other 
chain type that might otherwise bind with lower affinity when linear chains are 
not there (Figure 8, Figure 10 and Figure 13). 
 
Figure 20: Structures of K63-linked ubiquitin chains in complex with the NEMO-
UBAN. A) A model of a putative structure, showing how K63-linked tetraUb might 
bind  the  NEMO-UBAN  in  a  perpendicular  way,  thus  interacting  with  both  distal 
patches of the UBAN-dimer. Modified from
99. B) Structure of K63-linked diUb in 
complex with the NEMO-UBAN. The distal diUb-molecule binds with its I44 patch 
to the distal patch of one UBAN while the proximal diUb binds with its I44-patch to 
the distal patch of another UBAN homodimer. Modified from
120. 
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5.2 Ubiquitin chain length can influence UBD selectivity 
The interaction with ubiquitin is in many cases influenced by the length of 
the  chains85. For example  K48-linked tetraUb seems to  be  the  minimal  chain 
length for optimal proteasome receptor recognition22,23. In this case a chain with 
four  moieties  is  the  optimal  length  for  the  interaction  with  two  ubiquitin 
receptors  at  the  proteasome134.  In  other  instances  the  chain  length  can 
determine the specificity of interaction with one ubiquitin receptor or even only 
one UBD. The binding selectivity of NEMO and its UBAN e.g. partially depend on 
the length of the chains99 (Figure 11). The UBAN has a ~100 fold higher affinity 
towards linear diUb than towards K63-linked diUb, which is explained by their 
different binding modes seen in the respective structures99, 101, 120 (Figure 10 and 
Figure  20).  However,  this  selectivity  becomes  less  with  longer  lysine-linked 
chains, which weakly interact with the UBAN (Figure 11). These distinct binding 
features might play an important role in terms of signal regulation. Short chains 
might be a stringent signal for chain type selective UBDs, such as  the UBAN, 
while the interaction of NEMO with longer chains could have different effects in 
terms of quality, meaning different outcome, or quantity, meaning more or less 
of the same outcome. In this light it is interesting that linear diUb fused to NEMO 
is already sufficient to fully activate NF-κB, when overexpressed in HEK293-T 
cells,  since  the  fusion  of  NEMO  with  tri-  to  heptaUb  didn’t  increase  the 
activation135. This full activation of NF-κB depends on the specific binding of a 
linearly linked diUb by the UBAN, since the non-binding UBAN mutant F312A 
fused with polyubiquitin is not able to activate NF-κB and also monoubiquitin 
fused to wild type NEMO didn’t activate NF-κB. On the other hand it might be 
that the selective binding of NEMO to long K63- or other lysine-linked chains is 
also able to activate NF-κB, however only weakly, since UBAN mutants defective 
only in linear chain binding have been reported to partially activate NF-κB132. 
Thus  the  presence  of a  certain  chain  type  and  the  chain  length  could  decide 
about the outcome by determining a strong or a weak activation of NF-κB. 
Another indication for the relevance of diUb as a selective signal comes from a 
study where a mass spectrometrical analysis showed that RIP1 at the activated 
TNFR is modified with K48-, K11-, K63- and linear diUb55. These facts indicate Discussion 
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that diUb is a preferred chain length for stringent signalling at the TNFR, which 
might be recognized by selective ubiquitin receptors. Indeed, also the activation 
of  the  MAP3-kinase  TAK1  depends  on  the  interaction  of  its  adapter  proteins 
TAB2/3  with  ubiquitin  and  the  TAB2/3-NZF  specifically  interacts  with  K63-
linked diUb, but not with linear diUb67, 136. Thus linear diUb and K63-linked diUb 
might provide distinct selective signals for the activation of different signalling 
pathways. 
The importance of the chain length for UBD-selectivity is also displayed by the 
ubiquitin-binding of ZnF7 of A20 (Figure 14). ZnF7 has a clear binding preference 
for  linear  diUb  compared  to  lysine-linked  diUb  (Figure  14D).  A  clear  binding 
preference is also observed in a binding competition assay between K63- and 
linearly  linked  triUb  (Figure  14C).  However  this  preference  is  not  so  clear 
anymore between K63- and linearly-linked tetraUb (Figure 14B). On the other 
hand,  the  ZnF7  clearly  distinguishes  between  the  structurally  more  different 
K48,  -and  linear  tetraUb  (Figure  14A).  This  is  a  good  example  how  the  two 
features of a ubiquitin chain, the length and the linkage type, can individually or 
combined determine binding selectivity for a UBD. Short chains  show a clear 
ZnF7 binding preference depending on the linkage type (Figure 14D), while this 
selectivity gets gradually lost with longer chains (Figure 14B and C), however, 
still keeping a  selective distinction between structurally very different  chains 
(Figure 14A), such as elongated linear and more compact K48-linked chains. As 
A20 is an important negative regulator of NF-κB-signalling137 and many different 
ubiquitin chains are involved in the activation of this transcription factor106, this 
characteristic ubiquitin binding of the A20 ZnF7 as well as other A20-domains, 
seems  to  be  important  for  its  function124, 125.Taken  together  not  only  the 
ubiquitin topology, depending on the linkage, but also the chain length seems to 
be an important factor for UBD selectivity and thus cellular function. 
 
5.3  NEMO  binding  to  linear  ubiquitin  chains  is  important  for  NF-κB 
activation and TNFR-signalling 
Many different types of ubiquitin chains are involved in TNFR induced 
NF-κB signalling106. For some of these chain types their role is clear, e. g. K48-Discussion 
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linked chains are responsible for the degradation of the NF-κB inhibitors80. It has 
been known for a while that the first discovered non-degradative ubiquitin chain 
type, K63-linked chains, functions in NF-κB signalling and it has also been found 
recently that NEMO can interact with this chain type111, 113. Upon these findings it 
has been proposed that NEMO selectively binds to K63-linked ubiquitin chains to 
activate NF-κB. This led to a model where ubiquitin receptors such as TAB2/3 
and NEMO interact with long K63-linked ubiquitin chains, which are attached to 
adaptor  proteins  at  the  activated  TNFR  and  these  interactions  activate  MAP-
kinases and NF-κB77. 
However,  recently  it  has  been  discovered,  that  the  structurally  similar  linear 
ubiquitin chains are also important for the activation of NF-κB70, 99. This finding 
was surprising, since before the discovery of the linear ubiquitin chain specific 
E3-ligase LUBAC it was believed that these chains don’t have a physiological role 
in the cell, but are mere precursors for monoubiquitin11, 19. With the discovery of 
the role of linear chains, K63-linked chains as single non-degradative ubiquitin 
regulators  of  NF-κB  activation  got  questioned.  Moreover,  the  knock-out  of 
Ubc13, the only K63 chain specific E2, in mice, as well as the replacement of 
endogenous ubiquitin with K63-mutant ubiquitin in human cells, had no effect 
on the activation of NF-κB via the TNFR128, 129. This suggested that K63-linked 
chains  at  the  TNFR,  and  thus  K63-linked  chain  binding  of  NEMO,  are  not 
necessary for the activation of NF-κB. Interestingly, the first linear ubiquitylation 
substrate discovered was NEMO itself and this modification was shown to be 
important for NF-κB signalling70. Supporting the role of linear chains in NF-κB-
signalling were studies revealing that LUBAC is recruited to the TNFR and cells 
lacking  LUBAC  components  were  defective  in  NF-κB  activation54-56, 110.  In  the 
light  of  the  importance  of  linear  ubiquitin  chains  for  NF-κB-signalling  at  the 
activated TNFR it was interesting to find that the ubiquitin receptor NEMO is a 
high affinity binder of linear ubiquitin chains, while detailed analysis showed 
that the affinity to K63-linked chains is actually rather low99, 101, 102 (Figure 8B, 
Figure 10 and Figure 13). The clear preference of NEMO binding to linearly- over 
lysine-linked ubiquitin chains indicated a functional relevance of this interaction 
(Figure 12 and Figure 13). And indeed, mutants that are still able to bind K63-Discussion 
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linked ubiquitin99 (Figure 11), but selectively lost binding to linear chains, were 
impaired in the activation of NF-κB induced by TNFα99 (Figure 15 and Figure 19). 
This strongly indicates that K63-linked chains at the TNFR are not essential for 
the activation of NF-κB while linear chains are, and at least one of their functions, 
if not the most important one, is the regulation of the activity of the IKK-complex 
by binding to NEMO135. 
The importance of NEMO binding to linear ubiquitin chains in the activation of 
NF-κB was confirmed in NEMO deficient B-cells that were reconstituted with the 
linear chain binding deficient triple-mutant R309A, R312A, E313A99. Stimulation 
of these cells expressing the R309A, R312A, E313A-mutant with different NF-κB 
inducing compounds lead to significantly less activation of NF-κB compared to 
those reconstituted with wild-type NEMO. Further support for the relevance of 
linear chains in NF-κB signalling brought the finding that LUBAC components are 
also present in the activated CD40-receptor, which is also a member of the TNFR 
superfamily, and that LUBAC is important for CD-40 signalling55. Additionally, 
the activation of NF-κB in different cell types, which lack any of the three LUBAC 
components,  is  defective54-56, 70, 110.  Cells  that  lack  SHARPIN  seem  especially 
defective in TNFR-family dependent activation of NF-κB while IL-1βR or TLR-
signalling  is  not  as  much  attenuated54-56.  Interestingly,  although  the  non-
canonical NF-κB-pathway gets mainly activated by TNFR-family members it is 
not affected by the lack of expression of LUBAC-components, which is in sharp 
contrast to the canonical pathway56. For instance the lymphotoxin β-receptor 
(LTβR) induces the canonical and the non-canonical pathway138, however upon 
stimulation of SHARPIN deficient cells with LTβ only the phosphorylation and 
degradation  of  IκB  is  inhibited,  while  the  processing  of  p100  to  the 
transcriptional  active p52 is  not effected56. Since  one  of the main differences 
between the canonical and the non-canonical NF-κB-pathway is that NEMO is not 
involved in the non-canonical pathway94, and the lack of linear chains leads to a 
specific impairment of the canonical pathway, this indicates that one of the main 
function of linear ubiquitin chains in NF-κB activation is constituting a signal for 
the IKK-regulator NEMO. Discussion 
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The  TNFR  can  also  activate  Caspase-8  dependent  apoptosis,  which  is  usually 
inhibited by the pro-survival activity of NEMO and NF-κB130. Without NEMO and 
the  activation  of  NF-κB  cells  undergo  rapid  TNFα  induced  apoptosis131 
(Figure 16). Additionally to the activation of anti-apoptotic genes there is also an 
NF-κB independent role of NEMO in the inhibition of TNFα-induced apoptosis, 
since when NEMO knock-out MEFs, reconstituted with wild-type NEMO, were 
treated  with  TNFα  they  didn’t  die  by  apoptosis,  despite  the  fact  that  gene 
expression was blocked by cyclohexamide (Figure 16). Interestingly, the ability of 
NEMO to rescue cells from TNFα -induced apoptosis depended on its ability to 
bind to ubiquitin, since when the cells were reconstituted with ubiquitin binding 
deficient NEMO-mutants they died from apoptosis, just as NEMO knock-out cells 
(Figure  16).  Moreover,  the  specific  binding  of  NEMO  to  linear  chains  was 
necessary  to  rescue  the  cells  from  apoptosis,  since  mutants  in  the  proximal 
UBAN-patch also died upon treatment with TNFα (Figure 16). This indicates that 
the specific high affinity binding of NEMO to linear ubiquitin chains, additionally 
to  the  regulating of IKK-activity, is  also  crucial for the  regulation  of the  pro-
survival  pathway.  This  is  in  line  with  studies  showing  that  linear  chains  are 
important  to  rescue  cells  from  TNFα-induced  apoptosis54, 139.  For  example 
SHARPIN  deficient  mice  have  the  immunodeficiency  disease  CPDM  (chronic 
proliferative dermatitis) that also has hallmarks of apoptosis and this phenotype 
is  rescued  when  crossed  with  mice  that  lack  TNFα,  indicating  a  linear  chain 
dependent  pro-survival signal  at the  TNFR54, 55.  Additionally,  there is  another 
survival  pathway  that  is  regulated  by  the  binding  of  NEMO  to  ubiquitylated 
RIP1140.  The  activated  TNFR  can  also  induce  necrosis  when  the  pro-survival 
pathway and apoptosis are inhibited141. In a recent study by O’Donnell et al. it 
was  shown  that  NEMO  deficient  cells  die  from  TNFα-induced  necrosis,  when 
Caspases are inhibited, and this can be rescued by reconstitution with wild-type 
NEMO but not with ubiquitin binding deficient NEMO140. This is in line with the 
necessity of NEMO to bind linear ubiquitin chains to rescue cells from TNFα-
induced apoptosis. Taken together these studies reveal an overall importance of 
NEMO binding to linear ubiquitin chains in the regulation of TNFR-signalling. Discussion 
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The discovery of many different types of ubiquitin chains revealed a complex 
signalling system at the TNFR that can give signalling a regulated directionality 
through  the  binding  of  selective  ubiquitin  receptors  but  also  provide  certain 
redundancy in the signalling events85, 91, 107. For example the interaction of linear 
chain binding deficient NEMO with K63-linked ubiquitin can in some instances 
still  partially  activate  NF-κB132  (Figure 19).  Also  the  NF-κB  inhibiting  protein 
A20 can interact with K63-linked and linearly linked chains via its C-terminal 
zinc fingers and the ZnF7 shows selective binding to short linear chains, but also 
a bit more plasticity towards longer ubiquitin chains123 (Figure 14). However, 
many  ubiquitin  receptors  at  the  TNFRSC  have  a  selective  affinity  towards  a 
certain chain type, at least up to a certain length or concentration67, 68 (Figure 11, 
Figure 13 and Figure 14). Thus it might be that signalling events at the TNFR are 
tightly regulated by an orchestrated production of different types of ubiquitin 
chains with different lengths. Possibly short ubiquitin chains produced at the 
right time on the right place could give the TNFR a regulated directionality that is 
necessary for deciding which pathway will be activated. This is in accordance 
with the mass spectrometrical analysis of the activated TNFRSC that found that 
RIP1 was modified with K63-, K48-, K11- and linear diUb55. Thus, the activation 
of NF-κB at the TNFR seems to have a regulated sequence of events that was 
partially delineated by a study, which analysed the recruitment of components to 
the activated TNFR110. Upon activation the proteins TRADD, RIP1 and TRAF2/5 
bind the TNFR. TRAF2 recruits cIAP1/2, which can synthesise different kinds of 
lysine  linked  ubiquitin  chains108,  and  this  process  is  required  for  TNFR-
function110.  These  E3-ligases  build  lysine-linked  ubiquitin  chains  on  many 
components  at  the  receptor  that  might  have  different  lengths55,  which  then 
recruit HOIP and thus LUBAC by the interaction of its UBD110. Long lysine-linked 
chains could recruit and activate a small amount of IKK by binding to NEMO132 
(Figure 8B and Figure 13F). LUBAC then synthesises linear ubiquitin chains on 
NEMO-molecules  already  present,  RIP1  and  possibly  other  substrates54, 55, 70. 
Finally  these  linear  chains  constitute  a  strong  signal  to  recruit  and  activate 
NEMO for a full and efficient activation of NF-κB. Here it is interesting to note 
that the steady state concentration of linear ubiquitin chains in the cell is rather Discussion 
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low54. However, experiments using the absolute protein quantification method 
AQUA could show that upon activation of LUBAC their concentration increases 
rapidly54. Considering the highly efficient binding of NEMO to linear ubiquitin 
this could be a strong specific signal for efficient recruitment and activation of 
IKK and thus NF-κB (Figure 13 and Figure 15). Indeed, already linear diUb is able 
to activate the purified IKK-complex while K63- or K48-linked diUb is not135. 
Moreover, linear diUb-fused to NEMO is sufficient to fully activate NF-κB because 
adding longer chains doesn’t increase the activation. This stringent regulation of 
NF-κB  activation  by  linear  ubiquitin  chains  also  became  apparent  by  the 
experiments that showed that the TAB2-NZF containing NEMO-chimeras, with 
high binding selectivity for K63-linked chains, are also impaired in the activation 
of  NF-κB,  although  the  affinity  is  similar  to  that  of  the  UBAN  towards  linear 
chains (Figure 17 and Figure 19). This confirms that binding of NEMO to K63-
linked chains cannot serve as an efficient NF-κB activating signal at the TNFR. 
K63-linked chains on the other hand can activate the MAP-kinase pathway by 
selective  interaction  with  the  TAK1-adapters  TAB2/3  via  their  NZF-
domains67, 136. Thus, due to the chain type selective receptors TAB2/3 and NEMO 
the  TNFR  has  the  possibility  to  regulate  the  MAPK-  and  the  NF-κB-pathway 
independently, which is supported by the fact that the impairment of NEMO to 
bind linear chains and activated NF-κB, doesn’t affect the activation of JNK and 
p38 (Figure 15 and Figure 19). Taken together, the activation of the TNFR leads 
to the recruitment of proteins, of which many can get ubiquitylated by cIAPs 
(Figure 21). This can lead to a weak recruitment and activation of IKK through 
weak interactions of NEMO with lysine-linked ubiquitin chain. Only when LUBAC 
produces linear ubiquitin chains at the TNFR the signal for NEMO recruitment 
and IKK activation is strong enough to fully activate NF-κB (Figure 15, Figure 19 
and Figure 21). 
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Figure 21: Schematic model how linear ubiquitin chains induce strong and efficient 
NF-κB  activation.  A)  Activation  of  the  TNFR  triggers  its  trimerisation  and  the 
recruitment of TRADD, RIP1, TRAFs, cIAP1/2 and other proteins. TRAFs and cIAPs 
are E3-ligases that can produce lysine linked ubiquitin chains. NEMO can weakly 
bind to these chains and induce NF-κB, though inefficiently. B) The recruitment of 
LUBAC to the TNFR through lysine linked ubiquitin chains enables the production of 
linear ubiquitin chains, e.g. on RIP1 to which NEMO can bind strongly. NEMO itself 
gets linearly ubiquitylated and due to its high affinity to linear chains many IKK-
complexes can cluster very stably, which creates a strong NF-κB activation signal. 
 
 
The model where different ubiquitin chain types facilitated a tight regulation, but 
also some redundancy, of the signalling events at the TNFR might also hold true 
for the downregulation of TNFR induced NF-κB-signalling. Apart from NEMO, 
there are at least four other protein containing a UBAN-domain, which are called 
ABIN1/2/3 and optineurin98. It was shown that the other UBANs also bind linear 
ubiquitin  chains  and  ABIN1  and  optineurin  are  negative  regulators  of 
NF-κB98, 100, 142. ABIN1 seems to bind to ubiquitin chains on NEMO to recruit A20 
which can deubiquitylate NEMO98. For optineurin it was shown that it competes 
with NEMO for the binding to ubiquitylated RIP1 to inhibit NF-κB-signalling142. 
In this study it was assumed that it is the binding of optineurin to K63-linked 
chains that inhibits NF-κB-signalling, however, knowing now about the role of 
linear  ubiquitin  chains  and  that  both,  NEMO  and  optineurin  are  linear  chain Discussion 
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receptors100, 143 (Figure 10 and Figure 13), the concept of competitive binding of 
NEMO  and  optineurin  might  also  be  true  for  linear  chains.  Thus,  UBAN 
containing  NF-κB-inhibitors  might  specifically  downregulate  linear  ubiquitin 
chain mediated signalling but might also be involved in the inhibition of K63-
linked  ubiquitin  chain  signalling.  Another  study  discovered  that  optineurin 
inhibits NF-κB-signalling by recruiting the DUB CYLD to the TNFRSC, which is an 
important  DUB  in  the  downregulation  of  NF-κB73, 144.  CYLD  has  a  high  DUB 
activity  against  K63-linked  ubiquitin  chains,  which  has  been  shown  to  be 
important  for  silencing  NF-κB145.  However  CYLD  also  deubiquitylates  linear 
ubiquitin chains and since this chain type and CYLD play important roles in the 
TNFRSC it is possible that this DUB also removes linear chains from proteins that 
can activate NF-κB20. 
Recently K11-linked ubiquitin chains have been implicated in TNFR-signalling 
and  they  also  interact  with  the  UBAN  of  NEMO55, 108.  Interestingly,  the  DUB 
Cezanne,  that  is  known  for  silencing  NF-κB  at  the  TNFR146,  preferentially 
hydrolyses  this  chain  type112.  Thus,  K11-linked  ubiquitin  chains  constitute 
another chain type in the ubiquitin network and my help to activated signalling. 
K11-linkd chains can weakly interact with the UBAN, but so far no UBD is known 
that  specifically  interacts  with  this  chain  typ.  However,  since  Cezanne  is 
important  for  silencing  NF-κB  and  preferentially  removes  K11-linked  chains, 
there might be a specific role for this chain type which is yet unknown. 
A20, another important DUB for silencing TNFR-signalling, has been shown to 
have a special function at the TNFR by removing K63-linked chains from and 
adding  K48-linked  chains  to  RIP1113.  However,  the  function  of  A20  is  more 
complicated,  because  in  vitro  it  preferentially  hydrolyses  K48-linked  chains, 
which  suggests  that  there  are  other  proteins  that  assist  A20  in  the 
aforementioned process20. Recently it was discovered that A20 can interact with 
K63-linked ubiquitin chains via its ZnF4 and 7 and this interaction is important 
for the inhibition of NF-κB signalling123, 124. In line with this, the present study 
shows  a  certain  affinity  of  the  A20  ZnF7  for  K63-linked  ubiquitin  chains 
(Figure 14B).  However,  these  binding  experiments  revealed  an  overall 
preference of ZnF7 for linear ubiquitin chains, which becomes most evident with Discussion 
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diUb, a chain length where linear chains are the exclusive binder of the ZnF7 
(Figure  14D).  In  functional  studies  it  could  be  shown  that  this  ubiquitin 
interaction  of  the  ZnF7  is  important  for  inhibiting  TNFα-induced  NF-κB-
signalling125. Moreover, the ZnF7 was specifically responsible for the inhibition 
of LUBAC induced NF-κB activation, while the ZnF4 didn’t have an inhibitory 
effect.  This  indicates  a  certain  specificity  but  also  some  redundancy  in  the 
inhibitory function of A20 by binding to ubiquitin chains. For shorter chains the 
ZnF7 can specifically inhibit the NF-κB-inducing function of linear chains. This 
might be important because of the strong signal inducing effect of this chain type, 
since it was shown that already diUb is enough to activate NF-κB135. On the other 
hand can the ZnF4 and the ZnF7 together interact with longer K63- and possibly 
other lysine-linked chains and thus also influence their signalling capacity. 
Taken  together,  it  seems  that  short  ubiquitin  chains  can  regulate  specific 
signalling events at the TNFR by selectively interacting with dedicated UBDs, 
while longer ubiquitin chains might confer a certain redundancy, which might 
have a weaker and more general function by binding with lower affinity, more 
promiscuously, to a broader range of ubiquitin receptors. Linear ubiquitin chains 
have an important signalling function at the TNFR and it seems that many of 
these functions are mediated by binding to the IKK-regulator NEMO. 
 Summery and Future Perspectives 
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6. Summery and Future Perspectives 
 
Many  types  of  ubiquitin  chains  can  modify  several  proteins  at  the  activated 
TNFR. Additionally many UBD-containing ubiquitin receptors localise there to 
mediate the signal constituted by these chains. Among these ubiquitin receptors 
is the NF-κB regulator NEMO and in the present study it was shown that NEMO 
preferentially binds linear ubiquitin chains and that this interaction is important 
for its function at the TNFR. The ZnF7 of A20 also has a selective affinity towards 
linear  ubiquitin  chains,  however,  it  can  interact  with  longer  lysine  linked 
ubiquitin chains as well and its ZnF4 was shown to preferentially interact with 
K63-linked chains.  
A lot of progress has been made in the understanding of the role of ubiquitin at 
the TNFRSC. However, many details are still not very clear. Although  various 
proteins  have  been  identified  to  be  ubiquitylated,  the  specific  role  of  the 
respective modification is most of the time not clear or controversial. E. g. the 
ubiquitylation of RIP1 was shown to be important for the activation of NF-κB113, 
however in another study RIP1 deficient MEFs can still activate TNFR-dependent 
NF-κB signalling147. Thus a future task is to exactly identify the substrates for 
ubiquitylation  as  well  as  their  residues  and  then  analyse  the  role  of  this 
modification  in  vivo.  This  could  be  accomplished  with  sophisticated  protein 
purification  and  separation  methods  combined  with  mass  spectrometrical 
analysis. For instance ubiquitylated substrates at the activated TNFR could be 
isolated  with  ubiquitin-linkage  specific  antibodies  or  UBDs  and  separated  by 
2D-gel  electrophoresis.  Such  purified  ubiquitylation  substrates  could  then  be 
identified by mass spectrometrical analysis. In order to confirm the importance 
of a given modification, knock-out cells could be utilised to reconstitute them 
with  mutants  of  residues  of  proteins  discovered  to  be  modified  in  the  mass 
spectrometrical analysis and the activation of the TNFR-signalling could then be 
monitored. This way it might also be possible to detect further substrates for 
linear ubiquitin chains in the TNFRSC that might be crucial for the interaction 
with NEMO and the induction of NF-κB signalling. Summery and Future Perspectives 
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It is also important to dissect when ubiquitylation happens and how long the 
chains  are.  This  could  be  accomplished  by  utilising  ubiquitin  chain  selective 
sensors in vivo. The usage of such sensors has recently been shown in a study 
from van Wijk et al., where the K63-linked chain specific UIMs of RAP80 and the 
linear ubiquitin chain specific UBAN-domain of NEMO were applied to selectively 
detect these chain types in fixed as well as in living cells148. In order to detect the 
production  of  certain  ubiquitin  chains  at  the  TNFR  and  to  get  a  temporal 
resolution of this process, FRET (fluorescent resonance energy transfer)-sensors 
could be utilised. To this end e. g. a TNFR-RAP80-UIM-chimera could be tagged 
with  a  YFP-protein,  while  ubiquitin  mutants  that  can  only  form  K63-linked 
chains  could  be  tagged  with  CFP,  which  together  form  a  FRET-couple  that 
enables detection of binding in real-time. A sudden production of K63-linked 
ubiquitin chains upon TNFR activation could thus be detected as a FRET-signal 
as soon as these chains would interact with the UIMs at the TNFR and this would 
indicate the time of the chain production.  
So far the role of the interaction of NEMO with linear ubiquitins chain has mainly 
been studied at the TNFR. Some reports indicated a role for LUBAC in the CD4056 
the RIG-1149 and the NOD2150 signalling pathways and there is also evidence that 
different stimuli rely on the interaction of NEMO with linear ubiquitin chains to 
activate NF-κB, however detailed analysis of the role of linear ubiquitin chains 
hasn’t been performed99. Thus it would be interesting to analyse in more detail if 
the interaction of NEMO with linear ubiquitin chains is also responsible for the 
regulation of NF-κB with other stimuli and in other cell types. 
Additionally, it is mechanistically not clear how the interaction of NEMO with 
linear ubiquitin chains activates the IKK-complex. The structure of the UBAN 
with linear diUb shows that the binding of diUb induces a conformational change 
in the UBAN, which might play a role in the activation of IKK99. However, it is also 
possible that the interaction with linear ubiquitin chains provokes just the right 
concentration of the IKK-complex on the right site at the right time, which is 
necessary for its efficient activation. A more detailed structural analysis of the 
IKK-complex with and without linear ubiquitin chains could help to understand 
ubiquitin induced conformational changes that might lead to IKK activation. Summery and Future Perspectives 
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An  immune  system  that  is  not  properly  regulated  can  lead  to  autoimmune 
diseases  or  uncontrolled  inflammation,  which  might  be  responsible  for  the 
development of cancer151. Since NEMO is the central regulator of NF-κB, which is 
an important transcription factor for genes promoting inflammation, the detailed 
understanding of the processes that lead to NEMO dependent activation of NF-κB 
by ubiquitin interaction, could help to develop drugs that specifically target these 
interactions.  
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8. Appendix 
 
8.1 Abbreviations 
ABIN – A20 binding inhibitor of NF-κB 
APC/C – anaphase-promoting complex/cyclosome  
APS – ammonium persulfate  
ATG – autophagy related  
ATM – Ataxia telangiectasia mutated 
ATP – adenosine-5’-triphosphate 
BAFF – B-cell activating factor 
BCR – B-cell receptor 
BRCA1 – breast cancer 1, early onset  
BSA – Bovine serum albumin 
di-, tri,- tetra,- hexa-, hepta-, deca-, polyUb – x-ubiquitin 
CD40 – cluster of differentiation 40 
Cdc34 – cell-division cycle  
CHX – cyclohexamide 
cIAP – cellular inhibitor of apoptosis 
CRL – cullin ring ligase 
Ct – cycle threshold 
CYLD – cylindromatosis  
DAPI – 4’-6-Diamidin-2-phenylindol 
DD – death domain 
DMEM – Dulbecco's Modified Eagle's Medium  
DTT – 1,4-dithio-DL-threitol 
DUB – deubiquitylating enzyme 
E1 – ubiquitin activating enzyme 
E2 – ubiquitin conjugating enzyme 
E3 – ubiquitin ligating enzyme 
E6AP – E6-associated protein 
EDTA – ethylenediaminetetraacetic acid 
EGTA – ethylene glycol tetraacetic acid  Appendix 
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ERAD – Endosplasmatic reticulum associated degradation 
FADD – Fas-Associated protein with Death Domain 
GABARAP – Gamma-aminobutyric acid receptor-associated protein 
GAPDH – Glyceraldehyde 3-phosphate dehydrogenase  
GST – glutathione S-transferase  
H – hour 
HECT – Homologous to the E6-AP Carboxyl Terminus  
HEK-cells – human embryonic kidney cells 
HOIL-1L – haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1  
HOIP – HOIL-1L interacting protein  
HRP – horse reddish peroxidase 
IL-1β – interleukin-1 β  
IκB – inhibitor of NF-κB 
IKK – inhibitor of NF-κB kinase 
IPTG – Isopropyl β-D-1-thiogalactopyranoside  
ISG15 – interferon stimulated gene 15 
IsoT – isopeptidase T  
JAMM – Jab1/Mov34/Mpr1 Pad1 N-terminal+  
JNK – c-Jun N-terminal kinase  
Kd – dissociation constant  
kDa – kilo Dalton 
LC3 – microtubule-associated protein 1 light chain 3  
LTβR – lymphotoxin β receptor  
LUBAC – linear ubiquitin chain assembly complex  
M – molar 
MAP – Mitogen-activated protein kinase 
MBP – Maltose binding protein 
MEF – mouse embryonic fibroblast 
MVB – multiple vesicular bodies 
NBD – NEMO binding domain 
Nedd8 – Neuronal precursor cell expressed, developmentally downregulated 8  
NEM – N-Ethylmaleimide  Appendix 
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NEMO – NF-κB essential modulator 
NF-κB – Nuclear Factor of kappa light polypeptide gene enhancer in B cells  
NIK – NF-κB inducing kinase 
Ni-NTA – nickel-nitrilotriacetic acid  
NOD – Nucleotide-binding oligomerization domain-containing protein  
NZF – Npl4 zinc finger  
OTU – ovarian tumour  
PARP – Poly (ADP-ribose) polymerase  
PBS – phosphate buffered saline 
PCNA – Proliferating Cell Nuclear Antigen  
PCR – polymerase chain reaction 
PDB – protein database 
PFA – paraform aldehyde 
PH-domain – pleckstrin homology domain  
PTM – posttranslational modification 
PVDF – polyvinylidene fluoride  
RAD23A – RADiation sensitivity abnormal 
RANK – receptor activator of NF-κB 
RAP80 – receptor associated protein 80 
RBR – RING-between-RING 
Rcf – relative centrifugal force  
RHD – Rel homology domain 
RIG-I – retinoic acid inducible gene I  
RING – really interesting new gene 
RIP1 – Receptor-Interacting Protein 1  
RNF – ring finger  
ROS – reactive oxygen species 
RPN – regulatory particle, non-ATPase-like family member 
RPS27A – 40S ribosomal protein S27a  
RT – room temperature 
SAE1 – SUMO-activating enzyme subunit 1  
SCFβTrCP – Skp1-cullin-F-box/β-transducin repeat-containing protein Appendix 
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SDS – Sodium dodecyl sulfate  
SDS-PAGE – SDS-polyacrylamide gel electrophoresis 
SEM – standard error of the mean  
SHARPIN – SHANK-associated RH domain interactor  
SUMO – small ubiquitin like modifier 
TAB2 – TAK1-binding protein 2  
TAD – transactivation domain 
TAE – Tris-acetate-EDTA  
TAK1 – TGFβ-activated kinase 1  
TBS – tris buffered saline 
TCR – T-cell receptor 
TEMED – Tetramethylethylenediamine  
TLR – toll like receptor 
TNF – Tumour necrosis factor 
TNFR – TNF-receptor 
TNFRSC – TNFR signalling complex 
TRAF – TNF-receptor-associated factor  
UBA – ubiquitin associated  
Uba – ubiquitin-activating enzyme 
UBA52 – ubiquitin A-52 residue ribosomal protein fusion product  
UBAN – UBD in ABIN proteins and NEMO  
UBB – ubiquitin gene b  
UBC – ubiquitin gene c  
Ubc – ubiquitin conjugating  
UbcH –human ubiquitin conjugating  
UBD – ubiquitin binding domain 
UBL – ubiquitin-like protein  
UBZ – ubiquitin binding zinc finger 
UCH – ubiquitin c-terminal hydrolase 
Uev1a – ubiquitin-conjugating enzyme variant  
UFM1 – Ubiquitin-fold modifier 1  
UIM – ubiquitin interacting motif Appendix 
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ULD – ubiquitin like domain 
URM1 – ubiquitin-related modifier  
USP – ubiquitin specific protease  
UV – ultra violet 
ZnF – zinc finger Appendix 
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Abstract 
Posttranslationale  Modifikationen  regulieren  wesentliche  Eigenschaften  von 
Proteinen,  wie  z. B.  Lokalisation,  Konformation,  Aktivität,  Stabilität  und 
Interaktionsfähigkeit.  Eine  besondere  Form  der  Proteinmodifikation  ist  die 
Ubiquitylierung,  bei  der  das  kleine  Protein  Ubiquitin  mit  seinem  C-Terminus 
kovalent an ein Substratprotein gebunden wird.  
Die  am  besten  untersuchte  Funktion  der  Ubiquitylierung  ist  die  Markierung 
eines  Substrates  für  den  Abbau  durch  das  Proteasom.  In  den  letzten  Jahren 
wurde jedoch entdeckt, dass Ubiquitylierung in vielen Bereichen der Zelle eine 
wichtige Rolle spielt. Dazu gehören der Transport von Vesikeln, die Reparatur 
von DNA-Schäden und zelluläre Signalübertragung. Ubiquitin kann verschieden-
artige Ketten bilden, indem ein Ubiquitin an eines der sieben Lysine (K6, K11, 
K27, K29, K33, K48, K63) oder den N-Terminus eines anderen gebunden wird. 
Diese  unterschiedlichen  Kettentypen  regulieren  verschiedene  Prozesse.  Z. B. 
dienen K48-verknüpfte Ubiquitinketten als Signal für den proteasomalen Abbau, 
wohingegen  über  K63  verknüpfte  Ketten  hauptsächlich  eine  Rolle  bei 
Signalübertragungen spielen.  
Die  meisten  Funktionen  die  durch  Ubiquitylierung  reguliert  werden,  werden 
durch  Ubiquitinrezeptoren  vermittelt,  die  eine  Ubiquitinbindedomäne  (UBD) 
besitzen. Manche UBDs binden selektiv nur einen Ubiquitinkettentyp und sind 
somit in der Lage gezielt Prozesse regulieren zu können, indem sie nur durch 
diesen speziellen Kettentyp aktiviert werden. 
Das  Protein  NEMO  ist  ein  Ubiquitinrezeptor,  dessen  UBD  UBAN  selektiv 
bestimmte  Ubiquitinketten  bindet.  NEMO  spielt  eine  zentrale  Rolle  bei  der 
Aktivierung  der  Transkriptionsfaktorfamilie  NF-κB,  indem  es  den  IKK-
Kinasekomplex  reguliert.  Dieser  Kinasekomplex  sorgt  durch  die 
Phosphorylierung des NF-κB-Inhibitors IκBα für dessen proteasomalen Abbau, 
wodurch  schließlich  NF-κB  aktiviert  wird.  Die  NF-κB-Aktivierung  kann  u. a. 
durch den TNF-Rezeptor (TNFR) induziert werden. Am aktivierten TNFR werden 
viele  Proteine  durch  verschiedene  Ubiquitinketten  modifiziert.  Bisher  wurde 
angenommen,  dass  die  spezifische  Bindung  von  NEMO  an  K63-verknüpfte 
Ubiquitinketten ausschlaggebend für die Aktivierung von IKK ist. Jedoch spielen 
lineare  Ubiquitinketten,  die  über  den  N-Terminus  verknüpft  sind,  auch  eine  
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wichtige Rolle bei der Aktivierung von NF-κB und die UBAN von NEMO hat eine 
sehr hohe Affinität zu linearen Ubiquitinketten. 
Um die genauen Vorgänge zu verstehen, die zur Aktivierung von NF-κB am TNFR 
führen, ist es nötig, zu analysieren, welche Proteine mit welchen Ubiquitinketten 
modifiziert werden und welche Ubiquitinrezeptoren daran binden.  
In  dieser  Studie  sollte  detailliert  untersucht  werden,  mit  welchen  Ubiquitin-
ketten NEMO bevorzugt interagiert. Dazu wurden in vitro-Bindungsstudien mit 
bakteriell  aufgereinigtem  NEMO  und  verschiedenen  Ubiquitinketten 
durchgeführt. Des Weiteren sollte geprüft werden, wie die Bindung von NEMO 
an bestimmte Ubiquitinketten die Aktivierung von NF-κB reguliert.  
Dabei  ergab  sich,  dass  sowohl  NEMO  in  voller  Länge,  als  auch  die  UBAN, 
bevorzugt mit linearen Ubiquitinketten interagieren, wohingegen die Interaktion 
von NEMO mit anderen Ubiquitinketten relativ schwach ist. Ausgehend von einer 
Kristallstruktur  eines  Komplexes  aus  der  NEMO-UBAN  und  linearem  di-
Ubiquitin,  wurden  NEMO-Mutanten  generiert,  die  seletkiv  die  Bindung  von 
NEMO an lineare Ubiquitinketten verhindern, während die schwache Bindung 
von NEMO an längere K63-verknüpfte Ketten erhalten blieb. Um die Relevanz 
der Interaktion von NEMO mit linearen Ubiquitinketten für die Aktivierung von 
NF-κB zu überprüfen, wurden diese NEMO-Mutanten dann verwendet um Zellen 
die kein NEMO exprimieren zu rekonstituieren. Nach Stimulation dieser Zellen 
mit  TNFα  wurde  NF-κB  kaum  aktiviert,  womit  gezeigt  werden  konnte,  dass 
NEMO gezielt an lineare Ubiquitinketten binden muss, um NF-κB zu aktivieren. 
Zusätzlich zu seiner Rolle bei der Aktivierung von NF-κB ist NEMO ein wichtiger 
Inhibitor  der  durch  den  TNFR  induzierten  Apoptose.  In  dieser  Studie  wurde 
gezeigt, dass diese Apoptoseinhibierung abhängig von der Bindung von NEMO an 
lineare Ubiquitinketten ist, da die Zellen die NEMO-Mutanten exprimierten, die 
keine linearen Ketten binden können, durch Apoptose starben, währen Wildtyp-
Zellen überlebten. 
Zusammenfassend  konnte  in  dieser  Studie  gezeigt  werden,  dass  NEMO 
bevorzugt  und  mit  vergleichsweise  hoher  Affinität  an  lineare  Ubiquitinketten 
bindet und dass diese spezifische Bindung wichtig für die Inhibierung von TNFR-
induzierter Apoptose sowie für die Aktivierung von NF-κB ist.  